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Oxyresveratrol (OXY) belongs to the group of phytochemicals known as 
hydroxystilbenoids, and has a molecular structure similar to the well-known 
phytochemical resveratrol. It is found to be particularly concentrated in the heartwood of 
Artocarpus lakoocha Wall. ex Roxb. (Family: Moraceae), an indigenous plant in 
Thailand. This species has been used as a Thai traditional medicine for the treatment of 
various parasitic diseases. Previous studies have also reported that it may exhibit pro-
oxidative properties, which associated with the amount of the main compound in the 
extracts. OXY may share biological activities with resveratrol and be developed as an 
anticancer agent. This thesis aimed to investigate the cytotoxicity of OXY, consequently. 
The heartwood was ground, dried and extracted. The chromatographic and spectroscopic 
analyses were carried out and OXY was identified as the major component in the extracts 
(33.55%, 37.81% and 64.23 % w/w in water, ethanol and ethyl acetate, respectively). 
Resveratrol was quantified as a minor compound, (0.37%, 0.45% and 0.65% w/w in 
water, ethanol and ethyl acetate extracts, respectively). The pro-oxidant activity was 
investigated using DNA–nick, reactive oxygen species (ROS), copper reducing and 
glutathione depletion assays. The results showed that OXY induced DNA damage dose-
dependently in the presence of copper (II) ions. It was also found to generate ROS in a 
dose-dependent manner, reduce copper (II) to copper (I) and depleting glutathione. OXY 
was able to show higher capability than resveratrol at the same doses, while the trans–
stilbene did not show the activities. The three A. lakoocha extracts also showed damaged 
DNA consistent with the amount of OXY presented. The cytotoxicity of  OXY to different 
kinds of cancer cell lines including Human Caucasian lung carcinoma cells (A549), 
human colorectal cancer cells (CACO–2), Human Caucasian hepatocyte carcinoma cells 
(HepG2), Human breast cancer cells (MCF7), Caucasian prostate adenocarcinoma cells 
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(PC–3), Mouse macrophage cells (RAW 264.7) and the two non-transformed cell lines 
including Human foetal lung cells (MRC–5) and normal human breast cells (MCF10A), 
was investigated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide). Cells were either pre-treated with 50µM Cu(OAc)2 for 24 h, or OXY in the 
medium supplemented with 50µM Cu(OAc)2 then exposed to OXY for 48 h compared to 
the control with no Cu(OAc)2. More than 80% of the cells treated with OXY in the 
presence of copper showed less toxicity than the condition without copper. MCF7 cell 
was the most susceptible to the compound and therefore chosen to be a model studying 
molecular effects. The cells that OXY caused toxicity (IC50) to were MCF7 (30.64±4.79 
µM), HepG2 (104.47±0.82 µM), PC–3 (106.90±8.63 µM), RAW 264.7 (115.95±11.28 
µM) and A549 (148.63±4.48 µM). Whereas, the compound was not toxic to non-
transformed cells (MRC–5 and MCF10A). Moreover, OXY and OXY–copper (II) did not 
increase intracellular ROS and damage the DNA in MCF7 at the concentration 
investigated. MCF7 was chosen to be a cell line model for gene expression investigation. 
The gene-level expression of more than 20,000 human well-annotated genes was 
determined using Clariom Affymetrix microarray under two different OXY treatments 
(50 μM and 100 μM) for 24 h. A total of 686 genes were found to have altered mRNA 
expression levels of two-fold or more in the 50 μM OXY-treated group (262 upregulated 
and 424 downregulated genes). Total 2,338 genes were differentially expressed in the 100 
µM-treated group (907 upregulated and 1,431 downregulated genes). The relevant 
visualized global expression patterns of genes and pathways were generated; genes 
involved in cell cycle control, apoptosis and autophagy, as well as DNA repair, showed 
the greatest differences in expression relative to controls. Gene expression was validated 
by quantitative PCR and western blot protein analysis. OXY induced apoptosis in MCF7 
and HepG2 cells. The cascade events were activated through extrinsic and intrinsic 
pathways through various genes including caspase 3. The final stage was activated 
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resulting in losing cell membrane integrity, losing mitochondrial membrane potential, 
chromatin condensation and eventually cell death. However, OXY did not cause TP53 
activation, ROS generation and severe cellular DNA breakage. OXY also down-regulated 
genes controlling cell migration and metastasis, especially genes in the non–canonical 
pathway (SMAD–independent) such as PI3K/AKT, CXCR4 and its ligand (CXCL12)  
which may consequently affect cell growth, proliferation and cell survival. Interestingly, 
OXY inhibited the gene expression in the cancer DNA repair pathway; the most 
significantly affected were RAD51 (P < 0.0001) and genes in homologous recombination. 
These results indicated that OXY could overcome drug resistance, enhance the efficacy 
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1.1 Cancer and its hallmarks 
Cancer is one of the leading causes of death globally; 9.6 million deaths are estimated to 
occur in 2018 and the new incident number is projected to increase from 18 million in 
2018 to 29.5 million cases in 2040 (WHO, 2020). The most common types of cancer in 
men are lung and prostate cancers while in women are breast, colorectal and cervical 
cancers. The cancer burden continues to grow exerting physical, emotional and financial 
strain on individuals, communities and countries globally.  
Cancer is a multi–step process in which cells proliferate in an excessive and uncontrolled 
manner. Cancer causes major alterations in genetics and epigenetics (Merlo et al., 2006). 
The genetic change is the alteration that modifies the DNA sequence; several thousand of 
the genes (3,000–5,000) encode proteins involved in genetic programmes deregulated in 
cancer. The causes of DNA sequence’s change are point mutations on a genome–wide 
basis, insertions and deletions, copy number changes and genomic rearrangements 
(Stratton et al., 2009). These changes arise through the accumulation of modifications in 
the genetic programmes that control the molecular and cellular activities including cell 
proliferation, cellular defence mechanism, self–repair, cell differentiation, migration, 
relationships with neighbouring cells, and capacity to escape the immune system. This 
process results in the formation of a mass of deregulated cells, which can cause cells to 
become unstable and uncontrollable. For example, a mutation in a gene called Kirsten rat 
sarcoma viral oncogene homolog (KRAS), one of the oncogenes, can promote 
uncontrollable cell division and cell proliferation or the dysfunction of TP53, the cancer 
suppressor gene, which becomes unable to stop the proliferation of cells when needed. 
The other way is epigenetics, which changes the programme of cells such as modifying 
the conformation of chromatin or DNA strands, micro RNA, copying and repairing 







Figure 1 Genetics and epigenetics changes cause a normal cell to be a cancer cell because 
of genome instability and alteration of epigenetic enzymes (Chen et al., 2014). 
 
The causes of genetic and epigenetic changes are numerous. The genome contains 3 
billion base pairs and there may be affected and modified by reactions with a variety of 
chemical, physical and toxicological agents. For instance, some chemicals classified as 
carcinogens can cause changes in DNA bases, bind to them and modify the DNA 
sequence resulting in the mistranslation of the enzymes. UV light can form the pyrimidine 
dimer, called double mutations, which are the signature of mutagenesis by UV light of 
skin cancers. The ionising radiations also induce single or double DNA strand breaks. 
Each time there is a perfect proofreading and repair reading systems. However, the error 
may occur and remain unrepaired, leading to mutation and malignant tumour 
development (Chen et al., 2014).  
In general, cancer cells have defects in the regulation of cell proliferation and 




collectively dictating malignant growth including evasion of programmed cell death 
(apoptosis), self–sufficiency in growth signals, insensitivity to growth–inhibitory 
(antigrowth), limitless replicative potential, sustainment of angiogenesis, and tissue 
invasion and metastasis (Figure 2). 
 
Figure 2 The hallmarks of cancer associated with the six major biological processes 
adapted from Hanahan and Weinberg (2000) 
 
Evasion of apoptosis: The evasion of apoptosis is a key mechanism by which cancer 
develops oncogenes such as BCL–2 are anti–apoptotic activity e.g. BCL-2, BCL-XL, 
BCL-W, MCL-1, BFL-1/A1. The expression of BCL–2 promoted the survival of B–
lymphoid tumours in mice and the co cooperation with c–myc promoted proliferation of 
B–cell precursors, some of which became tumourigenic (Suvarna et al., 2019). One of 
the most common losses of pro–apoptotic activity involved the mutation of TP53 tumour 




The p53 protein has been known to be the DNA damage sensor that induces apoptotic 
cascade (Aubrey et al., 2018). 
Sustainment of proliferative signal: Normal cells maintain their cellular quiescence state 
and homeostasis by receiving growth inhibitors and immobilized inhibitors embedded in 
the extracellular matrix and on the surfaces of nearby cells. The extracellular signals 
couple with transmembrane receptors and then induce the cells from active proliferative 
cycle into G0 phase of the cell cycle. The other mechanism is that the cells are forced to 
stop proliferative potential by being induced to enter into post–mitotic states (Matson and 
Cook, 2017). 
Retinoblastoma protein (pRb) is one of the enzymes playing the crucial role in anti–
proliferative that can block and alter E2F transcription factor that controls the expression 
of many enzymes in the procession of G1 to S phase of the cell cycle (Farra et al., 2019). 
The transforming growth factor–beta family (TGF–β) is a multifunctional cytokine this 
protein can be competitive to pRb by preventing the phosphorylation and inactivating the 
enzyme. Therefore, the cells are blocked through G1 phase. Moreover, TGF–β also causes 
synthesis p15INK4B and p21 proteins, which blocks the reaction of cyclin: CDK and then 
sequentially effects to the pRb phosphorylation (Datto et al., 1997; Principe et al., 2017).  
Insensitivity to antigrowth signals: Cancer cells deregulate the production and release of 
growth–promoting signals to control the progression of cell cycle and growth (Matson 
and Cook, 2017).  
Tissue invasion and metastasis: Metastasis is the process of cancers travelling into the 
other sites and settles new colonies, which the cause of more than 90% human cancer 
deaths (Guan, 2015). Several classes of proteins are involved in this process. The main 




immunoglobulin and calcium–dependent cadherin and integrin protein, which mediates 
the cell–to–cell interaction and link the cells to extracellular substrates (Basu et al., 2018).   
Enablement of replicative immortality: The immortal property of cancers means that they 
could overcome cell senescence to unlimited proliferation. Human cancer cells can 
counter the erosion or shortening of telomeres and losing telomere–binding proteins by 
expressing the significantly vast majority (∼90%) of telomerase enzyme compared to 
normal cells. Mice that lack telomerase activity and are more resistant to cancer (Shay 
and Wright, 2000; Blasco, 2005). 
Induction of angiogenesis: Tumour–associated neovasculature is a process to sustain 
nutrient and oxygen for neoplastic growths. The molecular mechanism of angiogenesis is 
controlled by the inducer or inhibitor, which are vascular endothelial growth factor–A 
(VEGF–A) and thrombospondin–1 (TSP–1), respectively (Hanahan and Weinberg, 
2011). 
According to the knowledge of the cancer hallmarks, this brings about the subsequent 
evolution of cancer treatment; the therapy targeting actionable alterations oncogenes–
driven cancers. Technology such as gene sequencing or human genome project acquire 
tumour molecular profiling and the discovery of predictive molecular targets 
(Zugazagoitia et al., 2016).  
Cancer treatment has become more effective. The combination of gene-targeted therapy 
with immune-targeted approaches to overcome the complexity of tumour biology has 
been developed such as checkpoint blockade, personalized vaccines and/or chimeric 
antigen receptor T-cells), hormonal therapy, chemotherapy and/or novel agents 
(Tsimberidou et al., 2020). However, it found that cancer treatment practically based on 




worsen side effects and drug resistance. There are mainly five types of chemotherapeutics 
including alkylating agents, antimetabolites, anti–microtubule agents, topoisomerase 
inhibitors and cytotoxic antibiotics, of which the mechanism of actions interfere with 
DNA, RNA or proteins regarding blocking DNA synthesis and cell proliferation without 
specificity to cancer cells (Figure 3).  
  
 
Figure 3 Chemotherapeutics and mechanisms of action; there are five types of 
chemotherapeutics including alkylating agents, anti-metabolites, anti-microtubule agents, 
topoisomerase inhibitors and cytotoxic antibiotics that cause DNA damage through 
apoptosis pathway (Huang et al., 2017). 
 
1.2 Cancer drugs from medicinal plants 
Herbal medicines have been used mostly in developing countries as the primary sources 
of medical treatment for human diseases including cancer. They are considered effective, 
less toxic side effects and less cost consuming compared to current chemotherapy (Desai 




presenting in plants such as polyphenols, flavonoids, protein and stilbenoids show 
beneficial health effects and may reduce cancer incidence (Greenwell and Rahman, 
2015). The biological activities of encounter the hallmarks of cancer cells without or less 
toxic effect to normal cells via the various mechanism of actions including reduction of 
cell cycle progression, anti–proliferative effects, inhibition of tumour growth and 
progression, inhibition of cyclin–dependent kinases, immunomodulatory activity, anti–
angiogenesis, migration, invasion and metastasis, inhibition of DNA repair and induction 
of apoptosis (Schnekenburger et al., 2014).   
Numerous phytochemicals, some already in clinical use and others in clinical trials as 
anticancer agents, encounter intracellular targets of cancer cells reported. For instance, 
vincristine is one of the first plant-derived anticancer drugs approved by The United 
States Food and Drug Administration (USFDA) in 1963. It is the alkaloid extracted from 
the leaves of Catharanthus roseus (L.) G.Don, which has been effectively used as 
chemotherapy for acute lymphoblastic leukemia, rhabdomyosarcoma, neuroblastoma, 
lymphomas and nephroblastoma. The mechanism of action involves the interaction with 
the spindle tubulins during mitosis, which leads to the dismissal of cell proliferation (Seca 
and Pinto, 2018). Paclitaxel is the blockbuster of the plant-derived anticancer agent, 
which has a tremendous impact on the pharmaceutical industry. This compound was 
isolated from the bark of Taxus brevifolia Nutt. (Pacific Yew) and then sold under the 
commercial name as Taxol® since 1993. The mechanism of action is tubulin-assembly 
promotion and inhibition of cell proliferation and DNA repair that showed great success 
in the treatment of breast, ovarian and lung cancers (Weaver, 2014; Bernabeu et al., 
2017). Because of the development for the last few decades, there has been generated 
several derivatives such as Lipusu®, Abraxane®, Taxotere® and Jevtana®, which increased 
its effectiveness and reduced side effects (Seca and Pinto, 2018). Another well–known 




molecular mechanisms and pathways against cancer cells by inducing cell cycle arrest, 
autophagy, apoptosis, angiogenesis and invasion/metastasis mediated through 
PI3K/Akt/mTOR, Wnt, ROS, NF–κB, BAX/Bcl–2, AMPK, ERK, MAPK signalling 
pathways (Figure 4) (Kim and Kim, 2018). These phytochemicals have been studied both 
in preclinical and clinical trials. Therefore, further active experimental research on these 
molecules or chemical structure–related compounds can give us a deeper understanding 
of their mechanisms of action and therapeutic effects on cancer or other human diseases. 
 
 
Figure 4 Effect of resveratrol on signalling pathways, Black arrows indicate activation 
cascade, while red lines indicate the inhibition cascade (Kim and Kim, 2018). 
 
Apoptosis is the central mechanism of chemotherapeutics and of most of plant–derived 
anticancer drugs (Cragg and Pezzuto, 2016). Moreover, some polyphenolic compounds 
have been already investigated to have the DNA breakage activity in the presence of only 
themselves or oxidized metal ions. For example, Fe3+, Cu2+, Zn2+ or Ni2+ could trigger the 
Fenton–mediated ROS generation. The pro–oxidant property of phytochemicals was also 
considered one of the mechanisms against cancer cells (Yamada et al., 1985; Lopes et al., 




property of phytochemicals could be used for pre–screening the compounds anti–cancer 




Figure 5 DNA damage causing cell death is the central mechanism of chemotherapeutics 
(Huang et al., 2017). Plant-derived compounds with the pro-oxidant property may 
consequently damage the DNA. 
 
1.3 DNA damage caused by phytochemicals 
Some phytochemicals have antioxidant property. However, they can behave like pro–
oxidants in some conditions such as high concentration, the high partial pressure of 
dioxygen(pO2) or with transition metals such as Cu
2+, Fe3+ or Cr3+ by generating ROS 
such as superoxide (•O2
−), hydroxyl (•OH) or peroxyl (ROO•) radicals (Valko et al., 
2004). All ROS are likely to interact with the cellular components including DNA or 




example, carotenoid presents itself as a pro–oxidant at a higher pO2 condition. Carotenoid 
radical (Carotenoid•) reacts to oxygen generating carotenoid–peroxy radical 
(Carotenoid–OO•), at this stage the radical acts as a pro–oxidant by promoting the 
oxidation of unsaturated lipid (RH). Finally, the lipid radical (R•) reacts to O2 and 
generates peroxy radicals (ROO•); the reactions shown in  Scheme 1 (Valko et al., 2004). 
 
Carotenoid• + O2 → Carotenoid –OO
• 
Carotenoid –OO• + RH → Carotenoid –OOH + R• 
R•   + O2  → ROO
• 
 
Scheme 1 The mechanism of ROS production by carotenoids 
Ascorbic acid is a reducing agent that can also act as a pro–oxidant. Ascorbate in aqueous 
solution is oxidised by ferric (III) or cupric (II) into ascorbyl radicals. Then the reduced 
metals produce the hydroxyl radicals by using hydrogen peroxide through the Fenton 
reaction; the reactions shown in  Scheme 2 (Carr and Frei, 1999). 
 
Ascorbate– + Fe3+ →  Ascorbyl radical + Fe2+  + H+ 
Ascorbate– + Cu2+ →  Ascorbyl radical + Cu1+ + H+ 
H2O2  + Fe
2+  →  •OH  + Fe3+ + –OH 
H2O2  + Cu
1+ →  •OH  + Cu2+ + –OH 
 





Another well–known phytochemical; resveratrol in the presence of transition metals can 
also generate ROS. Resveratrol reduces cupric (II) into cuprous (I), then the cuprous 
reacts with O2 generating superoxide radical (•O2
−), the radical causes directly oxidative 
stress or reacts to hydrogen ions presenting hydrogen peroxide (H2O2). Lastly, the cupric 
ion and hydrogen peroxide in the reaction generate Cu1+Oxo–species complex, which 
damages  DNA; the reactions are shown in Scheme 3 (Subramanian et al., 2004). 
 
Resveratrol + Cu2+ → Cu1+ + Resveratrol·+ 




− + 4H+ → 2H2O2  + O2 
Cu1+  + 2H2O2 → Cu
1+  Oxo–species 
 
Scheme 3 The mechanism of ROS production by resveratrol 
 
The scavenging of ROS in the presence of copper by hydroxystilbenoids, such as 
resveratrol, is thought to be an important mechanism of action against carcinogenesis 
(Alarcon de la lastra and Villegas, 2007; Galindo et al., 2011). 
 
1.4 Copper ions in cancer cells 
Copper plays an important role in biological functions (Kalinowski et al., 2016). 
However, the excess copper also is found to be a potent catalyst of ROS generation and 
DNA damage (Theophanides and Anastassopoulou, 2002). It has also been reported that 




patients. The amount of copper in serum and tissues of cancer patients has been reviewed; 
the data shown were from the different age group of patients (10–50 years old), male and 
female and different geographical locations in a wide spectrum of tumours including 
acute lymphocytic leukaemia, breast cancer, colorectal cancer, lung cancer, ovarian 
cancer and prostate cancer (Gupte and Mumper, 2009). The copper level in serum in all 
kinds of the tumours was significantly higher than in normal patients. The highest 
elevated serum copper was found in acute lymphocytic leukaemia, roughly three times 
higher than the normal (around 100 µg/dL). Breast and colorectal cancer were raised to 
173 and 165 µg/dL, respectively. While in lung, ovarian and prostate cancers were 
increased to lower than 150 µg/dL. In tissues, the amount of copper in all types of cancer 
collected was also higher than in normal tissues. In leukemic cells were also found to 
present around three times higher than the normal (15 µg/106 cells) (Carpentieri et al., 
1986). In the solid tumours, breast cancer tissues gave the highest at 21 µg/g compared 
to the others, which were raised to lower than 5 µg/g. Indeed, the level of copper also was 
investigated in the different progression stages of tumours with later stages if tumour 
progression being associated with higher amounts of serum copper. 
Interestingly, serum copper levels have also been observed to be linked to drug resistance 
in cancer (Majumder et al., 2009). Indeed, cancer patients that did not respond to drug 
treatment demonstrated 130–160% higher levels of copper in their serum than treatment 
responsive patients (Majumder et al., 2009). Moreover, ceruloplasmin (Cp), the major 
copper–carrying protein, was reported to elevate in lung, breast, colon and gastrointestinal 
cancer patients (Linder et al., 1981). In addition, copper has associated with numerous 
angiogenic factors such as basic fibroblast growth factor (bFGF), tumour necrosis factor–
alpha (TNF–α), interleukin 1, IL–6, IL–8 and fibronectin (Carmeliet and Jain, 2000). This 
obvious evidence of raising copper levels in cancers triggers the cancer hallmarks to be 




1.5 Artocarpus lakoocha 
A. lakoocha Wall. ex Roxb. (Family: Moraceae), an indigenous plant in Thailand known 
as Ma–Haad, is widely distributed in the southeast and south Asia. There are different 
common names such as Monkey Jack (English), Dahu or Lakoocha (Hindi). There are 
more than 50 plant species in this genus, which are evergreen and deciduous trees. 
Different parts of the tree such as leaves, bark, stem or fruits contain different kinds and 
proportions of main compounds, which have been shown to possess various biological 
activities such as antibacterial, antiviral, antimalarial, antifungal, antidiabetic, antioxidant 















A. lakoocha have been used in Thai traditional medicine, an aqueous extracted product of 
its heartwood called Puag–Haad, is used for antihelminthic treatment. It has been 
effectively used to treat Taeniasis and other human and cattle parasitic tapeworms and 
also blood and liver fluke infection (Preyavichyapugdee et al., 2016). Moreover, it has 
been found to have strong tyrosinase inhibition activity over kojic acid and liquorice 
extract, and can be used as a potent skin whitening agent (Tengamnuay et al., 2006). The 
water– extracted compound also shows antibacterial activity to Enterococcus faecalis 
(Singhatong et al., 2010; Teanpaisan et al., 2013). The tree bark containing high tannin 
is used to treat skin ailments. Recently, it has been reported to be a valuable resource of 
phenolic compounds including flavonoids, tannins and stilbenoids (Maneechai et al., 
2009; Singhatong et al., 2010). More importantly, stilbenoids, especially OXY, seems to 
be the promising active compound in this natural resource. 
 
1.6 OXY  
OXY (OXY)(C14H12O4, M.W. 244.24 g/mol) is one of the small structure phytochemicals 
belonging to the group of the stilbenoids, which was richest in A. lakoocha heartwood. 
The amount of OXY (182,000 µg/g) and resveratrol (90,000 µg/g) were higher than 
resveratrol presenting in other plants such as grapes (0.5 µg/g), itadori (523 µg/g) or 
peanuts (5.1 µg/g) (Burns et al., 2002; Maneechai et al., 2009; Borah et al., 2017). 
Recently, these compounds have been extensively studied for their efficacy. The chemical 
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Figure 7 Chemical structure of OXY, resveratrol and trans–stilbene 
 
OXY has been shown to possess various potent bioactivities with the main property being 
an antioxidant (Lorenz et al., 2003). With other reported properties being anti–
inflammatory (Lee et al., 2015), anti–herpes, varicella–zoster virus, human 
immunodeficiency virus (HIV) and swine flu virus (Chuanasa et al., 2008; Galindo et al., 
2011), anti–cancer (Rahman et al., 2017), hepatoprotective (Choi et al., 2016), 
neuroprotective and anti–stroke (Andrabi et al., 2004; Weber et al., 2012), DNA 
protective (Hu et al., 2015), anti–diabetes (Tan et al., 2015), antiglycation (Povichit et 
al., 2010) and tyrosinase inhibition (Likhitwitayawuid et al., 2006). In consideration of 
these traditional uses, this compound provides opportunities for the development of 




However, concerns have been raised over the toxicity of the tree’s crude extract and OXY. 
It has been previously reported these compounds might act as pro–oxidants causing lipid 
peroxidation to human blood at the concentration 50 and 100 µg/mL (Singhatong et al., 
2010). Moreover, it has been reported that the chemically related resveratrol and some 
hydroxystilbenes could cause DNA breakage in normal human lymphocyte cells in the 
presence of Cu2+ ion and oxygen (Subramanian et al., 2004).  
 
1.7 Molecular targets of OXY and trans– stilbenoids in cancer cells 
Stilbenoids, such as resveratrol, pterostilbene and piceatannol, has been intensively 
studied for cytotoxicity against cancers and some molecular targets have been identified 
(Varoni et al., 2016). These compounds share a common backbone structure but differ in 
the nature and position of substituents. Therefore, they may share biological activities 
including anticancer properties. At clinical trial resveratrol has been found to have several 
molecular targets, with its efficacy depending upon the type and stage of cancers, dosage 
levels and treatment periods. Moreover, there have been a number of investigations on 
stilbenoids focusing on their cellular mechanism of action (Berman et al., 2017). In 
consideration of the cancer hallmarks mentioned previously. OXY has been shown to 
affect several hallmarks. In particular, it has been found to be a selective target multiple 







Figure 8 Potential molecular targets of anti-cancer compounds adapted from Hanahan 




Apoptosis is the mechanism of programmed cell death activated through two different 
intracellular signals; the intrinsic and extrinsic pathways, which referred to the 
mitochondrial and death receptor signalling, respectively. Cancer therapy targeting 
apoptosis is effective to all types of cancer because apoptosis evasion is one of the 
important hallmarks of cancer (Pfeffer and Singh, 2018).  
OXY has  been reported to induce the  intrinsic pathway of apoptosis in neuroblastoma 
cells (Rahman et al., 2017). Rahman et al. (2017) have provided the supporting evidence 
of the apoptotic cell morphology changes that the OXY–treated cells shrank and became 
rounded with membrane blebbing and apoptotic vacuoles. The molecular targets of this 




mitochondrial apoptosis, resulting in significant changes in the Bax/Bcl–2 ratio and the 
mitochondria membrane potential of neuroblastoma cells was greatly depolarized by 
OXY. Likewise, resveratrol has been intensively investigated for the property of 
apoptotic activation in several cancer cells. For instance, it also increased the expression 
of proapoptotic proteins such as Bax, Bcl–2 –antagonist/killer–1 (Bak), p53 upregulated 
modulator of apoptosis, the Bcl–2 Homology (BH)3–containing proteins, TRAIL death 
receptors (Fulda and Debatin, 2005). Whereas anti–apoptotic proteins including Bcl–2, 
B-cell lymphoma-extra large (Bcl–XL), survivin, and X-linked inhibitor of apoptosis 
protein (XIAP) were downregulated (Shankar et al., 2007). Other stilbenoids derivatives 
including deoxyrhaponticin, rhaponticin, pterostilbene, and piceatannol have also been 
confirmed to exhibit apoptosis induction in human acute promyelocytic leukaemia and 
acute lymphoblastic leukaemia cell lines (Czop et al., 2019). Other phenolic compounds 
including stilbenoids also showed an anti–TRAIL expression property, which could be a 
promising approach to kill resistant cancer cells (Jacquemin et al., 2010). 
 
1.7.2 Anti–proliferative signalling 
Several phytochemicals inhibit cancer cell proliferation by modulating the genes that 
control several aspects of the cell cycle. Cyclin–dependent kinases (CDKs) and E3 
ubiquitin ligases mainly play a crucial role throughout the process (Duronio and Xiong, 
2013).  
OXY inhibited Human SH–SY5Y neuroblastoma cell growth dose–dependently and 
found to arrest G2/M phase. The molecular target was investigated to reduce cyclin D1, 




Resveratrol also caused the growth inhibition of human epidermoid carcinoma (A431) 
cells via cell cycle arrest and apoptosis induction. Treatment with resveratrol (1–50 μM 
for 24 h) causes an induction of WAF1/p21 that inhibits cyclin D1/D2–CDK6, cyclin 
D1/D2– CDK4, and cyclin E–CDK2 complexes, thereby imposing an artificial 
checkpoint at the G1→S transition of the cell cycle (Ahmad et al., 2001). More evidence 
of cell cycle arrest property was investigated via pRb–E2F/DP pathway; 
hyperphosphorylated was decreased with hypophosphorylated pRb was relatively 
increased and E2F protein expression was downregulated (Adhami et al., 2001).  
 
1.7.3 Growth suppression  
Generally, epidermal growth factor (EGF) and related receptor (EGF–R) stimulate cell 
growth and differentiation while transforming growth factor–beta (TGF–β) functions as 
a potent cell proliferation inhibitor (Plaut, 1993). Resveratrol shows antigrowth signalling 
activity by inhibiting EGF and related receptor (EGF–R), a transmembrane tyrosine 
kinase activated by ligands and TGF–β. In breast cancer cells, TGF–β promotes the 
migration and invasion abilities of breast cancer cells, along with the increase in EGFR 
expression through Smad3 signalling pathway (Zhao et al., 2018). Some studies 
illustrated that TGF–β, IGF1 and EGF signalling inhibitors could be the key mechanism 
of cancer therapeutics (Yingling et al., 2004). Resveratrol also showed the growth 
inhibition in SKOV–3 and OVCAR–8 ovarian cancer cells by the cleaving PARP–1, 
reducing the phosphorylation of human epidermal growth factor receptor 2 (Her–2), 





1.7.4 Anti–migration, anti–invasion and metastasis 
OXY suppressed cell migration of Jurkat T cells in response to stromal cell-derived factor 
1 (SDF–1). The mechanistic study indicated that OXY diminished CXCR4 –mediated T–
cell migration via inhibition of the MEK/ERK signalling cascade (Chen et al., 2013). 
Resveratrol showed anti–migration and invasion by down–regulating and inactivating 
Akt. Moreover, the compound also showed its efficacy in in vivo experiment by oral 
administration of 1 mg resveratrol in the malignant mouse model in three weeks. 
Interestingly, the tumour volume was inhibited more than 60% (p=0.001) compared to 
the control group. The study was concluded that resveratrol could reduce the malignant 
properties of highly invasive melanoma cells by inactivating Akt (Bhattacharya et al., 
2011). The other stilbene, Pterostilbene suppressed AKT/ERK–regulated assembly on 
suspended Lewis lung carcinoma cells and pulmonary metastasis. The compound also 
possessed potency in both preventing and treating metastasis of lung cancer cells in 




Autophagy meaning, “self–eating”, is an evolutionarily conserved catabolic pathway in 
eukaryotes and it plays a significant role in the recycling of cellular components as part 
of a housekeeping function. A compound–triggered cell via this pathway was described 
to be a promising, novel mechanism for enhancing anticancer treatments and overcoming 
current challenges such as chemotherapy resistance (Duffy et al., 2015). During 
autophagy, some autophagy–related proteins were activated such as Beclin1, Atg5, Atg6, 
Atg12 and LC3 and played an essential role in mediating autophagosome initiation and 




autophagy independently from apoptosis in neuroblastoma cells. The molecular targets 
were mostly via inhibition of PI3K/AKT/mTOR/pS6 signalling and activation of p38 
MAPK pathway (Rahman et al., 2017). 
 
1.7.7 PARP and other DNA repair inhibitors 
Poly (ADP–ribose) polymerases (PARPs) are enzymes involved in DNA–damage repair. 
Recently, inhibition of PARP is a promising strategy for targeting cancers with defective 
DNA–damage repair, including BRCA1 and BRCA2 mutation–associated breast and 
ovarian cancers (Livraghi and Garber, 2015). The original concept of the activity of PARP 
inhibitors was that they acted through synthetic lethality by targeting the base excision 
repair pathway (BER) in BRCA–deficient tumour. Therefore, disruption of the two 
pathways led to cell death (Iglehart and Silver, 2009). Resveratrol has been reported to 
show cleavage induction of PARP1 (Demoulin et al., 2015). The compound also reduced 
the expression of genes in homologous recombination (HR) of the DNA damage repair 
pathway including RAD51 in MCF7 cells, which enhance the antiproliferative effect of 
cisplatin (Leon-Galicia et al., 2018). RAD51 is an important part of the mechanism and 
has been observed that the gene was overexpressed in chemoresistant cancers (Slupianek 
et al., 2001; Hannay et al., 2007).  
 
1.7.8 Inhibitors of VEGF signalling (angiogenesis)  
The vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have been 
shown to play major roles not only in physiological but also in most pathological 
angiogenesis such as cancers. The major VEGF–A ligand is a single gene product and it 
utilizes only two receptors (VEGFR–1 and VEGFR–2) involved in pathological 




micro–lymphatic vessel density in the lymph node metastasis by inhibiting the expression 
of CD31, VEGFR3, and VEGF–C (Liu et al., 2018). More evidence from resveratrol, it 
also has the synergised effect of paclitaxel on EBC–1 cells through p27kip1, E–cadherin, 
EGFR and Bcl–2 expression (Kubota et al., 2003).   
 
1.7.9 Anti–inflammatory 
Epidemiological studies have revealed that chronic inflammation predisposes to different 
forms of cancer. Molecular and cellular pathways linking inflammation and cancer have 
been identified. The main pathway linking to inflammation and cancer includes 
transcription factors (e.g. nuclear factor kappa–B (NFκB)), cytokines (e.g. TNF), and 
chemokines (Mantovani et al., 2010). OXY showed anti‐inflammatory properties in 
murine macrophage cell line RAW 264.7 by inhibiting the nitric oxide synthase (iNOS) 
and cyclooxygenase-2 (COX‐2) expression through down‐regulation of NF‐kB binding 
activity (Chung et al., 2003). 
There have been studies that have identified the molecular targets of stilbenoids on 
various kinds of cancer. The molecular targets and pathways in cancer cells of OXY are 



















Neuroblastoma  G2/M phase arrest, cyclin D1, 
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1.8 Aims & Objectives 
The aim of this research was to investigate the cytotoxicity of OXY and its effects 
on the expression of genes associated with the hallmarks of cancer. 
Objectives 
 Investigate and verify the phytochemical profile of A. lakoocha heartwood 
as a major source of OXY (Chapter 3). 
 Investigate the pro–oxidant activities of OXY and other stilbenoids in the 
presence and absence of copper (cell–free) (Chapter 4). 
 Identify a cell line model (transformed and non–transformed) in which 
cytotoxicity is demonstrated in response to OXY (with and without 
copper) (Chapter 5).  
 Elucidate gene–level expression profile, and assess changes in key genes 
and pathways that involved in the biological response to OXY using 
microarray and quantitative polymerase chain reaction analysis (Chapter 6). 
 Investigate the expression of key genes in apoptosis, cell proliferation, 
metastasis and DNA repair pathways following treatment with OXY 



































The materials and methods utilised in this research are listed in this chapter, along with 
the procedures and protocols.  
 
2.1 General chemicals 
 
Table 2 General chemicals and suppliers 
Chemicals Company City/ Country 
2′,7′ dichlorodihydrofluorescein 
diacetate (H2DCFDA) 
Sigma–Aldrich Jerusalem, Israel 
5,5′–dithiobis (2–nitrobenzoic 
acid) 
Sigma–Aldrich Saint Louis, MO, USA 
Acetic acid Thermo Fisher 
Scientific 
Waltham, MA, USA 
Acetonitrile, HPLC grade Thermo Fisher 
Scientific 
New York, NY, USA 
Bathocuproinedisulfonic acid 
disodium salt hydrate 
Sigma–Aldrich New South Wales, 
Australia 
Copper acetate (CuOAc2) 
(99.99%) 
Sigma–Aldrich Darmstadt, Germany 




New York, NY, USA 





Table 2 Continue 
Ethyl acetate Sigma–Aldrich Darmstadt, Germany 
Ethylene diamine tetraacetic acid, 
anhydrous (≥99%) 
Sigma–Aldrich  Darmstadt, Germany 
Glutathione reduced Sigma–Aldrich Tokyo, Japan 
Hoechst 33342 Thermo Fisher 
Scientific 
New York, NY, USA 




New York, NY, USA 
Iron (III) chloridehexahydrate 
(FeCl3·6H2O) (≥99%) 
Sigma–Aldrich Saint Louis, MO, USA 
Methanol Fisher Scientific Loughborough, UK 
NMR solvents including water 
(D2O), methanol (CD3OD), 
dimethyl sulfoxide (DMSO–d6) 
and acetone (acetone–d6) 
Cambridge Isotope 
Laboratories 
Tewksbury, MA, USA 
OXY (>97%) Sigma–Aldrich  Buchs, Switzerland 
Resveratrol (>99%) Sigma–Aldrich Saint Louis, MO, USA 
Trans–stilbene (96%) Sigma–Aldrich Milan, Italy 





2.2 Cell lines, media and reagents 
 
Names and tissues of origin of each cell lines used in this study are listed in Table 3 and 
media and reagents regarding cell culture work listed in Table 4. CACO–2, MCF7 were 
purchased from European Collection of Authenticated Cell Cultures (ECACC) 
(Salisbury, UK); while HCC1937 and MCF10A were from the American Type Culture 
Collection (ATCC) (Manassas, VA, USA); and the other cells were obtained from Dr 
Kenneth Ritchie cells bank (LJMU, Liverpool, UK). 




Adenocarcinoma human alveolar basal epithelial cells  
CACO–2 
Human colorectal cancer cells 
HCC1937 
Human breast cancer cell line (invasive cells) 
HepG2 
Human Caucasian hepatocyte carcinoma cells 
MCF7 
Human breast adenocarcinoma cells 
PC–3  
Human prostate cancer cell line 
RAW 264.7 
Mouse blood cells 
MRC–5 
Human foetal lung cells 
MCF10A 








Table 4 Media, reagents and suppliers 
Media/ reagents Company City/ Country 
0.25% trypsin/EDTA Sigma–Aldrich Saint louis, MO, USA 
0.4%Trypan blue stain Thermo Fisher 
Scientific 
New York, NY, USA 
1 M HEPES solution, pH 7.0–7.6 Sigma–Aldrich Darmstadt, Germany 
Agarose BioReagent, low EEO Sigma–Aldrich Saint Louis, MO, 
USA 
Cholera toxin Sigma–Aldrich Darmstadt, Germany 
Doxorubicin Sigma–Aldrich Saint Louis, MO, USA 
Dulbecco’s modified eagles 
(DMEM, high glucose) 
Biosera Europe Nuaille, France 
Dulbecco's modified eagle 




New York, NY, USA 
Foetal Bovine Serum (FBS) Thermo Fisher 
Scientific 
New York, NY, USA 
Horse serum Thermo Fisher 
Scientifi 
North Shore City, 
New Zealand 





Table 4 Continue 
Mammary Epithelial Cell Growth 
Kit 
ATCC Manassas, VA, USA 




New York, NY, USA 




New York, NY, USA 
pBR322 Supercoid plasmid DNA Thermo Fisher 
Scientific 
Vilnius, Lithunia 
Penicillin–Streptomycin (100X) Biosera Boussens , France 
Phosphate buffer saline (PBS) Sigma–Aldrich Saint louis, MO, USA 
Sodium Pyruvate (100 mM) Thermo Fisher 
Scientifi 
Paisley, UK 
Thiazolyl blue tetrazolium 
bromide (MTT) (98%) 
Sigma–Aldrich Saint Louis, MO, USA 











Table 5 Equipment and suppliers 
 
Equipment Company City/ Country 
High-Performance Liquid 
Chromatography (HPLC); the 
analysis was performed on a 
Phenomenex liquid chromatography 
system consisting of a Chomeleon 
system, WPS–3000TSL Autosampler 
and DAD–3000 detector 
Thermo Fisher 
Scientific  
New York, NY, USA 
Luna@ C18 column (4.6 mm×15cm, 
5 μm) 
Phenomenex Torrance, CA, USA 





Refrigerated centrifuge, 810R Eppendorf Hamburg, Germany 
Inverted microscope, Olympus 





Microplate reader, Clariostar MBG Labtech 
GmBH 
Ortenberg, Germany 
Gel documentation imaging system Bio–Rad Hercules, CA, USA 






All statistical analysis was carried out using Microsoft excel 2016 or GraphPad Prism 8 
(GraphPad Software, La Jolla, CA, USA). 
2.4.1. Investigate and verify the phytochemical profiles of A. lakoocha heartwood 
2.4.1.1 Plant collection  
A. lakoocha heartwood was collected from Chanthaburi province of Thailand seen in 
Figure 9, in June 2018. The voucher specimens were identified as DMSC 5237 and 
deposited voucher specimens at DMSC International Herbarium, Department of Medical 














Figure 9 Map showing Thailand geographical position and Chanthaburi province where 





2.4.1.2. Plant extraction  
2.4.1.2.1 Reflux extraction 
The heartwood was ground into a powder and dried until constant weight. The dried 
powder was extracted with two different solvents including distilled water and ethanol 
using reflux extraction method modified from Borah et al. (2017) as briefly described; 
250 g of the powder was filled in a round–bottomed flask containing 3,000 mL of solvent 
and connected to a reflux condenser. Constant boiling temperature and agitation were 
maintained throughout the 1.5 h. Afterwards, the solvent was collected and then the plant 
particles were further extracted with the fresh solvent and repeated twice the same 
procedure. All of the extracted solvents were pooled, filtered and dried by rotary 
















2.4.1.2.2 Soxhlet Apparatus 
Ethyl acetate fraction extracted by Soxhlet apparatus (showed in Figure 11) as briefly 
described; 800 g of dried powder was extracted with 4,500 mL ethyl acetate using Soxhlet 
apparatus constant boiling temperature and agitation were maintained for 18–h extraction 
period. Afterwards, the solvent was collected and filtered. Finally, the extract was 

















2.4.1.3 Preparation of standard solutions and quality control samples. 
Standard stock solutions of OXY and resveratrol were prepared at the concentration of 
1000  µg/mL in methanol. Then the stock solution was subsequently 2–fold diluted to 
obtain 5 different concentrations of working solution in the ranges 12.20–200.00 μg/mL 
for OXY and 1.25–20.00 μg/mL for resveratrol. All the solutions were freshly prepared 
in the vessel protected from light in the day of analysis.  
The sample solutions of the extracts were prepared at the concentration 1000  µg/mL in 








methanol and sonicated for 1 min. The volume was adjusted to reach 5 mL in volume 
metric flasks. Finally, the solutions were filtered by the solid phase extraction before 
analysing by HPLC. 
2.4.1.4 High–performance liquid chromatography  
 
HPLC was performed to analyse the amount of OXY and resveratrol. The standard curves 
of the two compounds were created to qualify the total content in A. lakoocha’s extracts. 
The phytochemical profiles of the three extracts were generated based on their retention 
times and UV spectra. The mobile phase was (A) water (0.5% acetic acid) and (B) 
acetonitrile using a gradient elution of 10–50% (v/v) B at 0–30 min, 50–100 % (v/v) B at 
30–33 min, 100 % B (v/v) at 33–35 min and 100–10 % (v/v) B at 35–37 min. The flow–
rate and injection volume were set at 1.0 mL/min and 20 μL, respectively.  
2.4.1.5 Nuclear magnetic resonance 
 
1H–NMR (600 MHz) spectra were used to investigate the configuration (cis– or trans–), 
purity of the compound and configuration stability of the compounds using TMS (for 1H–
NMR) as an internal standard at 25°C. OXY was dissolved in four different solvents 
including water–d2, methanol–d4, dimethyl sulfoxide–d6 and acetone–d6 and then all 
solutions were transferred to 5 mm NMR sample tubes and then measured 1H–NMR. 
 
2.4.1.6 In–Line Liquid Chromatography/ Mass Spectrometry  
 
Analyses were performed using an inline Liquid Chromatography–Ultraviolet–Mass 
Spectroscopy (LC–UV–MS) system equipped with an electrospray ion source. All of the 




Waters 2695 series Alliance quaternary pump (Waters, Milford, MA, USA) equipped 
with model Waters 2487 dual λ absorbance detector. Injection volume was 20 μL. The 
LC column was 150 x 4.6 mm Luna C18 packed with 5 µm particles. A Luna C18 
cartridge C18 was used as the pre–column. The mobile phase consisted of aqueous formic 
(A) and acid acetonitrile (B) at the flow rate of 1 mL/min. The solvent delivered to the 
ESI interface was split in a 1:3 ratio, delivering 300 μL/min to the interface. Waters 
Micromass LCT instrument (Micromass, Manchester, UK) equipped with a 
pneumatically assisted electrospray interface. The system was controlled by Masslynx 
software version 3.4 (Micromass). The nebulizing gas (nitrogen, 99.999% purity) and the 
desolvation gas (nitrogen, 99.999% purity) were delivered at flow rates of 20 and 700 
L/h, respectively. Infusion experiments were conducted by infusing the standard solution 
of OXY (100 µg/mL) with a Harvard syringe pump (Harvard Apparatus, South Natick, 
MA, USA) at the flow rate of 20 μL/min. Full scan LC–MS analyses were carried out in 
positive ion mode. Optimized conditions of the interface were as follows: capillary 
voltage, 3 kV; cone voltage, 30 V; rf lens, 300 V; source temperature, 100 °C; desolvation 
temperature, 200°C. Full–scan mass spectra were acquired over the scan range m/z 150–
1000. 
 
2.4.2 Investigate the pro–oxidant of OXY and other stilbenes in the presence and 
absence of copper in a cell–free environment 
2.4.2.1 DNA nicking assay 
 
The reaction mixture (total volume 20 μL) contained 10 μL pBR322 plasmid DNA (200 
ng) and Cu(OAc)2 (50 µM) or 50 µM FeCl3 or 50 µM ZnCl2 in 10 μL of 10 mM HEPES 
buffer pH 7.2. The stock solutions of OXY, resveratrol and trans–stilbene were prepared 




heartwood extracts were prepared at the concentration of 1.00 mg/mL, total volume 5 
mL, in 1% (v/v) DMSO/Milli–Q water.  
To study the effect of OXY to cause nicks in DNA; the stock compound was diluted to 
six different concentrations including 1000, 500, 250, 50, 10 and 2 µM, respectively. The 
reactions were initiated by adding 5 μL of each dilution into 20 μL of the reaction mixture 
so that the final concentrations were 200, 100, 50, 10, 2 and 0.40 µM, respectively. After 
the addition of the compound, the tubes were incubated at 37 °C for 15 min.  
To study the effect of chelating metals to cause nicks in DNA; the three chelating metals 
including Cu(OAc)2, FeCl3·6H2O and ZnCl2 were prepared at the concentration of 50 µM 
in 10 mM HEPES buffer pH 7.2. OXY at the concentration of 50 µM was chosen to test. 
The reactions were initiated by adding 5 μL of OXY into each of the reaction mixtures 
and incubated at 37 °C. 
To study the effect of the amount of Cu(II) to cause nicks in DNA in the presence of a 
fixed concentration of OXY. The six different doses of Cu (II) were diluted including 
200, 100, 50, 10, 2 and 0.40 µM, respectively. OXY was chosen at the dose of 50 µM 
contained 200 ng of the plasmid DNA as the reaction mixture. The 10 μL of each diluted 
concentration was mixed with 10 μL of OXY. All tubes were spun down and incubated 
at 37 °C. 
To study the effect of other stilbenes to cause nicks in DNA; resveratrol and trans–
stilbene were prepared at the concentration of 50 µM in 10 mM HEPES buffer pH 7.2. 
Additionally, the three A. lakoocha heartwood extracts including water, ethanol and ethyl 
acetate fractions were also investigated and prepared at the concentration of 1.00 mg/mL 
in the presence and absence of Cu(OAc)2. The other two stilbenes were added into the 
reaction mixture the same volume as OXY. While each fraction of the A. lakoocha’s 




3.13 µg/mL, respectively. The reaction was initiated by adding 5 μL of each compound 
into 20 μL of the reaction mixture and incubated at 37 °C for 15 min. 
After the incubation, the reaction was terminated by placing the tubes on ice and adding 
DNA gel loading dye before loading to 0.8% agarose gel, which was consisted of 2 μL of 
Gelred. The samples were loaded in the gel and subjected to electrophoresis at 75 V for 
1.50 h. After the running period, the gel was removed and visualized under UV light. The 
image of the gel was quantified by Bio–Rad documentation imaging system. 
 
2.4.2.2 Reactive oxygen species assay 
DCFH2 preparation 
Total 2.5 mg of 2',7'–dichlorodihydrofluorescein diacetate (H2DCFDA) was weighed and 
dissolved in 5 mL methanol, then 500 μL of the solution was added to 2 mL of 0.01 N 
sodium hydroxide (NaOH). The mixed solution was incubated for 30 min at room 
temperature. After that 8 mL of 10 mM HEPES buffer pH 7.2 was added. In this 
experiments, 50 μL of this solution was added to the reaction solutions in 96–well plate 
format so that the final concentration of H2DCFDA was 10 μM as previously described 






Figure 12 H2DCFDA transformation to DCF (Fluorescent) 
  
 
ROS assay of OXY, stilbenes and the extracts 
The stock solution of OXY was freshly prepared at the concentration of 1000 µM in 1% 
DMSO/Milli–Q water, volume 5.00 mL. Then, it was 2–fold serially diluted for different 
eight concentrations of 3.13–400.00 µM. Total 100 μL of each concentration was pipetted 
into each well of the 96–well plate for triplicates. The reaction was initiated by adding 50 
μL of 200 µM Cu(II) or HEPES buffer into each well to make 200 μL total volume so 
that the final concentration of OXY were 200, 100, 50, 25, 12.50, 6.25, 3.13  and 1.56 
µM, respectively. After addition, the tubes were incubated at 37 °C for 15 min. DCF, the 
fluorescence product of the reaction, was quantitated spectrofluorimetrically with 
excitation and emission wavelengths of 492 nm and 525 nm, respectively. 
Resveratrol and trans–stilbene were also prepared at the concentration of 1000 µM in 1% 




Moreover, the thee solutions of A. lakoocha heartwood extracts were prepared at the 
concentration of 1.00 mg/mL in 1% DMSO /HEPES buffer and was investigated the ROS 
production at the concentration of 1.56–200 µg/mL. 
 
2.4.2.3 Copper reducing assay 
 
Cu(II) reduction by OXY was determined colourimetrically using the Cu(I)–stabilizing 
reagent bathocuproine disulfonic acid adapted from Subramanian et al. (2004). The stock 
solution of OXY (resveratrol or trans–stilbene) was prepared at the concentration of 1000 
µg/mL and diluted to eight different concentrations between 3.13–400 µg/mL in 10 mM 
HEPES buffer pH 7.0. The reaction mixture (total volume for each tested concentration 
200 μL) contained 50 μL of 2,000 mM bathocuproine disulfonic acid and 100 μL of OXY 
in 10 mM HEPES buffer. The reaction was initiated by adding 50 μL of 200 mM 
Cu(OAc)2 in the sample tubes and the absorbance of the mixture at 484 nm was read at 
the end of 5 min. Appropriate blanks, without OXY, were used in each experiment. The 







Figure 13 Formation of Cu(I)–stabilizing reagent bathocuproine disulfonic acid 
 
 
2.4.2.4 Glutathione (GSH) assay 
Standard curve of glutathione 
Glutathione stock solution was prepared at 4,000 nmol/mL, volume 5.00 mL in phosphate 
buffer–EDTA. Then it was diluted to different ten concentrations between 7.51–100 
nmol/mL of 200 μL total volume. The triplicates of each concentration were measured by 
adding 20 μL of 2.5 mM solution of 5,5′–dithiobis (2–nitrobenzoic acid) (DTNB) in 
phosphate buffer/EDTA (pH 7.0). The yellow reaction product of 5′–dithiobenzoic acid 











Figure 14 Transformation of 5,5′–dithiobis (2–nitrobenzoic acid) (DTNB) to 5′–
dithiobenzoic acid (TNB) 
 
 
GSH assay of OXY, resveratrol and trans–stilbene 
OXY was prepared at the concentration of 1000 µM and was diluted to seven different 
concentrations in phosphate buffer (pH 7.0) with and without 100 µM Cu(OAc)2. Each 
concentration of OXY (50 μL) was initiated by adding 50 μL Cu(II)(50 µM) or PBS. The 
mixtures were incubated at 37ºC for 30 min. After that, 100 μL of 100 nmol/mL GSH in 
PBS–EDTA was added to 96–well microliter plates and continued incubation for 1 h. The 
GSH was detected by adding 20 μL of 2.5 mM solution of 5,5′–dithiobis (2–nitrobenzoic 
acid) (DTNB) in phosphate buffer/EDTA (pH 7.0) by spectrophotometry at the 





2.4.3. In-vitro cytotoxicity assays  
2.4.3.1. Growth curve study 
 
The growth of cells in a 96–well plate was studied to ensure that cells number was suitable 
and cells were grown in the log phase of the growth by counting the cell under the 
microscope. CACO–2, HepG2, MCF7, and MRC–5 cells were cultured in EMEM. While, 
A549, PC–3 and RAW 264.7 cells were maintained in DMEM; both EMEM and DMEM 
media were supplemented with 2 mM glutamine, 1% (v/v) NEAA and 10% (v/v) FBS in 
cell culture incubator at 37°C and 5% CO2. Whereas, MCF10A cells were cultured in 
DMEM/F12 medium supplemented with 5% horse serum, 20 ng/mL Epithelial growth 
factor, 0.5 mg/mL hydrocortisone, 100 ng/mL cholera toxin, 10 µg/mL insulin and 1X 
penicillin–streptomycin. All cells were maintained in growth media. On the day of the 
experiment, the cells were trypsinised, resuspended with the medium and centrifuged to 
collect the cells. After receiving the cell pellet, the medium solution was discarded and 
resuspended the pellet with fresh growth medium. The viable cells were counted using a 
haemocytometer and trypan blue stain. The non–viable cells would be stained in blue. 
The viable cells were counted and the cell density was recorded. The cell suspension 
volumes were calculated to make the initial cell density at 5x103, 7 x103, 1x104 and               
2 x104 cells per well. Each cell group was seeded in duplicated wells to be counted daily 
for four consecutive days. The cell number was counted each day and average±SD cells 







2.4.3.2 Cell viability using MTT assay 
 
Total 1.2 mg of OXY was dissolved in 5 mL 1% DMSO/growth medium to reach 1000 
µM and then diluted to 200 µM as a working solution. It was serially 2–fold diluted for 
seven concentrations for cell treatment. Doxorubicin was used as a standard drug in the 
experiment (Chatsumpun et al., 2016). The stock solution was prepared at 2 mg/mL and 
then was diluted to 10 µg/mL as a working solution. It was serially 2–fold diluted for 
seven concentrations for cell treatment. Total 0.5 mg/mL MTT solution was prepared by 
dissolving 50 mg in 10 mL PBS. It then was diluted 10 times before incubating with cells. 
Cells were seeded at 5x103 cells (1x104 cells for MCF7 and PC–3) (optimal growth) in 
100 μL medium per well of 96–well plates and left in the incubator for 24 h. The medium 
was removed and the cells were treated with eight different concentrations of OXY in 
triplicate and then incubated for 48 h. The medium was removed and 200–μL MTT 
reagent was added in each well, and then continued to incubate for 4 h. The MTT solution 
was discarded and 100 μL DMSO was added to each well to dissolve the purple formazan 
product. The cell control did not add the tested chemical and the blank wells were no 
seeded cells used for determining background absorbance. The absorbance of the 
formazan product of viable cells was read using the microplate reader at 570 nm. The 
mean absorbance and standard deviation were calculated for each concentration of OXY, 
controlled cells and blank. The background absorbance was reduced by the blank. The 
mean % cell viability was calculated as follows; 
 





The 50% inhibitory concentration (IC50) was calculated using GraphPad software. The 





Figure 15 MTT transformation to formazan 
 
2.4.3.3 Toxicity of OXY to cancer cells in the presence or absence of copper 
 
Copper (II) acetate was diluted with cell media to between 1–200 µM and then cells 
treated the cells using an MTT assay described above. The non–toxic concentration of 
copper for each cell was chosen to investigate the toxicity of OXY in the presence and 
absence of copper; the investigation was separated into two procedures. The first, cells 
were pre–incubated with 50 µM Cu(OAc)2 (OXY–Pre–Cu
2+) for 24 h in 96–well plate, 
after that the cells were rinsed with the culture medium and replaced with different 
concentrations of OXY for 48 h. The other procedure was that the cells were treated for 
48 h with different concentrations of OXY (without copper pre–incubation), which was 
diluted with medium supplemented with 50 µM Cu(OAc)2(OXY–Cu
2+). Cell viability 




The cell lines which had demonstrated OXY toxicity (IC50 ≤ or around 100 µM) were 
chosen to investigate further (pre–treatment with different concentrations of copper). 
Four different concentrations of copper at 25, 50, 100 and 200 µM were used for pre–
treatment. Then they were treated with OXY for 48 h. The cell viability was detected 
using MTT assay.  
The intracellular ROS production was also investigated. Cells were pre–treated with 
different concentrations of copper at the dosed of 25, 50 and 100 µM, and then treated 
with OXY. They were determined intracellular ROS levels generated at the time 2, 6, 24 
and 48 h of the incubation followed the protocol described by (Panich et al., 2012). The 
cells were washed twice with 100 μL PBS and then incubated with 5µM DCFH2DA for 
1 h at 37ºC. DCF fluorescence intensity of ROS formation was evaluated by 
spectrofluorometry at the excitation/emission wavelength of 485/530 nm. The data were 
expressed as the percentage of intracellular oxidant formation (relative fluorescence units, 
RFUs) of the control cells. 
 
2.4.4 Investigation of the mechanisms of action 
2.4.4.1 Microarray gene expression assay 
RNA extraction 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany) pre–
treated with on–column DNase digestion with RNase–free DNase set (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. RNA was recovered in 30 μL of 
nuclease–free water and stored at −80°C until further analysis. The amount and quality 
of the RNA samples were analysed by NanoDrop2000 Thermo Fisher Scientific (New 




RNA integrity using the 2100 Expert Software (Agilent Technologies, Palo Alto, CA, 
USA). RNA integrity numbers were measured from 8.1 to 9.0.  
 
Amplification and labelling process 
Total RNA was processed using GeneChipTM WT PLUS Reagents (Thermo Fisher 
Scientific, Palo Alto, CA, USA) containing WT amplification kit module 1, WT 
amplification kit module 2, Poly–A RNA Control Kit, WT Terminal Labelling Kit and 
Hybridisation Control Kit. The workflow step of the amplification and labelling process 







Figure 16 Amplification and labelling process, the RNA sample was converted into 
cDNA and then the second-strand cDNA was synthesised and used as a template for 
cRNA amplification. In the last amplification process, the sense-strand DNA (with dUTP) 
was generated, fragmented using UDG & APE1and labelled with biotin. Finally, the oligo 




Prepare total RNA/poly–A RNA control mixture 
 Total 3 μL of total RNA samples (100 ng total input) were prepared, and then added 2 
μL of the 4th dilution Poly–A spike controls, for a final volume of 5 μL each sample. 
Synthesis first–strand cDNA 
In the reverse transcription procedure, total RNA was primed with primers containing a 
T7 promoter sequence. The reaction synthesised single–stranded cDNA with T7 promoter 
sequence at the 5' end.  
The procedure was briefly described; the first–strand master mix was prepared in a 
nuclease–free tube on ice (4 μL first–strand buffer and 1 μL first–strand enzyme for a 
reaction). The tubes were thoroughly mixed by gentle vortexing and then were briefly 
centrifuged. The 5 μL of the total RNA/Poly–A RNA control mixtures were transferred 
into the tube containing 5 μL of the first–strand master mix, the samples were thoroughly 
mixed by gentle vortexing. The sample tubes were incubated in a thermal cycler for 1 h 
at 25°C, then for 1 h at 42°C, and finally incubated for at least 2 min at 4°C. After the 
incubation, the tubes were immediately centrifuged to collect the first–strand cDNA at 
the bottom of the tube or well and then the samples were placed on ice for 2 min before 
proceeding immediately to the next step. 
Synthesis second–strand cDNA 
In this procedure, the single–stranded cDNA was converted to double–stranded cDNA, 
which acted as a template for in vitro transcription. The reaction used DNA polymerase 
and RNase H to simultaneously degrade the RNA and synthesis second–strand cDNA. 
The second–strand master mix was prepared in a nuclease–free tube on ice, which 




reaction (total volume 20 μL). The master mix was gently vortexed and briefly 
centrifuged. The 20 μL was transferred to each first–strand cDNA sample (10 μL) for a 
final reaction volume of 30 μL, then the tubes were gently vortexed and briefly 
centrifuged. The sample tubes were incubated in a thermal cycler for 1 h at 16°C, then 
for 10 min at 65°C, then the last for at least 2 min at 4°C. After that, the samples were 
briefly centrifuged to collect the second–strand cDNA, before proceeding to the next step. 
 Synthesis cRNA by in vitro transcription 
In this procedure, antisense RNA (complementary RNA or cRNA) was synthesised and 
amplified by in vitro transcription (IVT) of the second–stranded cDNA template using 
T7 RNA polymerase. 
The IVT master mix containing 24 μL IVT Buffer and 6 μL IVT Enzyme (30–μL total 
volume) was prepared at room temperature. Total 30 μL of the second–strand cDNA 
samples were transferred to each IVT master mix (30 μL) for a final reaction volume of 
60 μL. The tubes were gently vortexed and briefly centrifuged. The sample tubes were 
incubated in a thermal cycler for 16 h at 40°C, and then at 4°C. The samples were briefly 
centrifuged and then proceeded to purify cRNA. 
The cRNA products were purified using the purification beads. Total of 100 μL beads 
were added to each (60 μL) cRNA sample. Then, it was mixed by pipetting up and down 
10 times and transferred to a well of a U–bottom plate. The samples were incubated for 
10 min. The sample plate was moved to a magnetic stand to capture the purification beads 
catching cRNA. After 10 min placing, the supernatant was carefully aspirated and 
discarded without disturbing the beads. The plate was still kept on the magnetic stand, a 
200 μL of 80% ethanol wash solution was added to each well and incubated for 30 s. The 
wash solution was slowly aspirated and discarded from each well. The beads were washed 




completely removed, air–dried on the magnetic stand for 5 min until no liquid is visible. 
The plate was then removed from the magnetic stand, and 27 μL of the preheated (65°C) 
nuclease–free water was added to each sample. The sample was incubated for 1 min, then 
mixed by pipetting up and down 10 times. The plate was then moved back to the magnetic 
stand and placed for ~5 min. The supernatant which contained the eluted cRNA was 
transferred to a nuclease–free tube. The purified cRNA samples were placed on ice, RNA 
Yield was determined by UV Absorbance and quantified by 2100 Bioanalyzer 
Instrument. 
Synthesis 2nd–cycle single–stranded cDNA 
In this procedure, sense–strand cDNA is synthesised by the reverse transcription of cRNA 
using 2nd– cycle primers. The sense–strand cDNA contained dUTP at a fixed ratio relative 
to dTTP. Total 15 μg of cRNA was required for 2nd–cycle single–stranded cDNA 
synthesis. 15 μg cRNA in a volume of 24 μL(625 ng/μL) was prepared and placed on ice. 
The cRNA sample was added to 4 μL of 2nd–cycle primers, then thoroughly mixed and 
briefly centrifuged. The sample tubes were incubated for 5 min at 70°C, then 5 min at 
25°C, and the last for 2 min at 4°C. After that, the tubes were briefly centrifuged and 
immediately placed on ice. The 2nd–cycle ss–cDNA master mix was prepared by pipetting 
8 μL of 2nd–cycle ss–cDNA buffer and 4 μL of 2nd–cycle ss–cDNA enzyme for a reaction, 
then thoroughly mixed and briefly centrifuged. The sample tubes were incubated for 10 
min at 25°C, then 90 min at 42°C, then 10 min at 70°C, then for at least 2 min at 4°C. 
Afterwards, all samples were briefly centrifuged and placed on ice and immediately 






Hydrolyse RNA using RNase H 
In this procedure, RNase H hydrolysed the cRNA template leaving single–stranded 
cDNA. 
Total 4 μL of the RNase H was added to 2nd–cycle ss–cDNA sample (40 μL) for a final 
reaction volume of 44 μL, and then the tubes were thoroughly mixed and briefly 
centrifuged. The tubes incubated for 45 min at 37°C, then for 5 min at 95°C, and the last 
step for at least 2 min at 4°C. The samples were briefly centrifuged and placed on ice. 
Total 11 μL of nuclease–free water was added to each hydrolyzed 2nd–cycle ss–cDNA 
sample for a final reaction volume of 55 μL, thoroughly mixed and briefly centrifuged. 
The samples were placed on ice, then purified, or immediately frozen at –20°C for 
storage.  
Purify 2nd–cycle single–stranded cDNA  
After hydrolysis, the 2nd–cycle single–stranded cDNA was purified to remove enzymes, 
salts and unincorporated dNTPs. This step prepared the cDNA for fragmentation and 
labelling. 
Total 100 μL purification beads were added of to each 2nd–cycle ss–cDNA sample (55 
μL), then mixed by pipetting up and down, and transferred to a well of a u–bottom plate. 
50 μL of 100% ethanol was added to the ss–cDNA/Beads sample. The sample was mixed 
well by pipetting up and down 10 times and then incubated at room temperature for 20 
min. The plate was moved to a magnetic stand to capture the purification beads. After 10 
min placing, the supernatant was carefully aspirated and discarded without disturbing the 
beads. The plate was still kept on the magnetic stand, total 200 μL of 80% ethanol wash 
solution was added to each well and incubated for 30 s. The washing solution was slowly 




μL of 80% ethanol wash solution. The final wash solution was completely removed, air–
dried on the magnetic stand for 5 min until no liquid is visible. 
The plate was then removed from the magnetic stand, and 30 μL of the preheated (65°C) 
nuclease–free water was added to each sample and incubated for 1 min, then mixed well 
by pipetting up and down 10 times. The plate was then moved back to the magnetic stand 
and placed for ~5 min. The supernatant that contained eluted ss–cDNA was pipetted to a 
nuclease–free tube. The samples were put on ice, and the single–stranded cDNA was 
assessed for yield and size distribution, or immediately frozen at –20°C for storage. 
Fragment and label single–stranded cDNA 
In this procedure, the purified, sense–strand cDNA was fragmented by uracil–DNA 
glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE 1) at the unnatural 
dUTP residues and broke the DNA strand. The fragmented cDNA was labelled by 
terminal deoxynucleotidyl transferase (TdT) using the proprietary DNA labelling reagent 
that was covalently linked to biotin. All 5.5 μg of single–stranded cDNA was required for 
fragmentation and labelling. 
Total 5.5 μg of ss–cDNA in a volume of 31.2 μL (176 ng/μL) was prepared and placed 
on ice. The fragmentation master mix (16.8 μL total volume for a reaction) was prepared 
in a nuclease–free tube containing 10 μL of nuclease–free water, 4.8 μL of 10X cDNA 
Fragmentation Buffer, 1 μL of 10 U/μL UDG and 1 μL of 1000  U/μL APE 1. The master 
mix (16.8 μL) was transferred to each purified ss–cDNA sample (31.2 μL) for a final 
reaction volume of 48 μL. All tubes were then gently vortexed and briefly centrifuged. 
The sample tubes were incubated for 1 h at 37°C, then for 2 min at 93°C, and then the 





Total 45 μL of the fragmented ss–cDNA sample was transferred to a new tube or well 
tube or well. The labelling master mix was prepared in a nuclease–free tube (15.0 μL total 
volume for a reaction), which combined the components following 12 μL of 5X TdT 
buffer, 1 μL of 5 mM DNA labelling reagent and 2 μL of 30 U/μL TdT. The tubes were 
gently vortexed and briefly centrifuged. 15 μL of the Labelling Master Mix was added to 
each fragmented ss–cDNA sample (45 μL) for a final reaction volume of 60 μL, then 
gently vortexed and briefly centrifuged. The sample tubes were incubated for 1 h at 37°C, 
then for 10 min at 70°C, then for at least 2 min at 4°C. The samples were placed on ice, 
then proceeded to array hybridisation, or immediately froze at –20°C for storage.  
Array hybridisation 
The samples were hybridised in biological triplicate to Human Clariom S arrays (a 400 
format array), following the manufacturer’s recommendations. Briefly, the hybridisation 
master mix  (73 μL total volume for a reaction) was prepared by mixing components 
including 1.7 μL of control oligo B2 (3 nM), 5 μL of 20X hybridisation controls (bioB, 
bioC, bioD, cre), 50 μL of 2X hybridisation mix, 7 μL of DMSO and 9.3 μL of nuclease–
free water.  The solution was gently vortexed and briefly centrifuged. The hybridisation 
master mix was added to each 27 μL (2.3 µg) fragmented and biotin–labelled ss–cDNA 
sample to prepare the hybridisation cocktail for each array. The hybridisation cocktail 
reaction was gently vortexed and briefly centrifuged, before incubated in a thermal cycler 
for 5 min at 99°C (tubes) or 95°C (plates), then for 5 min at 45°C. After the incubation, 
the cocktail solution was briefly centrifuged, and then 80 μL of each hybridisation mix 
was loaded into the array. The arrays were sealed with tough spots and placed into 
hybridisation oven trays. Finally, the trays were loaded into the GeneChipTM 
hybridisation oven 645 and incubated with rotation at 60 rpm for 16 h at 45°C. The 
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Washing and staining 
The arrays were removed from the oven. The tough–spots also removed and released the 
hybridisation cocktail mix from each array. Wash buffer A was filled into each array and 
allowed the arrays to equilibrate at room temperature before washing and staining. The 
vials of stain cocktail and array holding buffer were placed into sample holders on the 
GeneChipTM Fluidics Station 450 (Thermo Fisher Scientific, Palo Alto, CA, USA). The 
washing and staining script used was FS450_0007. 
Scanning  
A GeneChip 3000G scanner (Affymetrix Inc.) and the Expression Console software 
(Affymetrix Inc.) was used to obtain fluorescent signals and quality control data of the 
scanned arrays. Signal intensities from each array were analysed using Partek Genomic 
Suite version 6.4 (Partek, St Louis, MO, USA).  
Data processing and analysis 
The microarray data were deposited at the NCBI GEO database [GEO: GSE151139]. To 
identify those biological processes that show differentially expressed genes, The 
Transcriptome Analysis Console (TAC) Software (Thermo Fisher Scientific, Palo Alto, 
CA, USA), a bioinformatic tool used for the visualization of the expression data in the 
biological pathways context. The data set was analysed using this tool and a gene 
expression fold change > 2 or < –2. Ebayes was used for statistical analysis with a 






2.4.4.2 Quantitative polymerase chain reaction assay 
Reverse–transcription  
The RNA sample was ready for reverse transcription using a master mix prepared from 
Quantiscript Reverse Transcriptase, Quantiscript RT Buffer, and RT Primer Mix. The 
entire reaction took place at 42°C and then was inactivated at 95°C. 
The reverse–transcription master mix was prepared by pipetting 2 μL Quantiscript 
Reverse Transcriptase, 8 μL Quantiscript RT Buffer (5x) and 2 μL RT primer mix 
template for the total volume of 12 μL reaction. Then the 28 μL of 2 µg template RNA 
was added to each tube of the master mix. All tubes were mixed by pipetting and placed 
on ice. The tubes were incubated at 42 ºC for 15 min, then incubated at 95 ºC for 3 min. 
The cDNA products were quantified by NanoDrop2000 and then proceeded qPCR or 
stored at -20°C. 
Quantitative polymerase chain reaction (qPCR) 
This procedure the cDNA templates were amplified using QuantiTect SYBR Green PCR 
Kit (Qiagen, Valencia, CA, USA) and QuantiTect Primer Assay (Qiagen, Valencia, CA, 
USA). The fluorescent dye SYBR Green I in the master mix enabled the analysis of 
different targeted genes without having to synthesize target–specific labelled probes. 
High specificity and sensitivity in PCR are achieved by the use of the hot–start enzyme 
HotStarTaq DNA Polymerase together with a specialized PCR buffer. The buffer also 
contained ROX dye, which allows fluorescence normalization on certain cyclers. 
QuantiTect SYBR Green PCR Master Mix, 10x QuantiTect Primer Assay, template 
cDNA and RNase–free were thawed and mixed individual solutions. The reaction mix 
was prepared by pipetting 25 μL of 2x QuantiTect SYBR Green (PCR master mix), added 




individual PCR tubes containing the reaction mix. The real–time cycler was programmed 
the steps, temperature and time details in Table 4.  
 
 
              Table 3 Polymerase chain reaction programme 
Step Temperature (°C) Time 
PCR initial 95 15 min 
Denaturation 94 15 s 
Annealing 50–60* 30 s 
Extension 72 30 s 
Number of cycles 35–45  
 
*Approximately 5–8°C below Tm of primers 
 
The PCR tubes were placed in the real–time cycler, and the cycling program was started. 
mRNA ratios relative to the glyceraldehyde 3–phosphate dehydrogenase (GAPDH) 
housekeeping gene were calculated for the standardization of gene expression levels. A 
melting curve analysis was also performed to verify the specificity and identity of PCR 
products. Finally, the products were run agarose gel electrophoresis to check the 






Data analysis using the 2−ΔΔCt method 
For selected genes, real–time PCR was performed on the corresponding cDNA 
synthesized from each sample. The data were analysed using the equation described by 
Livak and Schmittgen (2001). Amount of target was equal to 2−ΔΔCt; The average Ct of 
GAPDH in each treatment was used to calculate ΔCt of the target genes and the ΔCt from 
OXY–untreated MCF7 cells was used as a calibrator for each gene to generate ΔΔCt. 
Each gene was performed in triplicate and data were presented as mean±SD. Statistical 
evaluation of significant differences was carried out the unpaired t–test using GraphPad 
Prism 8. Differences of P value less than 0.05 were considered statistically significant. 
 
2.4.4.3 Lactate dehydrogenase release 
 
To determine cellular toxicity of OXY, the level of lactate dehydrogenase (LDH) released 
from MCF7 cells was measured. After exposure to OXY for 48 h, cell–free supernatant 
aliquots were collected from each experimental sample, and LDH in the culture 
supernatants was measured using the Pierce LDH Cytotoxicity Assay Kit 
(ThermoScientific, Rockford, Illinois, USA). The protocol was followed by the 
manufacture’s instructions. All samples were assayed in triplicate for LDH content by a 
microplate reader at the wavelength of 490 nm and 680 nm. The cytotoxicity was 
calculated by subtracting the background of the blank control. LDH activity of the 
spontaneous LDH release control (untreated) and the OXY treated groups were calculated 






2.4.4.4 Nuclear morphological detection using Hoechst 33342 staining 
 
The nuclear morphological changes of chromatin condensation and chromosome 
fragmentation induced by OXY was examined using Hoechst 33342 staining. The 
protocol was followed by the manufacture’s instruction. Briefly, the cells were treated 
with different concentrations of OXY in 6–well plates for 24 and 48 h.  The 10 mg/mL 
Hoechst stock solution was prepared and diluted with PBS (1:2000). The medium was 
removed from each well and then 500 μL of the dye working solution was added. The 
plate was incubated in the cell incubator protected from light for 10 min. Afterwards, the 
cells were washed with 1 mL PBS for 3 times. The cells were viewed under the 
fluorescence microscope (Olympus, Hamburg, Germany). The mode of cell death was 
then determined in term of distinct morphological changes, including membrane 
blebbing, nuclear and cytosolic condensation and nuclear fragmentation in the treated 
group compared to the untreated cells served as the control. 
 
2.4.4.5 Determination of intracellular ROS  
 
The intracellular ROS detection was adapted from Panich et al. (2012). Cells were pre-
treated with different three concentrations of Cu(OAc)2 for 24 h and then treated (fixed-
dose) with 50 µM (for MCF7 ) or 100 µM (for HepG2) OXY for 2, 6, 24 and 48 h, 
respectively. The cells were washed twice with 100 µL PBS and then incubated with 5 
µM DCFHDA for 1 h at 37ºC. DCF fluorescence intensity of ROS formation evaluated 
by spectrofluorometry at the excitation/emission wavelength of 485/530 nm. The data 
were expressed as percentage of intracellular oxidant formation (relative fluorescence 





2.4.4.6 Measurement of DNA damage by Comet Assay 
 
The comet assay was performed under alkaline conditions. Cells were seeded in 6–well 
tissue–culture plates. They were treated with 25 and 50 µM OXY. After 24 and 48 h of 
exposure with OXY or 100 µM H2O2 for 4 h as the positive control, cells were collected 
by trypsinization, washed with PBS and resuspended in ice–cold PBS. About 10 μL of 
the resuspended cells was mixed with 100 μL of low melting point agarose at 37 °C and 
spread the suspension over the well with the pipette tip. The slides were placed at 4 °C in 
the dark until gelling occurred and then immersed in pre–chilled lysis buffer at 4 °C. After 
60 min incubation, the buffer was aspirated and replaced with pre–chilled alkaline 
solution for 30 min at 4 °C. After lysis and unwinding, the slides were placed in a 
horizontal electrophoresis tank filled with freshly prepared alkaline electrophoresis 
buffer. The electrophoresis was run for 25 min at 15V and 300 mA. After electrophoresis, 
the slides were transferred to pre–chilled distilled water and immerse for 2 min, aspirate 
and repeat twice. The final water rinse was aspirated and replaced with cold 70% ethanol 
for 5 min. Thereafter, the slides were allowed to air dry and 100 μL/well of diluted Vista 
Green DNA dye was added to each slide for 15 min in the dark at room temperature for 
DNA staining. DNA migration was observed using the fluorescence microscope at a 
magnification of 10X (Leica Microsystems CMS GmbH, Germany).  
 
2.4.4.7 Cell cycle analysis using flow cytometry 
 
Cell cycle analysis was conducted by BD Cycletest™ Plus kit (BD biosciences, San 
Diego, CA, USA) using propidium iodide as a DNA stain to determine DNA content in 
the cells. The effect of OXY treatment on the cell cycle was determined by flow 




cells were seeded at 2.5 x 105 cells/well in 6–well plates. MCF7 cells were treated with 
OXY at the concentration of 25, 50, and 100 μM, while HepG2 cells were treated at 50, 
100, and 200 μM for 6 and 24 h. Cells were trypsinised with 300 μL of 0.25% trypsin 
solution for 3 min in the cell incubator. A 200 μL of fetal bovine serum was added and 
then all of the cell suspension was transferred into a 15 mL centrifuge tube. The 
suspension was centrifuged at 300 rcf for 5 min. The supernatant was discarded, the cell 
pellet was resuspended with 1 mL buffer solution (contains sodium citrate, sucrose, and 
DMSO). The cells were centrifuged and resuspended one more time and then the cells 
were counted using hemocytometer for 5x105 cells. Cells were frozen in the freezer (–80 
ºC) for PI staining. The cell suspensions were thawed in a water bath, centrifuged at 400 
g for 5 min at room temperature (20°C–25°C). All the supernatant was carefully decanted. 
A 250 μL of solution A (trypsin buffer) was added to each tube and gently mix by tapping 
the tube by hand, incubated for 10 min at room temperature. Afterwards, a 200 μL of 
Solution B (trypsin inhibitor and RNase buffer) was added to each tube and gently mix 
by tapping the tube by hand, incubate for 10 min at room temperature. Finally, a 200 μL 
solution C (PI stain solution) was added to each tube and incubated for 10 min in the dark 
on ice or in the refrigerator (2–8°C) until analysed by flow cytometer. A total number of 
1 × 104 cells was subjected to cell cycle analysis using a flow cytometer. The detected 
cells were calculated into the percentage of cells population by the software.  
 
2.4.4.8 Quantification of apoptotic cells 
 
Annexin V is a 35–36 kDa, that was in the PE Annexin V Apoptosis Detection Kit I (BD 
Biosciences Inc., San Jose, CA, USA) and has a high affinity for negatively charged 
phospholipid phosphatidylserine, and binds to cells that are actively undergoing apoptosis 




described.   MCF7 and HepG2 cells were seeded in 6–well plates and then treated with 
OXY at different concentrations (0, 25, 50 and 100 μM for MCF–7, while 0, 50, 100 and 
200 μM for HepG2) for 3, 6, 24 and 48 h. The cells were trypsinised and washed twice 
with ice–cold PBS, and then cells were resuspended at a concentration of 1 × 106/mL 
cells in binding buffer. A 100 μL of the cell suspension was transferred into a 2 mL 
microcentrifuge tube and added 5 μL PE annexin V and 5 μL 7–amino–actinomycin D (a 
vital nucleic acid dye). The cells were gently mixed and incubated in the dark for 15 min 
at room temperature. Finally, a 400 μL of binding buffer was then added to each tube and 
the apoptotic cells were quantified using a flow cytometer within 1 h. Cells that stained 
positive for PE annexin V and negative for 7–amino–actinomycin D were undergoing 
apoptosis; cells that stain positive for both PE annexin V and 7–amino–actinomycin D 
were either in the end stage of apoptosis, are undergoing necrosis, or were already dead; 
and cells that stain negative for both PE annexin V and 7–amino–actinomycin D were 
alive and not undergoing measurable apoptosis. 
 
2.4.4.9 Determination of caspase–3 expression induced by OXY 
 
Active caspase–3 staining protocol was performed following the manufacturer's 
instructions (PE active caspase–3 apoptosis kit, BD biosciences, San Diego, CA, USA). 
The 5 x 105 cells of MCF7 and HepG2 treated with different concentrations of OXY were 
harvested and transferred into 15 mL centrifuge tubes and then the suspension was 
centrifuged at 300 xg for 5 min at 4 ºC. Cells were washed twice with 1 mL ice–cold PBS 
and then resuspended in 0.50 mL BD Cytofix/Cytoperm™ solution. The cells were 
incubated on ice for 20 min. After that the buffer was removed, the cells were washed 
twice with 0.50 mL BD Perm/Wash™ buffer at room temperature. Then, the cells were 




min at room temperature. Finally, the cells were washed with 1 mL washing buffer and 
re–suspended in 0.50 mL washing buffer. The cells were maintained at 4 °C until 
analysing by flow cytometer. 
 
2.4.4.10 Mitochondrial membrane potential (ΔΨm) analysis by JC–1 fluorescence 
 
Cellular mitochondrial dysfunction can be reflected by the loss of the mitochondrial 
membrane potential, which can be indirectly measured by the fluorescent probe JC–1 
using The BDTM MitoScreen Kit (BD Biosciences, Sandiego, CA, USA). The protocol 
was followed manufacturer’s instruction. Briefly, MCF7 and HepG2 treated with 
different concentrations of OXY were harvested and transferred into 15 mL centrifuge 
tubes and then the suspension was centrifuged at 300 x g for 5 min at 4 ºC. Then the cells 
were resuspended with 0.50 mL JC–1 working solution and incubated at 37ºC in a cell’s 
incubator for 15 min. The cells pellet was washed twice with 1X assay buffer (2 mL and 
1 mL, respectively). Finally, the cells were resuspended with 0.50 mL 1X assay buffer, 
then analysed by a flow cytometer. 
 
2.4.4.11 Wound healing assay (scratch test) 
 
Plates containing confluent cultures of MCF7 or HepG2 cells grown in the serum–
containing medium were scratched with a sterile 200 µL pipette tip. The medium was 
replaced with serum–reduced medium with OXY or DMSO and returned to 37°C for 
designated times. Cells were captured. Distances between the gaps formed by the scratch 
were measured with Olympus CellSense Entry 1.16 software. The wound–closure (fold) 




2.4.4.12 Invasion assay 
 
Migration assays were investigated using Corning® BioCoat™ Matrigel® invasion 
chamber (corning corporated, Tewksbury, MA, USA). It was coated on the lower surface 
with a 5 µg/mL fibronectin in FBS solution of overnight at 4°C. In a separate series of 
experiments to measure invasiveness, the upper surface of the inserts was coated with 
Matrigel and on the lower surface were coated with 5µg/mL fibronectin at 4°C for 24 h. 
Actively growing HCC1937 and HepG2 cells were trypsinized, washed and resuspended 
at 1×106 cells/mL in serum–free medium with either DMSO or OXY. Total 1×105 cells 
in 0.1 mL were carefully placed in the upper chamber. The upper and lower chambers 
contained the same media as the cell suspensions. Following incubation for 24 h, cells 
from the upper surface were wiped clear and cells on the lower surface were fixed with a 
4% buffered formaldehyde solution. Crystal violet stained membranes were then 
transferred to slides, coverslipped, photographed and cells were counted manually. 
 
2.4.4.13 Western blot analysis 
 
Cells were seeded on the 6–well dishes and wait for the adherence. Cells were treated 
with OXY at the concentrations of 50 µM and 100 µM for 24 h and then washed twice 
with ice–cold PBS. The cells were lysed in lysis buffer (protease inhibitor cocktail). After 
5 min incubation on ice, swirling the plate occasionally for uniform spreading, the 
solution was transferred to centrifuge tubes, sonicate the pellet for 30 seconds with 50% 
pulse and the lysates were centrifuged at ~14,000× g for 15 min to pellet the cell debris. 
The supernatants were collected, and protein concentrations were determined by the 
Bradford assay (Bio–Rad, Richmond CA, USA). An equal amount of protein sample (20 




95 °C for 5 min. The protein was loaded in the well of 7.5% Mini–PROTEAN® TGX 
Stain–Free™ protein gels (Bio–Rad, Richmond CA, USA) and run the gel for 1 h at 180 
V. The gel disassembled from the cassette and visualised via the Gel documentation 
system. Then, the gel was assembled to the transfer sandwich using Trans–Blot® Turbo™ 
mini PVDF transfer packs (Bio–Rad, Richmond CA, USA). Proteins were transferred 
onto PVDF membrane at 1.3 A for 7 min. Membranes were blocked with 5% skim 
milk/TBST for 1 h at RT and then probed with indicated primary antibody overnight at 4 
°C and then blotted with appropriate horseradish peroxidase–conjugated secondary anti–
rabbit antibody. Visualization was performed using an enhanced chemiluminescence kit 
(BioRad Inc., Hercules, CA) with Clarity™ Western ECL Substrate. Protein level was 
normalized to the matching densitometric value of the internal control β–actin. 
 
2.4.5 Statistical analysis 
 
All bioassay experiments were carried out in triplicate with a minimum of three replicates 
per assayed concentration. Data were expressed as means ± SEM (standard error of the 
mean). Statistical significance was assessed by One–way analysis of variance followed 
by Dunnett's test or the unpaired t–test using GraphPad Prism 8 (GraphPad Software, La 









































3.1 Introduction  
A. lakoocha is a medium to large deciduous tree distributed in tropical countries of Asia. 
Puag–Haad, a product from aqueous extract of its heartwood, has been traditionally used 
as an anthelminthic medicine, and contains high amounts of OXY (Maneechai et al., 
2009). Previous pieces of literature including the traditional extraction reported that the 
method generally used was aqueous reflux extraction or boiling, which could retrieve 
high yield of active compounds (Mongolsuk et al., 1957; Maneechai et al., 2009; 
Preyavichyapugdee et al., 2016; Borah et al., 2017). Several publications used ethanol as 
an extracting solvent focusing on the main compound, OXY (Maneechai et al., 2009; 
Povichit et al., 2010; Singhatong et al., 2010). whereas, a few studies used ethyl acetate 
to make it more soluble (Preyavichyapugdee et al., 2016). 
Geometric isomerism or configurational isomerisms (cis– or trans–) and stability of a 
compound in the environment also are important. In terms of stability, stilbenoids are 
sensitive to heat, air, light and oxidative enzymes. For example, ultraviolet and visible 
light could transform trans– to cis– isomerization of resveratrol (Silva et al., 2013). The 
trans form is known to be the more predominant and stable natural form of resveratrol 
(Rius et al., 2010). Therefore, the phytochemical properties of OXY illustrated in this 
chapter will be the background information for investigating its cytotoxicity. 
 
3.2 Aims 
To investigate the phytochemical profiles of the three A. lakoocha heartwood extracts, 
using chromatographic and spectroscopic methods. The stability of OXY was also 





3.3 Results  
3.3.1 Yield of extraction 
The heartwood was ground into a powder and dried at 45–50 ºC until constant weight. 
The powder was successively extracted with a reflux extraction using water and ethanol, 
and another fraction was extracted by a Soxhlet apparatus using ethyl acetate. The three 
extracts were obtained (Figure 17 and Table 4). As the three solvents used have different 
polarity index, the constituents of the plant were gradually extracted according to their 
affinity with each solvent. The highest yield percentage of extraction was that of ethanol 
with a 9.53 % recovery percentage while water and ethyl acetate yielded the lower 





Figure 17 A. lakoocha heartwood extracts a) water extract using reflux extraction; b) 










Table 4 Extraction method and the extractive content.  
 





Water extraction  250.00  18.23 7.29 
Ethanol extraction 250.00 23.83 9.53 
Ethyl acetate extraction 800.00 26.88 3.36 
 
 
3.3.2 Quantification of OXY and resveratrol 
OXY was reported as the most abundant compound in the heartwood of A. lakoocha  
(Burns et al., 2002; Maneechai et al., 2009; Borah et al., 2017). Therefore, the compound 
and the well–known stilbenoid, resveratrol were quantified in the three extracts using 
HPLC. The chemical profiles of the two compounds were shown in Figure 18 and Figure 
19; OXY was a dominant single peak at the retention time (RT) 14.0 min in the three 
extracts, while resveratrol was found to be one of the minor peaks at the RT 17.4 min. 
The relative amount of the compounds were calculated and shown in Table 5; OXY was 
found to be the highest amount in ethyl acetate fraction of 642.26±0.28 µg/mL (64.23%), 
while in ethanol and water extracts were found to be roughly half at 378.14 µg/mL 
(37.81%) and 335.45 µg/mL (33.55%), respectively. Whereas, resveratrol was quantified 
as a minor compound, which was 0.65%, 0.45 % and 0.37% in ethyl acetate, ethanol and 










Figure 18 Chromatograms of OXY in the different three extracts, inj. vol. 20 μL, 
monitored at 320 nm   a) water extract 250 µg/mL; b) ethanol extract 250 µg/mL; c) 
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Figure 19  Chromatograms of resveratrol in the different three extracts, inj. vol. 20 μL, 
monitored at 320 nm a) water extract 250 µg/mL; b) ethanol extract 250 µg/mL; c) ethyl 
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Table 5 Quantity of OXY and resveratrol in water, ethanol and ethyl acetate extracts. 










Water extract 335.45±0.83 33.55±0.08 3.73±0.00 0.37±0.00 
Ethanol extract 378.14±9.03 37.81±0.90 4.46±0.01 0.45±0.00 
Ethyl acetate 
extract 
642.26±0.28 64.23±0.03 6.54±0.14 0.65±0.01 
 
 
3.3.3 Structure elucidation of trans–OXY 
OXY collected from the peak of HPLC at the RT 14.0 min in the ethyl acetate extract was 
dried and obtained as a yellow powder. The authentication of the predominant peak was 
carried out using NMR with the 1H–NMR and 13C–NMR spectral patterns (Figure 20–
22) of main peak were in good agreement with those of standard OXY and also with those 
reported in the literature (Povichit et al., 2010).  
 
The signals of 1H–NMR and 13C–NMR of the peak were assigned as follows: δ (ppm) 
7.38 (1H, d, J=8.5 Hz, H–6), 7.31 (1H, d, J=16.4Hz, H–α), 6.86 (1H, d, J=16.4Hz, H–β), 
6.50 (2H, s, H–2’, H–6’), 6.40 (1H, d, J=2.4Hz, H–3), 6.38 (1H, dd, J=8.5, 2.4Hz, H–5), 
6.22 (1H, s, H–4’). 158.7 (C–5’ or C–3’), 158.7 (C–5’ or C–3’), 158.2 (C–4), 156.0 (C–
2), 140.7 (C–1’), 127.3 (C–6), 125.4 (olefinic C–β), 123.4 (olefinic C–α), 116.4 (C–1), 








Position δC δH m (J in Hz) Position δC δH m (J in Hz) 
1 116.4 – 1’ 140.7 – 
2 156.0 – 2’ 104.6 6.53 dd (2.1, 2.5) 
3 102.7 6.44 d (2.4) 3’ 158.6 – 
4 158.2 – 4’ 101.4 6.24 t (2.1) 
5 107.5 6.39 dd (2.4, 8.4) 5’ 158.6 – 
6 127.3  7.41 d (8.4)  6’ 104.6  6.53 dd (2.1, 2.5) 
α 123.4  7.41 d (16.4)  2–OH  8.48 brs 
β 125.4 6.89 d (16.4) 4–OH  8.30 brs 
   3’–OH  8.09 brs 
   5’–OH  8.09 brs 
 
 
Figure 20 13C NMR (300 MHz, Acetone-d6) and 
1H (300 MHz, Acetone-d6) data of 
OXY. 
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Mass spectra of standard OXY (Figure 23) gave the main and spectral patterns the same 
as the main peak detected at RT 14.0 in the three extracts of A. lakoocha (Figure 24–26).  
Its molecular formula C14H12O4  was deduced from the ESI–MS spectrum in positive ion 














































































3.3.4 Trans–OXY stability test in different solvents 
OXY dissolved in different solutions including D2O, DMSO–d6, CD3OD and acetone–d6 
were investigated the configuration stability. The coupling constant of H (JHα and JHβ) 
was analysed at the time of 0, 0.5, 1, 2, 4, 6, 24 and 48 h. In all solutions, the coupling 
constants were quite stable in the normal laboratory environment for 48 h. The JHα in 
D2O, DMSO–d6, CD3OD and Acetone–d6 were 16.46±0.11, 16.46±0.02, 16.47±0.04 and 
16.46±0.02, respectively. Whereas, The JHβ in D2O, DMSO–d6, CD3OD and Acetone–
d6 were 16.50±0.00, 16.44±0.21, 16.42±0.01 and 16.41±0.01, respectively. The coupling 
constants are shown in Table 6. 
 
Table 6 The coupling constant values (Hz) between H–α and H–β of OXY in different 
four solutions during the time 0–48 h. 
h D2O DMSO–d6 CD3OD Acetone–d6 
 JHα JHβ JHα JHβ JHα JHβ JHα JHβ 
0 16.53 16.50 16.47 16.32 16.47 16.41 16.47 16.41 
0.5 16.41 16.50 16.44 16.47 16.47 16.41 16.44 16.44 
1 16.50 16.50 16.44 16.53 16.47 16.41 16.44 16.41 
2 16.29 16.50 16.47 16.41 16.47 16.44 16.47 16.41 
4 16.65 16.50 16.47 16.11 16.44 16.41 16.47 16.41 
6 16.44 16.50 16.44 16.35 16.44 16.41 16.44 16.41 
24 16.50 16.50 16.47 16.83 16.47 16.41 16.47 16.41 








A. lakoocha is one of the plants in the genus Artocarpus (Moraceae), which is an 
important source of edible fruit, timber and more importantly, it has been traditionally 
used for illness treatment in Thailand and Southeast Asia (Jagtap and Bapat, 2010). The 
traditional preparation of heartwood is by boiling to produce a yellowish extract, which 
is abundant in OXY (Mongolsuk et al., 1957; Maneechai et al., 2009; Saowakon et al., 
2009). OXY is a small polyphenolic compound belonging to stilbenes, which could be 
well dissolved in alcohol and some organic solvents. OXY yield extracted from the three 
different solvents revealed that it was the dominant stilbene in the heartwood extracts that 
showed a dominant peak of HPLC chromatogram in different detector’s UV wavelengths 
of 260, 280 and 320 nm (Figure 19 a, b and c). Extraction using alcohol gave the highest 
yield (3.60 % w/w dried–heartwood powder), which was close to using hot water giving 
2.44 % w/w dried–heartwood powder. Whereas extraction in ethyl acetate, the low 
polarity solvent, gave the lowest yield of 2.15 % w/w dried–heartwood powder. However, 
OXY extracted using ethyl acetate gave the highest purity of 64.23% OXY (HPLC), more 
or less two times higher than using the two solvents. Therefore, the dried extracted 
powder was found to show a bright yellow colour in ethyl acetate fraction compared to 
the two crude powders extracted with water and ethanol found to show brown–yellowish 
colour. Therefore, the traditional extracting method using boiled water retrieved a high 
amount of OXY (Mongolsuk et al., 1957; Maneechai et al., 2009; Preyavichyapugdee et 
al., 2016; Borah et al., 2017), which reported to show potent anthelmintic activity higher 
than the standard praziquantel at the concentration of 175 µg/mL (Saowakon et al., 2009; 
Preyavichyapugdee et al., 2016). There were around 10 minor peaks in the HPCL 
chromatogram of the three solvents when they were expanded. Each peak was a minor 
component compared to OXY, which was less than 1% in the extracts. One of the peaks 




0.65 % w/w in water, ethanol and ethyl acetate, respectively. It has been reported 
previously that resveratrol was also found in A. lakoocha heartwood (Borah et al., 2017). 
Structure elucidation of OXY was carried out by spectroscopic analyses including 1D (1H 
and 13C NMR) and mass spectrometry. OXY collected from the dominant peak in ethyl 
acetate extract, which is the purest fraction. Mass spectrometry is a technique useful in 
the determination of the molecular weight of compounds, the possible molecular formula 
and fragmentation pattern (de Hoffmann et al., 2007). This technique was implemented 
to identify the compound at the peak, which was the same retention time as the standard 
OXY.  
OXY was evidently the most dominant compound in the three extracts of A. lakoocha 
heartwood. Extracting with ethanol gave a higher yield than what was achieved using 
either water or ethyl acetate. Whereas using ethyl acetate as the extracting solvent gave a 
higher purity than others did. The chemical profile of the extracts showed the main peak 
to be OXY (around 33–64%) and other peaks including resveratrol, which was lower than 
1% detected. Mass and NMR spectroscopic analysis identified that the main peak 
presented in the three extracts was trans–OXY and this configuration was stable in 
different solutions of aqueous and some organic solvents in the normal lab environment. 
These provided the phytochemical information of OXY for studying its chemical and 












CHAPTER 4 PRO–OXIDANT ACTIVITIES 





















4.1 Introduction  
OXY belongs to the group of phytochemicals known as hydroxystilbenoids, and has a 
molecular structure similar to the well–known phytochemical resveratrol (Riviere et al., 
2012). Both compounds demonstrate similar biological activities and are used in the 
treatment of atherosclerosis, inflammatory, pigmentation and carcinogenesis (Akinwumi 
et al., 2018). Interestingly, however, several biological activities are unique to OXY 
(antivirus and anthelminthic) (Galindo et al., 2011; Preyavichyapugdee et al., 2016). 
Further, several reports suggest that OXY or the heartwood extract of A. lakoocha might 
cause DNA damage and cause oxidative stress (Singhatong et al., 2010). Previous studies 
report that resveratrol and its derivatives are capable of double–stranded DNA cleavage 
specifically in the presence of copper ions and oxygen, generating ROS in the reaction. 
Speculation exists as to the exact mechanism responsible although it has been previously 
noted that Cu+–Oxo complexes can cause DNA damage (Subramanian et al., 2004). 
Piceatannol, a resveratrol derivative, is also able to fragment DNA in human peripheral 
blood (Azmi et al., 2005). Copper at some certain extent is well–known to be one of the 
transition metals paying an important role in biological functions. However, It has been 
reported that significantly elevated levels of copper have been found in both serum and 
tissue of cancer patients (Kuo et al., 2002). Moreover, elevated copper levels have been 
documented in breast, cervical, ovarian, lung, prostate, stomach cancers and leukemia. 
Serum copper concentration has also been found to correlate with tumour incidence and 
burden, malignant progression in Hodgkin's lymphoma, leukemic, sarcoma, brain, breast, 
cervical, liver and lung cancer (Gupte and Mumper, 2009). Some polyphenolic 
compounds are already well known to cause DNA damage and are being investigated as 




In this study, we consequently investigated the ability of OXY from the heartwood of A. 
lakoocha to induce DNA damage and the mechanism by which the damage occurs. 
 
4.2 Aims 
 To investigate the pro–oxidant properties of OXY and other stilbenes including the three 
extracts of A. lakoocha heartwood in the presence and absence of copper in a cell–free 
environment.  
 
4.3 Results and discussion 
4.3.1 DNA nicking assay 
The gel electrophoresis pattern (Figure 27–30) showed the DNA nicking ability of OXY 
in the presence of 50 µM copper (II). Figure 27 shows the dose–dependent effect on DNA 
cleavage of OXY; in the condition of presenting only the plasmid DNA or the DNA + 50 
µM OXY or the DNA + 50 µM Cu(OAc)2, there was no evidence of DNA cleavage (lane 
2–4). It was found that the compound damaged the double–stranded supercoil plasmid 
DNA dose–dependently (lane 5–10); 200 µM was by far the most active transforming all 
of the supercoil(S) DNA into nicked and a little linear(L) forms, while there was no 
nicking activity at the dose of 0.4–2.0 µM OXY (Figure 28). The DNA–nicking activity 
of OXY was found to be specific to the copper (II) ions, not to Fe(II) or Zn(II) shown in 
Figure 29. OXY in the presence of copper ion exhibited nicking DNA (lane5). Whereas, 
OXY or with the metal chelators themselves could not break the DNA strand (lane 3, 4, 
6 and 8). Moreover, the molecule incubated with iron (II) and zinc (II) did not give a 




compared to the small molecular stilbenes including resveratrol and trans–stilbene. The 
DNA cleavage activity was shown in Figure 29. OXY posed the damage higher than 
resveratrol at the concentration of 50 µM (lane 3 and 4), while trans–stilbene did not 
show the activity (lane 5). A. lakoocha extracts showed the DNA–breakage capability 
consistent with OXY (Figure 30). The three extracts could not break the DNA (lane 3–
5), while the activity of each extract was found to pose the damage in the condition 
presenting copper ions and be dependent on the dose of the extracts used (lane 6–14). The 
three different concentrations of water extract (lane 6–8); there was complete damage to 
supercoil DNA at 200 µg/mL, which presented some linear fragment of the DNA (lane 
6). While the nicking activity was lower at the concentrations of 25 µg/mL and 3.13 
µg/mL, which transformed supercoil form to open circular form in a big band and small 
band, respectively (lane 7 and 8). Similarly, the effect of the three concentrations of 
ethanol extract posing slightly higher effect (lane 9–11), than those with the water extract. 
Whereas, ethyl acetate extract at the doses of 200 µg/mL and 25 µg/mL completely 
damaged supercoil DNA (lane 12 and 13) and partially damaged at the lowest 

















Figure 27 Gel electrophoresis pattern of supercoiled pBR322 plasmid DNA cleavage by 
six different concentrations of OXY in the presence of Cu(OAc)2 (50 µM). 
Lane 1: Ladder, Lamda DNA Hind III digest 
Lane 2: pBR322 
Lane 3: pBR322+50 µM OXY 
Lane 4: pBR322 + 50 µM Cu(OAc)2  
Lane 5: pBR322 + 50 µM Cu(OAc)2  + 200 µM OXY 
Lane 6: pBR322 + 50 µM Cu(OAc)2  + 100 µM OXY 
Lane 7: pBR322 + 50 µM Cu(OAc)2  + 50 µM OXY 
Lane 8: pBR322 + 50 µM Cu(OAc)2  + 10 µM OXY 
Lane 9: pBR322 + 50 µM Cu(OAc)2  + 2 µM OXY 
Lane 10: pBR322 + 50 µM Cu(OAc)2  + 0.4 µM OXY 
 
O = open circular form or nicked DNA 
L = linear form 
















Figure 28 Gel electrophoresis pattern of supercoiled pBR322 plasmid DNA cleavage by 
50 µM OXY in the presence of different chelating metals; Cu(OAc)2, FeCl3·H2O and 
ZnCl2. 
Lane 1: Ladder, Lamda DNA Hind III digest 
Lane 2: pBR322 
Lane 3: pBR322+50 µM OXY 
Lane 4: pBR322 + 50 µM Cu(OAc)2   
Lane 5: pBR322 + 50 µM Cu(OAc)2  + 50 µM OXY 
Lane 6: pBR322 + 50 µM FeCl3 
Lane 7: pBR322 + 50 µM FeCl3+ 50 µM OXY 
Lane 8: pBR322 + 50 µM ZnCl2 
Lane 9: pBR322 + 50 µM ZnCl2 + 50 µM OXY 
 
O = open circular form or nicked DNA 
S = circular form or supercoiled DNA 
 
 












Figure 29 Gel electrophoresis pattern of supercoiled pBR322 plasmid DNA cleavage by 
50 µM OXY, 50 µM resveratrol and 50 µM trans–stilbene in the presence of Cu(OAc)2. 
Lane 1: Ladder, Lamda DNA Hind III digest 
Lane 2: pBR322 
Lane 3: pBR322+50 µM OXY 
Lane 4: pBR322+50 µM resveratrol 
Lane 5: pBR322+50 µM trans–stilbene 
 
O = open circular form or nicked DNA 















Figure 30 Gel electrophoresis pattern of supercoiled pBR322 plasmid DNA cleavage by 
A. lakoocha heartwood’s extracts in the presence and absence of Cu(OAc)2. 
Lane 1: Ladder, Lamda DNA Hind III digest 
Lane 2: pBR322 
Lane 3: pBR322+25 µg/mL water–extracted fraction 
Lane 4: pBR322+25 µg/mL ethanol–extracted fraction 
Lane 5: pBR322+25 µg/mL ethyl acetate–extracted fraction  
Lane 6: pBR322 + 50 µM Cu(OAc)2  + 200 µg/mL water–extracted fraction 
Lane 7: pBR322 + 50 µM Cu(OAc)2  + 25 µg/mL water–extracted fraction 
Lane 8: pBR322 + 50 µM Cu(OAc)2  + 3.13 µg/mL water–extracted fraction 
Lane 9: pBR322 + 50 µM Cu(OAc)2  + 200 µg/mL ethanol–extracted fraction 
Lane 10: pBR322 + 50 µM Cu(OAc)2  + 25 µg/mL ethanol–extracted fraction 
Lane 11: pBR322 + 50 µM Cu(OAc)2  + 3.13 µg/mL ethanol–extracted fraction 
Lane 12: pBR322 + 50 µM Cu(OAc)2  + 200 µg/mL ethyl acetate–extracted fraction 
Lane 13: pBR322 + 50 µM Cu(OAc)2  + 25 µg/mL ethyl acetate–extracted fraction 
Lane 14: pBR322 + 50 µM Cu(OAc)2  + 3.13 µg/mL ethyl acetate–extracted fraction 
 
O = open circular form or nicked DNA 
L = linear form 












4.3.2 Reactive oxygen species assay 
The ability of OXY or A. lakoocha extracts to generate reactive radical species in the 
presence or absence of copper (II) was compared with its derivatives including resveratrol 
and trans–stilbene. Figure 31 shows the dose–dependent formation of OXY increasing 
the relative fluorescence signals. The formation of the relative fluorescence sharply 
increased from around 800 – 2,400 RFU at the low doses between 1.56 – 50 µM and 
linearly raised from around 2,400 – 3,300 RFU at the doses of 50 – 200 µM–OXY. These 
results indicated that OXY in the presence of 50 µM–copper (II) generated ROS dose–
dependently. Whilst in the absence of copper ions, OXY did not cause ROS (the negative 
control). Comparison with its derivatives (Figure 32), OXY generated ROS formation 
higher than resveratrol at the same concentrations (1.56–200 µM) which resveratrol 
generated the fluorescence signals from around 579–2,600 RFU. While the formation did 
not raise in trans–stilbene. ROS generation by the three extracts of A. lakoocha was also 
investigated shown in Figure 33; the relative fluorescence signals generated by ethyl 
acetate extract was the highest compared to the others in the condition with copper. It 
dramatically increased at the doses tested (1.56–200.00 µg/mL). Whereas, the formation 
of water and ethanol extracts were similar; the relative fluorescence of the ethanol extract 
slightly increased from the baseline around 900 RFU at 1.56 µg/mL to reach 3,000 RFU 
at 200 µg/mL, but of which water extract showed a little bit lower than ethanoic extract 
at the highest dose. However, there was no significant formation of ROS raised by the 













Figure 31 The relationship between the concentration of copper (µM) and the relative 
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Figure 32 The relationship between the concentration of stilbenes (µM) and the relative 

































































Figure 33 The relationship between the concentration of A. lakoocha heartwood extracts 
(µg/mL) and the relative fluorescence in the presence and absence of Cu(OAc)2 (50µM). 
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4.3.3 Copper reducing assay 
The Copper (II) reducing abilities of OXY was investigated using the Cu (I)–stabilizing 
reagent bathocuproine disulfonic acid. Copper (I), the product of the reactions between 
OXY or resveratrol with copper (II) reacted to bathocuproine disulfonic acid generating 
cu(I)– bathocuproinedisulfonate complex, which was detected at the wavelength 484 nm. 
Figure 34 showed the absorbance at 484 nm detected the reaction’s product of OXY and 
copper (II); it was raised dose–dependently from 0.04–0.65 OD at the concentrations of 
1.56–100 µM–OXY. While there was no signal increased in the condition absent of 
copper (II). These results indicated that OXY reduced copper (II) to copper (I). When 
compared to its derivatives, the reducing ability of OXY was more potent compared to 
resveratrol. However, the formation of copper (I) in the reactions of the two stilbenes 
tended to remain constant at the concentration of 50–100 µM. The trans–stilbene clearly 





















Figure 34 The relationship between the concentration of OXY (µM) and the absorbance 
of the Cu(I)– bathocuproinedisulfonate complex at 484 nm in the presence and absence 













































Figure 35 The relationship between the concentration (µM) of OXY, resveratrol or trans–
stilbene and the absorbance of the Cu(I)–bathocuproinedisulfonate complex at 484 nm in 










































4.3.4 GSH assay 
The depletion of authentic GSH was investigated in the reaction of OXY and copper (II) 
ions. After ROS was generated in the reaction, the authentic reduced GSH 50 nmol/mL 
was incubated in the reaction for 1 hour. Then the remaining GSH was measured using 
spectrophotometry.  
The reduced GSH decreased from 100 % of control to around 93% at the concentration 
of OXY treated (6.25–400 µM) in the presence of copper (II). However, the GSH amount 
remained close to 100% of control in the reaction of OXY without copper. These results 
were consistent with ROS assay previously. The graph is illustrated in Figure 36. The 
depletion of reduced GSH was also investigated for resveratrol and trans–stilbene; OXY 
reduced GSH dose–dependently between 6.26–400 µM. The GSH depletion ability of 



















Figure 36 The relationship between the concentration (log µM) of OXY or Cu(OAc)2 














GSH depleted by oxyresveratrol
































Figure 37 The relationship between the concentration (µM) of OXY, resveratrol and 
















GSH depleted by oxyresveratrol and derivatives































Reports of DNA breakage mediated by hydroxystilbenoids has gained momentum in the 
last few years, especially resveratrol and derivatives because the compounds are capable 
of double–stranded DNA breakage specifically in the presence of copper ions. The 
condition included oxygen to promote a Cu+–oxo intermediate and some amount of 
superoxide damaging the DNA. This property was expected to be the promising 
mechanisms of cytotoxic or anti–cancer agents (Subramanian et al., 2004). The DNA 
break in cellular systems was confirmed in lymphocytes isolated from human peripheral 
blood using comet assay; the results indicated that piceatannol, which has more hydroxyl 
group than resveratrol, was more potent activity. Whereas, trans–stilbene, which does not 
have any hydroxyl groups, is inactive (Azmi et al., 2005). Some polyphenolic compounds 
have been already well–known to behave as pro–oxidants in the condition of presenting 
only themselves or oxidized metal ions such as Fe3+, Cu2+, Zn2+ or Ni2+, which trigger the 
Fenton–mediated ROS generation (Yamada et al., 1985; Lopes et al., 1999). 
This current study found that OXY showed a higher ability to cleave supercoiled plasmid 
pBR322 DNA. The higher doses of the compound could break the supercoiled form into 
open circular and linear forms. The DNA nick ability was specifically induced by copper 
ions, one of the most abundant metal ions in the biological system (Kalinowski et al., 
2016), which might trigger the Fenton mediated ROS generation the same mechanism as 
other phenolic compounds previously reported (Moran et al., 1997). More interestingly, 
the three extracts also showed to nick DNA at similar doses to OXY. The three dilutions 
of A. lakoocha heartwood including 200, 25 and 3.13 µg/mL of ethyl acetate extract were 
equivalent to OXY around 525, 65 and 8 µM, respectively. Therefore, the damaged bands of 
DNA were similar to those in Figure 27. Copper at some certain extent is well–known to be 




has been reported that significantly elevated levels of copper have been found in both 
serum and tissue of cancer patients (Kuo et al., 2002). 
The copper (I) detected tended to be dose–dependent on OXY. However, at the dose of 
50–100 µM the formation was constant. The formation of copper (I) remained constant 
because it could be oxidized by O2 or O2
•– in the reaction and returned to copper (II) 
(Subramanian et al., 2004; Valko et al., 2004; Gupte and Mumper, 2009). The results of 
the three stilbenes also correlated well with their ROS generating abilities. 
Glutathione (GSH) is one of the most vital antioxidants in living organisms. It is able to 
prevent damage to an important intracellular component from ROS, the toxicity of 
xenobiotic electrophiles and maintaining redox homeostasis (Forman et al., 2009).   
Glutathione exists in reduced (GSH) and oxidized (GSSG) states. The ratio of reduced 
glutathione to oxidized glutathione within cells is a measure of cellular oxidative stress, 
therefore the conversion of GSH to oxidised GSSG  is used as a model to measure ROS 
generated in any reaction (Babich et al., 2009). The pro–oxidant activity of OXY, which 
caused GSH depletion was similar to the activity noted for phytochemical extracts in a 
previous report (Babich et al., 2009). Gingko biloba leaf extract was found to cause pro–
glutathione oxidation both in cell–free reaction and in HSC–2 cells. The property of pro–
oxidant of the plant–derived compounds is illustrated and well documented to link 
directly to apoptosis causing cytotoxicity to cancers (Vallejo et al, 2017). 
In this chapter should be concluded that OXY exhibited the pro–oxidant activity generating 
ROS in the specific presence of copper (II) ions. This could cause damage to double–
stranded DNA into the open chain or linear forms. OXY was able to show higher capability 
than resveratrol at the same doses, while the trans–stilbene did not show the activity. The 
three A. lakoocha extracts also showed the damaged DNA consistent with the amount of 




(II) to copper (I) and depleting GSH. In consideration of these findings, it can be implied 
that OXY has the potential to be developed as a promising anticancer drug candidate and to 





























CHAPTER 5 CYTOTOXICITY OF OXY IN 


















5.1 Introduction  
OXY has been shown to possess various potent bioactivities with the main property being 
an antioxidant (Lorenz et al., 2003), anti–inflammatory (Lee et al., 2015), tyrosinase 
inhibition (Likhitwitayawuid et al., 2006) anti–virus (Chuanasa et al., 2008) and anti–
cancer (Rahman et al., 2017).  
In consideration of its chemical structure, which is similar to the well–known antioxidant 
and anticancer property, resveratrol, OXY may share anti–cancer property. The previous 
report found that OXY posed cytotoxicity in vitro to some kinds of cancerous cell lines 
such as human hormone–dependent breast cancer (T47D), human cervical 
adenocarcinoma (HeLa), human non–small–cell lung carcinoma (A549) (Chatsumpun et 
al., 2016). There have been no reports regarding the molecular targets or biological 
pathways affected by elevated copper levels in cancer cells.  
 
5.2 Aims 
To identify a cell line model (transformed and non–transformed) in which cytotoxicity is 
demonstrated in response to OXY. 
 
5.3 Results  
5.3.1 Growth curve analysis  
The growth curve of different kinds of cancerous cells in the study including A549, 
CACO–2, HepG2, MCF7, PC–3, RAW264.7 and the two non–transformed cell lines 




were investigated in 96–well plates to optimize the cell number used in the cytotoxicity 
assay. The cells were grown in growth medium depending on cell designation and then 
the cell number was counted for four consecutive days. The initial cell number that gave 
the growth curve in log phase was chosen to be optimal and used in the MTT cytotoxic 
assay. Growth curves of the eight cells used in the experiment were shown in Figure 39. 
A549, CACO–2, HepG2, MCF10A, MCF7 have an epithelial-like morphology. MRC–5 
and PC–3 cells have fibroblast-like morphology. While RAW 264.7 cells are 
monocyte/macrophage-like cells.   The initial cell number for seeding in 96–well plates 
were chosen from the results in Figure 39. All cell lines were initially seeded at 5x103, 
7.5x103, 1x104 and 2x104 cells and left in the incubator for 4 days. The cell number was 
counted every day. Figure 39 showed that A–549, CACO–2, HepG2, MCF10A and RAW 
264.7 increased cell number  quickly; the seeding densities of 1x104 and 2x104 cells 
reached the plateau phase in 3 days. MRC–5 cells had linear growth curves for the three 
initial seeding densities. Whereas, MCF7 and PC–3 cells grew more slowly; Therefore, 
A549, CACO–2, HepG2, RAW264.7, MRC–5 and MCF10A cells were selected to be 
used at a seeding density of 5x103 cells/ well, while MCF7 and PC–3 cells were used at 




































Figure 39 Growth curves of the cells used in the study with different initial cell numbers 
counted for four consecutive days. Values express mean ± SD (n=3). 
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5.3.2 Cytotoxicity of copper 
Toxicity of Cu(OAc)2  was also evaluated to make sure that the copper added to the 
reaction did not directly cause damage to the cells. The viability of the cells after 
incubated to different concentrations of copper (II) for 48 h shown in Figure 40.  
Copper tended to cause toxicity to the cells dose–dependently between the doses of 0.13–
400 µM, except in RAW 264.7 cells. A549 and MCF10A cells were significantly 
sensitive and vulnerable to the low doses of 1.25 up to 400–µM copper. CACO–2 cells 
were in moderate; 25 µM caused significant (P<0.01) toxicity and at the high dose of 400 
µM reduced cell viability down to around 10%. Whereas, HepG2, MCF7, MRC–5 and 
PC–3 cells were tolerant to Cu(OAc)2 at the dose between 0.13– 100 µM, while the higher 





















Figure 40 Toxicity of Cu(OAc)2 to the cells used in the study; the cells were incubated 
with Cu(OAc)2 with different concentrations (0.13 – 400 µM) for 48 h. Then cell viability 
was detect by MTT assay. Values express mean ± SD (n=3). Statistical analysis was 
carried out using One–way ANOVA and Dunnett’s post hoc test. The significant 
difference was compared relatively to the control (*P < 0.1, **P < 0.01, ***P < 0.001 



























Toxicity of Cu(OAc)2 to A-459 cells


















































Toxicity of Cu(OAc)2 to Caco-2 cells


















































Toxicity of Cu(OAc)2 to HepG2 cells
















































Toxicity of Cu(OAc)2 to MCF10A cells




















































Toxicity of Cu(OAc)2 to MCF7 cells












































Toxicity of Cu(OAc)2 to MRC-5 cells












































Toxicity of Cu(OAc)2 to PC-3 cells













































Toxicity of Cu(OAc)2 to 264.7 cells



























5.3.3 Toxicity of OXY to cancer cells in the presence or absence of copper 
This assay aimed at investigating the effect of copper ions on the cytotoxicity of OXY in 
cancerous cells. The cells were either pre–treated with 50µM Cu(OAc)2 for 24 h (OXY–
Pre–Cu), or OXY in medium supplemented with 50µM Cu(OAc)2 (OXY+Cu) and no 
Cu(OAc)2 (OXY) then exposed to OXY for 48 h. The cell viability was calculated to the 
percentage of cell control and the non–linear regression graph of log concentration (µM) 
and percent viability shown in Figure 41. The inhibitory concentration (IC50) of each 
condition was generated and summarized in Table 7. The cells that OXY caused 
cytotoxicity to several cell lines ranged from the highest (low IC50) to the lowest (high 
IC50) were MCF7, HepG2, PC–3, RAW 264.7 and A549 with the IC50 of 30.64±4.79, 
104.47±0.82, 106.90±8.63, 115.95±11.28 and 148.63±4.48 µM, respectively. Whereas, 
the compound showed low toxicity to CACO–2, MCF10A and MRC–5 (IC50 >200 µM). 
Interestingly, copper (50 µM) tended to make OXY less or no toxic to the cells. The 
copper–preincubated cells (OXY–Pre–Cu2+) (MCF7, PC–3 and RAW 264.7) were not 
significantly different (P>0.1) in the IC50 values compared to the OXY–treated cells 
without copper (OXY). There was mild toxicity but not significantly different (P>0.1) 
from MCF10A and MRC–5. OXY in the presence of copper (OXY+Cu2+) showed less 
toxicity to the cells than treated with only OXY, which was a significant difference 














Figure 41 Cell viability (% of control) after treated with different concentrations of OXY, 
pre–treat with copper and treat with OXY. OXY–Pre–Cu = cells pre–treated with 50 µM 
Cu(OAc)2 for 24 h then rinsed with medium and treated with OXY; OXY+Cu = cells 
treated with OXY in the medium supplemented with 50µM Cu(OAc)2; and OXY= cells 
treated with OXY without Cu(OAc)2. Values express mean ± SD (n=3). 


























































































































































































































































PC-3 RAW 264.7 


































































































































































































































































Table 7 Inhibitory concentration (IC50, µM) of OXY to the cells; A549, CACO–2, 
HepG2, MFC7, PC–3, RAW 264.7, MRC–5 and MCF10A cells in medium; cells pre–
treated with 50µM Cu(OAc)2 for 24 h (OXY–Pre–Cu), OXY in medium supplemented 
with 50 µM Cu(OAc)2 (OXY+Cu)  and no Cu(OAc)2 (OXY). Values express mean ± 
SEM (n=3). Statistical analysis was carried out using One–way ANOVA and Dunnett’s 
post hoc test or unpaired t-test. The significant difference was compared relatively to the 










A549 148.63±4.48 >200 >200 2.21±0.08 
CACO–2 >200 >200 >200 13.39±4.34 
HepG2 104.47±0.82 136.90±12.08* >200 3.44±0.33 
MCF7 30.64±4.79 31.31±8.25 102.17±24.37* 0.86±0.29 
PC–3  106.90±8.63 109.35±9.63 >200 12.61±1.97 
RAW 264.7 115.95±11.28 125.90±4.32 164.28±4.87** 0.86±0.29 
MRC–5 >200 164.16±6.91 >200 1.51±0.04 













5.3.4 Investigation of synergizing activity between copper and OXY 
MCF7 and HepG2 cells, the cell lines that demonstrated the greatest degree of OXY-
induced toxicity, were chosen to study synergizing effect with copper. According to the 
method modified from (Andrade Volkart et al., 2017), they were pre–treated with 
different three levels of copper including 25, 50 and 100 µM then treated with OXY. The 
results were illustrated in Figure 42 showing that the cells pre–incubated with the higher 
levels of copper were not significantly different (P>0.1) compared to those treated only 










Figure 42 Cell viability (% of control) after pre–incubated with three different 
concentrations of copper for 24 h and then treated with 50 µM (MCF7 cells) or 100 µM 
(HepG2 cells) of OXY for 48 h. Values express mean ± SD (n=3). Statistical analysis was 
carried out using One–way ANOVA and Dunnett’s post hoc test. The significant 









































































































































































5.3.5 Determination of intracellular ROS production in the reactions between 
copper and OXY 
ROS formation was investigated in the cells pre–treated with copper (II) and then treated 
with the fixed–dose of OXY. The intracellular ROS detected was not raised after the cells 
were pre–treated with copper or OXY compared relatively to cell control. Moreover, there 
was no correlation between the dose of copper and the time of treatment to the ROS 




Figure 43 Relative fluorescence (% of control) of ROS formation in MCF7 cells (A) and 
HepG2 cells (B) after pre-treatment with  three  different concentrations of Cu(OAc)2 for 
24 h followed by  with 50 µM (for MCF7) or 100 µM (for HepG2) OXY for 2, 6, 24 and 







The cancerous cells chosen to test cytotoxicity in this chapter were chosen following 
consideration of previous literature that reported elevation of copper level in serum and 
tissue of cancer patients (Gupte and Mumper, 2009)  
The main cell viability–cytotoxicity assay used was MTT metabolic assay, which is 
suitable for high throughput screening of the cell viability that transformed MTT into 
formazan product. The amount of formazan is generally proportional to the number of 
metabolically active viable cells in log phase growth as demonstrated by the linearity of 
response. Therefore, each cell line needed to be evaluated the growth curve during the 
period of 48–72 h before implementing the assay (Riss et al, 2013). The results showed 
that the optimal cells seeded in 96–well plate were between 5x103–1x104 cells/well, 
which gave log phase growth during the treating time. 
Cu(OAc)2 caused toxicity to almost of the cells at high doses. Some cell lines were 
vulnerable at the very low dose (1.25 µM or 25 µM) such as MCF10A and CACO–2 
cells. The previous study reported that copper(II) overload caused toxicity to HepG2 
(220.5 ± 23.8 μg/mL) by inducing stress genes including c–fos, HMTIIA, HSP70, 
GRP78, RARE, GADD153, and RARE (Tchounwou et al., 2008). Copper was (200 μM) 
also found to induce cytotoxicity in the human colon carcinoma cell line HT–29, which 
correlated with the induction of cell apoptosis, increased oxidative stress, alteration of 
mitochondrial β oxidation, and the configuration of lipid metabolism and energy 
metabolism (Xiao et al., 2016). 
In the condition supplemented with 50 µM Cu(OAc)2, demonstrated copper(II) has the 
tendency to make OXY less toxic to the cells than Oxy–Pre–Cu2+. Copper ions oxidized 
OXY the same way as Fe(II) has been reported previously for piceatannol, catechin, 




resveratrol (Shingai et al., 2011). Moreover, the medium with sodium bicarbonate can 
oxidize or reduce the amount of phytochemicals such as resveratrol (Yang et al., 2010). 
Therefore, the potency of OXY was attenuated. Both approaches were found to make 
OXY less cytotoxic. It can be assumed that copper penetrated into MCF7 cells but the 
amount was very low. Additionally, the intracellular copper was lower in the presence of 
stilbenoids (Volkart et al, 2017). 
The synergizing effect of copper (II) to OXY toxicity was investigated by varying the 
pre–incubated doses of copper in the presence of 50 µM OXY in MCF7 cells or 100 µM 
OXY in HepG2 cells. There was no significant difference (P>0.1) between the doses 
applied in the two kinds of cell. Moreover, there was no significant ROS formation 
changed in the conditions of pre–incubated with copper. Therefore, the assumption of 
intracellular copper enhancing the toxicity of OXY by generating ROS has not been 
verified in this study.  
In consideration of the abundant concentration of copper in breast cancer cells, OXY may 
potentially be cytotoxic to breast cancer cells in situ. Therefore, MCF7 cell line was 
chosen to be a model to study the molecular effects of OXY.  
In this chapter, it can be concluded that OXY caused toxicity to MCF7, HepG2, PC–3, 
RAW 264.7 and A549 cells with EC50 of 30.64±4.79, 104.47±0.82, 106.90±8.63, 
115.95±11.28 and 148.63±4.48µM, respectively without causing toxicity to the normal 
cells. Whereas, copper was likely to make OXY less toxic. OXY and OXY–copper (II) 



























6.1 Introduction  
The microarray–based technique or GeneChip (Figure 44) is a high–throughput 
technology for genetic explorations including gene expression analysis. It consists of the 
number of technologies that have been developed as a single platform, which provides 
extensive information on gene networks and functions on drug efficacy and toxicity 
(Taylor et al., 2005). Over the years, the kind of platform has been extensively 
implemented to evaluate the effect of OXY and derivatives, especially of resveratrol on 
several cancerous cell lines, such as multiple myeloma cells (Geng and Klionsky, 2008) 
and colorectal cancer (Lee et al., 2018). However, OXY showed toxicity to MCF7 cells 
in this study and has several unique properties different from other stilbenoids.  In 
consideration of this, gene expression and cellular consequences of OXY exposure need 
to be elucidated to provide the insight into the mechanism of actions of OXY in the cancer 
cells model.  
To explore the mechanisms of action of a new drug or a promising compound, there are 
several platforms which may be used.  
In the work reported here, the microarray was implemented using the human Clariom S 
arrays (a 400 format array) (Affymetrix Inc., Santa Clara, CA, USA) as the gene probe. 
The targets or the RNA samples were obtained from MCF7 cells treated with OXY at the 
concentrations of 0, 50, and 100 μM for 24 h. The controls and data analysis followed the 
manufacturer’s recommendations. The genes most affected were then validated using 












 Figure 44 Affymetrix microarrays: Photolithographic synthesis of oligonucleotides on 
microarrays. A chip consists of hundreds of thousands of microscopically small probe 
cells. Each cell contains millions of copies of oligonucleotide sequences which serve as 
template for the hybridisation of the probes with their fluorescently labelled mRNA 
targets. The fluorescent signals are read by a high definition laser scanner and are 













To elucidate gene–level expression profile, and assess changes in key genes and pathways 
that are involved in the biological response to OXY using microarray and quantitative 
polymerase chain reaction analysis. 
 
6.3 Results  
6.3.1 Microarray assay 
Global expression patterns of genes and pathways were obtained using microarray 
technology and data analysis software. The genes responsive to the treatment of OXY for 
24 h was performed in three biological replicates, the samples proceeded as described in 
the materials and methods in chapter 2 (page 48-58). After analysis, the labelling and 
hybridising controls have passed the criteria. The number of different significantly 
(P<0.1) expressed genes under both conditions compared to the control group was 
observed. The gene expression summary in Figure 45 and Figure 46. The expressed genes 
in some significant pathways were illustrated in Figure 47.  
Total 686 genes were differentially expressed in the 50 µM–treated groups; among these, 
262 were upregulated and 424 were downregulated genes. While, 2,338 genes were 
differentially expressed in the 100 µM–treated groups; among these, 907 were 
upregulated and 1,431 were downregulated genes. 
More than 80% of the gene population changed in the two treatments were the multi–
complex genes. Therefore, the genes altered were the combinations of coding, noncoding 





WikiPathways (wikipathways.org), a biology community maintained website that 
displays biological pathways, allowed to identify those in the most relevant biological 
mechanisms, pathways and functions of the genes altered by OXY treatments in MCF7 
cells. 
The affected genes from these analyses showed that the most affected processes under 
both conditions of OXY treatment were cell cycle control, DNA repair and autophagy, as 
well as apoptosis pathway (Figure 47). Majority of the genes in cell cycle control and 



























Figure 45 Gene expression summary of MCF7 cells treated with 50 µM and 100 µM 
compared to the untreated control ; 686 genes changed in the 50 µM–OXY treatment 



















Coding = Genes contain only protein–coding transcripts; 
NonCoding = Genes contain only non–protein–coding transcripts; 
Multiple Complex = Gene contains more than one locus type above; 
Unassigned = Locus type could not be determined based on source data. 
 
 
Figure 46 Differential expressed genes  ; a) 686 out of 21,448 genes (3.2%) changed in 
the 50 µM–OXY treatment, while b) 2,338 out of 21,448 genes (10.9%) changed in the 
100 µM–OXY treatment, were classified as up– and down–regulated for coding, 








Figure 47 Gene ontology-based biological process pathways altered by OXY in MCF7  
breast cancer cells. Differentially expressed genes in MCF7 cells treated with 50 µM 
(A) or 100 µM (B) of OXY for 24 h. To determine the biological process pathways 
involved, the list of significant up-regulated (P<0.1) and down-regulated genes were 



























































































































































































































































































































































































































































































































































































Cell cycle control was one of the significantly-affected pathways (P<0.05). At the dose 
of 50 and 100 μM–treated MCF7 cells, DNA–damage–inducible alpha (GADD45A) and 
cyclin–dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) were the dramatically 
upregulated expression. Whereas, cyclin–dependent kinase 2 (CDK2), E2F transcription 
factor one (E2F1) were downregulated in G1 to S cell cycle phase (Figure 48). 
At the concentration of 100 μM–treated MCF7 cells compared to the cell control, OXY 
appeared to upregulate the expression of genes in apoptosis both in extrinsic and intrinsic 
pathways including Fas cell surface death receptor (FAS),  caspase 8, apoptosis–related 
cysteine peptidase (CASP8), tumour necrosis factor receptor superfamily, member 10b 
(TNFRSF10B), BCL2–associated X protein (Bax),  DIABLO, BCL2 binding component 
3; microRNA 3191 (BBC3) and jun proto–oncogene (Ho et al.) (Figure 49). The sample 
signals (average log 2) of the key genes in several biological pathways were elucidated 
in Figure 50–53. The pictures showed the signals of the genes affected by two–doses 
OXY treatments compared to the untreated control (0 µM OXY); CDK2 and E2F1 genes 
were significantly decreased (P<0.01)  doses dependently in the G1–S cell cycle control 
pathway. Most of the genes in apoptosis pathway were likely to be up–regulated such as 
FAS, CASP8, TNFRSF10B, Bax, DIABLO, BBC3 and MAPK8. Whereas, most of the 
genes in DNA repair pathway tend to be down–regulated including RAD51 recombinase 
(RAD51), breast cancer 1, early onset (BRCA1), breast cancer 2, early onset (BRCA2), 
X–ray repair complementing defective repair in Chinese hamster cells 2 (XRCC2), X–
ray repair complementing defective repair in Chinese hamster cells 3 (XRCC3) and 
poly(ADP–ribose) polymerase 1(PARP1). Some genes in senescence and autophagy in 
cancer pathway were upregulated significantly (P<0.1) such as microtubule–associated 
protein 1 light chain 3 beta (MAP1LC3B), sequestosome 1 (SQSTM1), GABA(A) 
receptor–associated protein like 2 (GABARAPL2), while AKT1 substrate 1 (proline rich) 








Figure 48 Cell cycle control pathway integrating expression data for MCF7  cells treated 









Figure 49 Apoptosis pathways integrating expression data for MCF7  cells treated with 


















Figure 50 Expressed gene signal (log 2) in G1 to S cell cycle control pathway of MCF7 
cells treated with OXY at 0 µM, 50 µM and 100 µM for 24 h. Data are the mean ± SD 
(n=3). Statistical analysis was carried out using One–way ANOVA and Dunnett’s post 
hoc test. The significant difference was compared relatively to the control (**P < 
0.01,***P < 0.001 and ****P < 0.0001). 
 
 






























Figure 51 Expressed gene signal (log 2) in apoptosis pathway of MCF7 cells treated with 
OXY at 0 µM, 50 µM and 100 µM for 24 h. Data are the mean ± SD (n=3). Statistical 
analysis was carried out using One–way ANOVA and Dunnett’s post hoc test. The 
significant difference was compared relatively to the control (**P < 0.01, ***P < 0.001 















































Figure 52 Expressed gene signal (log 2) in senescence and autophagy in cancer pathway 
of MCF7 cells treated with OXY at 0 µM, 50 µM and 100 µM for 24 h. Data are the mean 
± SD (n=3). Statistical analysis was carried out using One–way ANOVA and Dunnett’s 
post hoc test. The significant difference was compared relatively to the control (*P < 0.1, 
**P < 0.01, ***P < 0.001 and ****P < 0.0001). 
 




































Figure 53 Expressed gene signal (log 2) in G1 to DNA repair pathway of MCF7 cells 
treated with OXY at 0 µM, 50 µM and 100 µM for 24 h. Data are the mean ± SD (n=3). 
Statistical analysis was carried out using One–way ANOVA and Dunnett’s post hoc test. 
The significant difference was compared relatively to the control (*P < 0.1, **P < 0.01, 







































6.3.2 Quantitative polymerase chain reaction (qPCR)  
The gold standard approach for quantitative analysis of RNA expression is quantitative 
polymerase chain reaction (qPCR) due to its accuracy, sensitivity, specificity, 
reproducibility and the potential to be a high throughput analysis. Therefore, the 
technique is always chosen for validating expression of the genes after microarray assay 
(Bustin et al., 2005; Chen et al., 2016).  The cells were treated with OXY and extracted 
total RNA. All protocols followed the manufacture’s instruction, especially the primers, 
using the validated primer sets for human. 
The genes were randomly chosen and the expression was calculated as a relative 
quantification using the glyceraldehyde 3–phosphate dehydrogenase (GAPDH) for the 
standardization of gene expression levels. The Ct (cycle threshold) values from triplicates 
of each gene showed in Table 8.  
The relative quantification of the gene expression was followed by the 2−ΔΔCt Livak and 
Schmittgen method (Livak and Schmittgen, 2001). The untreated control (0 µM OXY) 
was used to normalise the two–OXY treatments for each target gene. The fold change of 
the target genes treated with 50 µM OXY and 100 µM OXY are shown in Figure 54.  
Total 12 out of 19 genes (63%), the expression was increased dose–dependently including 
Bax, CDKN1A, GADD45A, CASP8, DIABLO, FAS, JUNB, MAPK8, TNFSF10B, 
GABARAPL2, MAP1LC3B and SQSTM1, while the other genes (37%) (CDK2, E2F1, 
PARP1, BRCA1, RAD51, AKT1, ESR1) were suppressed by the compound. The fold 
change of GADD45A and FAS were quite high around 7.5 times in 50 µM OXY 
treatment and around 15 times in 100 µM OXY treatment compared to the untreated. 
Whereas, the others were roughly or below 5 fold for the two treatments. Bax, CDKN1A, 
GADD45A, FAS, MAP1LC3B and SQSTM1 were significantly up regulated (P<0.1) 
compared between the two treatments. While E2F1, PARP1, BRCA1 and RAD51 were 




Table 8 Ct (cycle threshold) values of each amplified gene from MCF–7–extracted RNA 
treated with 50–µM OXY and 100–µM OXY compared to untreated control. 
Genes Sample 0 µM OXY 50 µM OXY 100 µM OXY 
GAPDH replicate 1 10.26 11.33 11.97 
 replicate 2 10.34 11.87 10.98 
 replicate 3 10.43 11.71 11.06 
 
average 10.34 11.64 11.34 
 
SD 0.09 0.28 0.55 
CDK2 replicate 1 17.89 19.48 18.45 
 replicate 2 18.24 19.85 18.47 
 replicate 3 18.02 19.40 18.01 
 
average 18.05 19.58 18.31 
 
SD 0.18 0.24 0.26 
E2F replicate 1 20.32 21.59 21.30 
 replicate 2 20.10 21.68 21.48 
 replicate 3 19.49 22.03 21.57 
 
average 19.97 21.77 21.45 
 
SD 0.43 0.23 0.14 
BAX replicate 1 15.85 15.33 14.80 
 replicate 2 16.15 15.55 14.91 
 replicate 3 16.04 15.48 14.96 
 average 16.01 15.45 14.89 
 
SD 0.15 0.11 0.08 
CDKN1A replicate 1 17.44 15.34 14.54 
 replicate 2 17.40 15.51 14.56 
 replicate 3 17.23 15.60 14.59 
 
average 17.36 15.48 14.56 
 
SD 0.11 0.13 0.03 
GADD45A replicate 1 19.13 17.54 16.36 
 replicate 2 19.14 17.19 16.15 
 replicate 3 18.99 17.29 16.14 
 
average 19.09 17.34 16.22 
 





Table 9 continue 
CASP8 replicate 1 20.96 22.49 19.97 
 
replicate 2 22.22 21.81 19.87 
 replicate 3 21.23 22.53 19.75 
 
average 21.47 22.28 19.86 
 
SD 0.66 0.40 0.11 
DIABLO replicate 1 18.20 18.74 16.9 
 replicate 2 17.07 18.62 17.13 
 replicate 3 17.50 18.35 17.37 
 
average 17.59 18.57 17.13 
 
SD 0.57 0.20 0.24 
FAS replicate 1 22.91 21.50 19.10 
 replicate 2 22.82 21.47 19.30 
 replicate 3 22.90 21.22 19.38 
 
average 22.88 21.40 19.26 
 
SD 0.05 0.15 0.14 
JUNB replicate 1 24.39 25.16 29.98 
 replicate 2 24.58 24.82 29.46 
 replicate 3 24.41 25.00 29.65 
 
average 24.46 24.99 29.70 
 
SD 0.10 0.17 0.26 
MAPK8 replicate 1 18.94 19.90 18.43 
 replicate 2 18.95 19.74 18.60 
 replicate 3 19.02 19.82 18.30 
 
average 18.97 19.82 18.44 
 
SD 0.03 0.36 0.29 
TNFSF10 replicate 1 30.15 32.57 29.32 
 replicate 2 30.30 31.78 29.98 
 replicate 3 30.36 30.98 29.12 
 
average 30.27 31.78 29.47 
 







Table 9 continue 
PARP1 replicate 1 16.20 16.33 15.72 
 replicate 2 15.97 16.32 15.30 
 replicate 3 16.17 16.34 15.70 
 average 16.11 16.33 15.57 
 SD 0.13 0.01 0.24 
BRCA1 replicate 1 18.76 19.53 22.67 
 replicate 2 18.65 19.94 21.53 
 replicate 3 18.75 19.85 21.82 
 
average 18.72 19.77 22.01 
 
SD 0.06 0.22 0.59 
RAD51 replicate 1 17.64 19.04 20.40 
 replicate 2 17.65 18.86 20.38 
 replicate 3 17.70 19.02 20.38 
 
average 17.66 18.97 20.39 
 
SD 0.03 0.10 0.01 
AKT1 replicate 1 13.84 16.72 16.88 
 replicate 2 14.00 15.91 15.89 
 replicate 3 14.11 16.44 15.27 
 average 13.98 16.36 16.01 
 SD 0.14 0.41 0.81 
ESR1 replicate 1 17.07 18.99 19.3 
 
replicate 2 17.16 19.35 19.36 
 replicate 3 16.88 18.69 19.55 
 
average 17.04 19.01 19.40 
 
SD 0.14 0.33 0.13 
GABARAPL2 replicate 1 16.78 17.23 16.81 
 
replicate 2 16.23 17.27 16.53 
 replicate 3 16.65 16.85 16.8 
 
average 16.55 17.12 16.71 
 







Table 9 continue 
MAP1LC3 replicate 1 15.97 16.11 15.41 
 
replicate 2 16.06 15.97 15.37 
 replicate 3 16.17 15.96 15.08 
 
average 16.07 16.01 15.29 
 
SD 0.10 0.08 0.18 
RAD51 replicate 1 17.64 19.04 20.40 
 
replicate 2 17.65 18.86 20.38 
 replicate 3 17.70 19.02 20.38 
 
average 17.66 18.97 20.39 
 
SD 0.03 0.10 0.01 
SQSTM1 replicate 1 16.05 16.55 15.4 
 
replicate 2 16.06 16.62 15.26 
 replicate 3 15.9 16.66 15.36 
 
average 16.00 16.61 15.34 
 

















Figure 54 Relative quantity of mRNA extracted from MCF7 treated with 50 µM or 100 
µM of OXY; Validation of selected genes differentially expressed from MCF7 cells 
treated for 24 h with 50 µM or 100 µM of OXY versus the control data set (n=3). The 
statistical difference between the two treatments was carried out using unpaired t-test (*P 
































































































































The independent triplicate MCF7 cells of the control (untreated), 50 µM and 100 µM 
treated with OXY for 24 h (IC50 = 368.37 µM) were designed to analyse the gene 
expression, which the exposure time enough to study the main molecular changes at the 
early stage, especially well–known RNA and proteins inside the cells (Li and Sarkar, 
2002).  
The total all well–known, 21,448 human genes were investigated by the Clariom™ S 
assays, of which the probe sets consist of a subset of 10 probes per gene. There was 
enough to perform gene–level expression profiling studies and to assess changes in key 
genes and pathways affected by OXY (MacGregor and Squire, 2002).  
The analysis was performed using the data filter of probe sets with a fold change > 2 or 
< –2 and with a p–value < 0.05 for the data of 50µM–OXY treatment vs the control and 
100µM–OXY treatment vs the control. The statistical analysis was used eBayes 
correcting the variance of the ANOVA analysis with an empirical Bayes approach that 
used the information from all the probe sets to yield an improved estimate for the 
variance. The eBayes correction is especially important when the number of samples 
being analysed is small (Rahman et al., 2017).  
Total 686 genes (3.2%) passed the filter criteria in 50 µM–OXY treatment, while 2,338 
genes (10.9%) passed the filter criteria in 100 µM–OXY treatment compared to the 
untreated control. The number of genes changed in the two groups were down–regulated 
roughly twice higher than those up–regulated. The gene expression was the OXY–dose 
dependent. The genes changed more than 90% were coding and multiple complex genes, 
which can translate into proteins. 
The most affected and significant changed genes (P<0.1)  regarding DNA synthesis such 




were like to be down–regulated because the compound inhibited cell proliferation and 
cell growth as reported in chapter 5. The inhibition of the cell cycle pathway also links 
directly to the DNA repair mechanism and breast cancer pathway (Helleday et al., 2007). 
Apoptosis, programmed cell death was also induced by OXY exposure. OXY increased 
apoptosis genes the same as other stilbenoids, especially resveratrol (Varoni et al., 2016). 
OXY was found here to induce the expression of several genes in the cell senescence and 
autophagy pathway, which has also been reported that the compound increased levels of 
autophagy in neuroblastoma cell lines through the mediation of PI3K or mTOR genes 
(Rahman et al., 2017).  
All gene expression validated using qPCR gave the results consistent with those from 
microarrays. The apoptotic process has been reported to be one of the important 
therapeutic hallmarks of cancer. OXY was also confirmed posing cytotoxicity through 
apoptosis. The expression of genes in DNA repair was the highest significant difference 
(P<0.0001) between the two treatments especially RAD51. This gene has been reported 
overexpression in several cancers (Kiyohara et al., 2012). The suppression of DNA repair 
gene may also help increase drug sensitivity or mediate resistance.  Moreover, the 
mediation of cell proliferation, cell growth and metastasis may play the important 
mechanism of action of OXY. 
In this chapter should be concluded that OXY showed regulation of some genes that 
played an important role in the biological pathways during carcinogenesis in MCF7, 
human breast cancer cells. OXY decreased the expression of CDK2, E2F1 and the MCM 
complex, which affected the initial stage of G1–S phase of cell proliferation. OXY also 
enhanced apoptosis genes through extrinsic and intrinsic pathways, accompanying with 
autophagy and DNA repair genes. Therefore, further research is required to investigate 







CHAPTER 7 APOPTOSIS PATHWAY 

















7.1 Introduction  
Apoptosis or the process of programmed cell death is generally characterized by distinct 
morphological characteristics and energy–dependent biochemical mechanisms. 
Apoptosis is considered a vital component of various processes including normal cell 
turnover, proper development and functioning of the immune system, hormone–
dependent atrophy, embryonic development and chemical–induced cell death (Elmore, 
2007 ) . The ability to modulate the life or death of a cell is recognized for its immense 
therapeutic potential. Therefore, research continues to focus on the elucidation and 
analysis of signalling pathways that control apoptosis (Kruidering and Evan. 2000).  
There are two main pathways of apoptosis (Figure 55); extrinsic and intrinsic pathways. 
Each route requires specific triggering signals to begin an energy–dependent cascade of 
molecular events. Briefly, the extrinsic pathway involves transmembrane receptor–
mediated interactions. To illustrate, the interaction of FasL/FasR or TNF–α/TNFR1 then 
activates through procaspase–8 and caspase–8, respectively (Tummers and Green, 2017). 
The other, intrinsic pathway is non–receptor–mediated stimuli that produce intracellular 
signals within the cells or mitochondria. This cascade causes changes in the inner 
mitochondrial membrane resulting in losing the mitochondrial transmembrane potential, 
then releasing pro–apoptotic proteins such as BAX, tBID and Cytc from the 
intermembrane space into the cytosol (Elmore, 2007).  
Both pathways activate the executioners through caspase 2, 3, 6 and 7. The execution 
pathway results in characteristic cytomorphological features including cell shrinkage, 
chromatin condensation, the formation of cytoplasmic blebs and apoptotic bodies and 
finally phagocytosis of the apoptotic bodies by adjacent parenchymal cells, neoplastic 






Figure 55 Apoptosis pathway adapted from Kruidering & Evan (2000) 
 
7.2 Aims 
To investigate the expression of the key genes in the apoptosis pathway in MCF7 and 
HepG2 cells, following treatment with OXY. This was achieved by using microarray 
data, qPCR, as well as flow cytometry, to analyse apoptotic cell population, caspase 3 
activation and mitochondrial membrane potential (ΔΨm). Moreover, morphological 
changes including plasma membrane integrity, nuclear morphology, nuclear damage and 
intracellular ROS generation were also investigated. 
 
7.3 Results and discussion 
7.3.1 Apoptosis gene expression 
The picture (Figure 56) reveals the intensities (signal log2) of apoptotic genes in OXY–






activating factor 1 (APAF1), apolipoprotein L, 2 (APOL2), B–cell CLL/lymphoma 2 
(BCL2), BCL2–antagonist/killer 1 (BAK1), BCL2–associated X protein (BAX), caspase 
8, apoptosis–related cysteine peptidase (CASP8), cyclin–dependent kinase inhibitor 1A 
(p21, Cip1)(CDKN1A), diablo, IAP–binding mitochondrial protein (DIABLO), Fas cell 
surface death receptor (FAS), growth arrest and DNA–damage–inducible, alpha 
(GADD45A), jun B proto–oncogene (JUNB), mitogen–activated protein kinase 8 
(MAPK8), tumour necrosis factor receptor superfamily, member 10b (TNFRSF10B) and 
TP53. APAF1, APOL2, BAK1, BAX, CASP8, CDKN1A, DIABLO, FAS, GADD45A, 
JUNB, MAPK8 and TNFRSF10B were significantly up–regulated (P<0.1) compared to 
the untreated control, while BCL2 was not altered by the two doses of OXY treated.  
Interestingly, tumour protein p53 (TP53) gene was down–regulated by the compound 
dose–dependently.  
The selected genes were validated using RT–qPCR. Triplicates were performed for each 
gene and the amplification of each gene was used validated specific primer. In all cases, 
the RT–qPCR data confirmed those obtained from 50 and 100 μM–OXY treated array 
analyses (Figure 57). APARF1, APOL2, BAX, CASP8, CDKN1A, FAS, GADD45A 
and TNFSF10B have significantly increased (P<0.1) the expression dose–dependently. 
The two doses of OXY did not make significant changes (P>0.1) in BCL2 and TP53 








Figure 56 The expression signals of key genes in apoptotic pathways of MCF7 treated 
with two different doses of OXY( 50 µM and 100 µM) for 24 h. Data are the mean ± 
SEM (n=3). Statistical analysis was carried out using One–way ANOVA and Dunnett’s 
post hoc test. The significant difference was compared relatively to the control (*P < 0.1, 












Figure 57 Relative quantity of mRNA expression acquired from qPCR of MCF7 cells 
treated with different two doses of OXY. Data are the mean ± SD (n=3). The statistical 
difference between the two treatments was carried out using unpaired t-test (*P < 0.5 and 





































































































7.3.2 Quantification of apoptotic cells 
Apoptosis is a normal physiologic process, which occurs during embryonic development 
or in the maintenance of tissue homeostasis. In apoptotic cells, the membrane 
phospholipid phosphatidylserine (PS) is translocated from the inner to the outer leaflet of 
the plasma membrane, thereby exposing PS to the external cellular environment 
(Rothkamm et al.). Annexin V that has a high affinity for PS, conjugated to 
fluorochromes, phycoerythrin. Therefore, this method can be used for analysing cells that 
are undergoing apoptosis by flow cytometry. This platform was also provided with a vital 
dye, 7–Amino–Actinomycin (7–AAD) to identify early apoptotic cells (7–AAD negative, 
PE Annexin V positive). Viable cells with intact membranes exclude 7–AAD, whereas 
the membranes of dead and damaged cells are permeable to 7–AAD. 
Camptothecin, the standard compound induced apoptosis around 4% of the cell 
population in MCF7 and HepG2 cells after treated for 4 h at the concentration of 4 µM. 
The cells remained alive more than 80 % and roughly 10 % were at the end of apoptosis 
or already dead (Table 10 and Figure 58). 
Table 10 and Table 11 show OXY induced apoptosis in MCF7 cells dose–dependently at 
the concentrations tested of 25, 50 and 100 µM. This occurrence changed between 6–24 
h treatment; the cells treated with OXY 25, 50 and 100 µM at 3 and 6 h became apoptotic 
but not significantly different compared to controls (P>0.1), while those treated with 
OXY 50 and 100 µM at 24 h treatment were significantly different (P<0.0001) from the 
controls. The apoptotic cells were changed from 2.85±0.60 % of the control to 3.14±0.37, 
5.74±0.53 and 11.69±1.15 % of 25, 50 and 100 µM OXY, respectively.  These results 
illustrated that most of the cells treated with 50 and 100 µM OXY within 24 h underwent 




Apoptosis was induced in HepG2 cells following treatment with OXY, in a  dose– and 
time–dependent fashion, similar to that observed in MCF7 cells following OXY exposure 
seen in Table 12 and Table 13. There were no significant apoptotic cells during the 3–6 h 
treatment in HepG2 cells, while some cells turned apoptotic dose–dependently during 6–
24 h treatment; it was significantly different (P<0.01) at the doses of 100 and 200 µM–





















Table 9 Camptothecin (4 µM) induced apoptosis in MCF7 and HepG2 cells after treated 
for 4 h.  
 FSC  FL2–FL3 
MCF7   
HepG2   
 
Live = cell population (%) was indicated live cells (Annexin V PE and 7–AAD negative) 
Apoptotic = cell population (%) was indicated undergoing early apoptosis (Annexin V 
PE positive and 7–AAD negative) 










Figure 58 Apoptotic MCF7 and HepG2 cell population induced by 4 µM camptothecin 


















































































Table 10 OXY induced apoptosis in MCF7 cells dose– and time–dependently 
 
 
OXY concentration (µM) 
0 25 50 100 
3 h     
6 h     















Table 11 Effect of OXY in MCF7 cells determined using flow cytometry. Bar graphs 
showing the percentages of MCF7 cells population (live, apoptotic and dead cells) when 
treated with OXY 25–100 μM for 3, 6 and 24 h and then subjected to flow cytometric 
analysis. Data are the mean ± SD (n=3). 








*CTC = 4 µM Camptothecin  







Apopsis after 3 h exposure

























Apopsis after 6 h exposure

























Apopsis after 24 h exposure



























Table 12 OXY induced apoptosis in HepG2 cells dose– and time–dependently. 
 
 
OXY concentration (µM) 
0 50 100 200 
3 h     
6 h     















Table 13 Effect of OXY in HepG2 cells determined using flow cytometry. Bar graphs 
showing the percentages of HepG2 cells population (live, apoptotic and dead cells) when 
treated with OXY 25–100 μM for 3, 6 and 24 h and then subjected to flow cytometric 
analysis. Data are the mean ± SD (n=3). 








*CTC = 4 µM Camptothecin 
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Apopsis after 6 h exposure

























 Apopsis after 24 h exposure
























7.3.3 Determination of Caspase–3  
Camptothecin could induce the expression of caspase–3 in around 1% of MCF7 and 
HepG2 cells at 4 µM for 4 h in (Table 15 and Figure 59).  
 MCF7 cells treated with different concentrations of OXY at the doses of (25, 50 and 100 
µM for 24 h) showed a dramatically changed amount of caspase–3  compared to the 
control; more than 98% population was caspase–3 positive, while the cell population of 
the caspase–3 negative decreased. All treatments were significantly different (P<0.0001) 
compared with the control (Table 16 and Figure 60).  
Likewise, HepG2 cells were also investigated the expression of caspase–3 at 24h–OXY 
treatment. The results showed that the caspase–3 expression was dose–dependent; the 
expression remained roughly 86 % at 50 µM–OXY treatment and then they were 
increased to around 99% and close to 100% at the doses of 100 and 200 µM, respectively, 
while the population of caspase–3 negative were in the opposite direction. The expression 
of caspase–3 positive in HepG2 cells was also significantly different (P<0.01) compared 















Table 14 Camptothecin induced expression of active caspase–3 expression in MCF7 
and HepG2 cells. 
 
 FSC  FL2–A 
MCF7    
HepG2   
 
Caspase 3– = cell population (%) did not express caspase–3  









Figure 59 Caspase–3 expression of MCF7 and HepG2 cells following exposure to 4 µM 
camptothecin (CTC) for 4 h. The cells were stained with PE rabbit anti– caspase–3 and 
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Figure 60 Caspase–3 expression in MCF7 cells following exposure to various 
concentrations of OXY for 24 h and camptothecin (CTC) for 4 h. The cells were stained 
with anti– active caspase–3 and analysed by flow cytometry. Data are the mean ± SD 
(n=3). Statistical analysis was carried out using One-way ANOVA analysis of variance 
followed by Dunnett's test. The significant difference was compared relatively to control 
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Figure 61 Caspase–3 expression in HepG2 cells following exposure to various 
concentrations of OXY for 24 h and camptothecin (CTC) for 4 h. The cells were stained 
with anti– active caspase–3 and analysed by flow cytometry. Data are the mean ± SD 
(n=3). Statistical analysis was carried out using One-way ANOVA analysis of variance 
followed by Dunnett's test. The significant difference was compared relatively to control 














7.3.4 Mitochondrial membrane potential (ΔΨm) 
Camptothecin was used as a positive control in this assay to cause the loss of mitochondria 
membrane potential (MMP) in MCF7 and HepG2 cells as analysed using flow cytometry. 
The cells were exposed to 4 µM camptothecin for 4 h; MCF7 and HepG2 cells showed 
loss of membrane potential of 7.56±0.41 and 2.39 ±0.16 % cell population (Table 18 and 
Figure 62).  
MCF7 cells lost mitochondria membrane potential dose–dependently (Table 19 and 
Figure 63) following exposure to several concentrations of OXY, which caused MCF7 
cells to undergo apoptosis (24 h–treatment). They also were found to cause loss 
membrane potential to a significant degree (P<0.001) compared to the untreated control 
(4.15%±0.08, 4.77%±2.56 and 11.47%±2.75 for 25, 50 and 100 µM–OXY, respectively). 
Whereas, the normal potential cells also decreased significantly (P<0.001) with the higher 
doses treated.  
HepG2 cells also lost mitochondria potential following treatment with OXY at 100 and 
200 µM (Table 20 and Figure 64). The membrane potential loss in HepG2 cells was 














Table 17 Mitochondrial membrane potential of MCF7 cells following exposure to various 
concentrations of the standard drug, camptothecin at 4 µM for 4 h. The cells were stained 
with JC–1 and analysed by flow cytometry. 
 
 
FSC  JC–1A 
MCF7    
HepG2   
 
P1 = Single cells 
P4 = normal mitochondrial potential 










Figure 62 Mitochondrial membrane potential of MCF7 and HepG2 cells following 
exposure to 4 µM camptothecin (CTC) for 4 h. The cells were stained with JC–1 and 

























































































Table 18 Mitochondrial membrane potential of MCF7 cells following exposure to various 




FSC  JC–1A 
0   
25   
50   






Figure 63 Mitochondrial membrane potential of MCF7 cells following exposure to 
various concentrations of OXY for 24 h and camptothecin (CTC) for 4 h. The cells were 
stained with JC–1 and analysed by flow cytometry. Data are the mean ± SD (n=3). 
Statistical analysis was carried out using One-way ANOVA analysis of variance followed 
by Dunnett's test. The significant difference was compared relatively to the control (***P 

















Table 19 Mitochondrial membrane potential of HepG2 cells following exposure to 




FSC  JC–1A 
0   
50   
100   







Figure 64 Mitochondrial membrane potential of HepG2 cells following exposure to 
various concentrations of OXY for 24 h and camptothecin (CTC) for 4 h. The cells were 
stained with JC–1 and analysed by flow cytometry. Data are the mean ± SD (n=3). 
Statistical analysis was carried out using One-way ANOVA analysis of variance followed 
by Dunnett's test. The significant difference was compared relatively to the control (***P 

















7.3.5 Lactate dehydrogenase (LDH) cytotoxicity assay 
The results of LDH cytotoxic assay of OXY to MCF7 and HepG2 cells are shown in 
Figure 65. MCF7 cells released LDH dose–dependently after treatment with OXY for 48 
h with 11±4, 20±6, 28±5 and 41±9 % of the control at the concentration of 0, 25, 50 and 
100 µM–OXY. Whereas, HepG2 gave the LDH detected with 12±2, 13±2, 17±2 and 
81±27 % of the control at the concentration of 0, 50, 100 and 200 µM–OXY.  
 
7.3.6 Nuclear morphology detection using Hoechst 33342 staining 
MCF7 and HepG2 have been investigated the nuclear and chromatin changes after treated 
with OXY and the pictures of chromatin changed shown in Table 20. MCF7 cells were 
observed the chromatin condensation at all doses treated; the higher doses of 50 µM and 
100 µM gave clearly condensed chromatin. Likewise, HepG2 showed condensed 
chromatins at the high doses of 100 µM and 200 µM–OXY treatment. 
 
7.3.7 Measurement of DNA damage by Comet assay 
MCF7 cells treated with OXY were investigated the DNA damage shown in Table 21. 
The cells treated with 25 and 50 µM of OXY for 24 and 48 h were found not to have 
damage the DNA compared to the cell treated with 100 µM H2O2. OXY at the effective 














Figure 65 Lactate dehydrogenase cytotoxicity assay for MCF7 and HepG2 cells after 
OXY exposure. Data are the mean ± SEM (n=3). Statistical analysis was carried out using 
One-way ANOVA analysis of variance followed by Dunnett's test. The significant 














Table 20 MCF7 and HepG2 nuclei staining by Hoechst 33342 for apoptosis detection 
treated with different concentrations of OXY for 24 h (control cells are untreated). 












Oxy 25 µM 
Oxy 50 µM 
Oxy 100 µM 
Cell control 
Oxy 100 µM 
Oxy 200 µM 






Table 21 Photomicrographs of stained DNA of MCF7 cells for alkaline comet assay. 
Damaged DNA at the areas with white arrows. Magnification, ×20; scale bars, 200 µm. 
 
 24 h of OXY treatment 48 h of OXY treatment  


















Apoptosis has been triggered in MCF7 and HepG2 cells following treatment with OXY. 
The mechanisms of action via this pathway could be elucidated through two main routes: 
the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway. 
However, the two pathways have been proved that it is interconnected and the molecules 
in one could influence the other (Igney and Krammer, 2002). FAS and TNFRSF10B, the 
two well–characterised death receptors, were up–regulated (Ashkenazi and Dixit, 1998). 
FAS was activated and induced the recruitment of Fas–associated death domain (FADD), 
which then activated caspase–8 (CASP8). Apoptosis ligand 2/tumour necrosis factor–
related apoptosis–inducing ligand (Apo2L/TRAIL) is one of the pro–apoptotic ligands at 
the cell membrane, which can activate apoptosis through FADD and caspase 8. The 
activation of apoptosis via the Apo2L/TRAIL pathway has reported to be significant 
potential for cancer therapy and act independently from p53 (Ashkenazi et al., 1999). The 
cascade of apoptotic molecules was then activated through caspase 3 or mitochondrial 
routes; the genes up–regulated including BAX, BAK1, DIABLO and APAF1. The 
activation via caspase–8 is known to propagate the apoptotic signal either by directly 
cleaving and activating downstream caspases or by cleaving the BH3 Bcl2–interacting 
protein, which leads to the release of cytochrome c from mitochondria, triggering 
activation of caspase–9 in a complex with dATP and APAF1 and induce cells death 
(Kruidering and Evan, 2000).  
The induction of apoptosis by OXY in MCF7 cells was interesting because TP53 was not 
activated as indicated by the gene expression and comet assay results. Even though TP53 
functionally responds to cell cycle arrest, cell senescence, DNA repair, metabolic 
adaptation and cell death (Aubrey et al., 2018), The modulation of OXY dependently 
from TP53 has also been reported in neuroblastoma cell lines (Rahman et al., 2017) or 
prostate cancer cell lines treated with camptothecin. The report also found that p53–




(Ho et al., 2019). The results also found not to generate severe DNA damage and ROS 
generation (Chapter 5) at the doses apoptosis occurred. The genes responsible for ROS 
including adaptor–related protein complex 1 sigma (AP1), activating transcription factor 
1 (ATF1) and nuclear factor of kappa light polypeptide gene enhancer in B–cells 
1(NFKB1) (Turpaev, 2002) were not activated (data was not shown). OXY did not 
significantly cause loss of the cell membrane integrity after treated for 48 h, it may 
indicate the compound did not directly change the physical properties of the cells. The 
release of LDH detected in the two kinds of cells may be the effect of apoptosis in late stage. 
Caspase–3, a key protease in the executed phase of apoptosis, was also determined in 
MCF7 and HepG2 cells. Although MCF7 cells have been reported not to express caspase–
3 protein (Janicke, 2009), the antibody can be positive to key enzymes involved in cellular 
repair and maintenance such as poly(ADP–ribose) polymerase (PARP), the  70–kD unit 
of theU1–ribonucleoprotein (U1–70kD), the catalytic subunit of DNA–dependent protein 
kinase (DNA–PK) and sterol–regulatory element binding proteins (SREBP) (Alam et al., 
1997). These proteins are also involved in apoptosis events (Cohausz and Althaus, 2009). 
The loss of mitochondria membrane potential (MMP) in the two cell lines occurred dose–
dependently after OXY exposure 24 h. Therefore, OXY mainly modulated apoptosis 
pathway via intrinsic pathway dependent from TP53.  
In this chapter should be concluded that OXY induced apoptosis in MCF7 and HepG2 
cells. The cascade events were activated through extrinsic and extrinsic pathways. Death 
receptors, TNFRSF10B, FAS and Apo2L were increased in expression. CASP 8 caused 
activation via intrinsic genes and proteins including BAX, BAK, DIABLO and APAF1 
resulting in the loss of mitochondria membrane potential. The executioners, mainly 
caspase 3 and its paralogues were activated resulting in loss integrity of the cell 
membrane, chromatin condensation and eventually cell death. However, OXY did not 
cause TP53 activation, ROS generation and severe cellular DNA breakage. The findings 








CHAPTER 8 EFFECT OF OXY ON 

















Transforming growth factor–β (TGFβ) signalling, which is in TGFβ superfamily consists 
of more than 30 different members play crucial roles in tumour initiation, development 
and metastasis. Therefore, the inhibition of epidermal growth factor is one of the targets 
of cancer therapeutics (Smith et al., 2012; Neuzillet et al., 2015). Some stilbenes such as 
resveratrol, have been reported inhibiting epidermal growth factor (EGF) and related 
receptor (EGF–R), a transmembrane tyrosine kinase activated by ligands, and the 
transforming growth factor–beta (TGF–β) (Zhao et al., 2018). Some other genes in 
MEK/ERK signalling cascades such as CXCR4 and its ligands also take part in 
controlling proliferation and metastasis of cancer cells and may be mediated by 
stilbenoids (Bhattacharya et al., 2011; Chen et al., 2013; Wang et al., 2017). Therefore, 
such genes may be thought of as indicator genes that should be monitored if a compound, 
such as OXY is considered to shows anti–proliferation, anti–migration or anti–invasion 
in cancer cells.  
Cyclin–dependent kinases (CDKs) play a crucial role in cell proliferation and control of 
the cell cycle and are moderated by interactions with cyclins or CDKs inhibitors. For 
example, CDK2 and CDK4/6 in association with their respective catalytic partners 
including cyclin D and E types are responsible for retinoblastoma proteins (Rbs) and then 
bind to sequester members of the E2F family of transcription factors directly regulating 
S phase of the cell cycle (Lim and Kaldis, 2013). CDK2 could also be inhibited by p21 
(CDKN1A) which represents a major target of p53 activity. Recently, CDK2 inhibitor 
has been reported as a possible therapeutic target for new cancer therapeutics to limit 
tumour growth and help reduce the side effects of current chemotherapy drugs (Wood et 
al., 2019). P53 also strictly controls GADD45A, one of the apoptotic inducers, playing a 




 The interconnected link between the cell cycle and DNA repair is a cell cycle stage in 
which the double–strand breaks (DSB) may be generated. Most homologous 
recombination events occur during sister chromatid synthesised in S–G2 phase of the cell 
cycle (Rothkamm et al., 2003). The regulation of CDKs in the cell cycle is directly related 
to homologous recombination and restricted the process in G1–S phase in eukaryotic cells 
(Aylon et al., 2004). Therefore, inhibition of CDKs activities may affect the cell cycle 
process and homologous recombination repair accordingly. Cisplatin (Cis) is a platinum-
based chemotherapy drug widely used to treat several types of solid cancer including 
breast cancer. However, this drug can cause a toxic side effect and resistance to cancer 
(Dasari and Bernard Tchounwou, 2014). The inhibition of the gene overexpression in 
DNA repair pathway has been reported to be one of the new strategies to overcome the 
resistance or re-sensitise them to chemotherapeutic compounds (Kelley et al., 2014; 
Leon-Galicia et al., 2018). OXY was also investigated for its ability to increase the 
sensitivity of selected cancer cells to selected chemotherapeutic drugs.  
 
8.2 Aims 
To investigate the effect of OXY exposure on the key genes and proteins in cell 
proliferation, metastasis and DNA repair pathways in MCF7 and HepG2 cells. The 
investigation was carried out using microarray data, qPCR, as well as flow cytometry to 





8.3 Results  
8.3.1 Effect of OXY on cell proliferation and cell growth 
8.3.1.1 Genes expression  
OXY inhibited genes involving in transforming growth factor–β (TGFβ) signalling 
including TGFβ1, TGFRB2 and LTBP1 through down–streamed deregulation of Smad1, 
Smad3, Smad4, Smad6, Smad7 and Smad9 (Figure 66–68). Moreover, OXY also down–
regulated genes in SMAD–independent pathways including NFkB, TNF, MAPK of 
TGFβ signalling family and genes in PI3K/AKT signal transduction pathways (Figure 
66), which involved in cell proliferation process. OXY significantly (P<0.05) inhibited 
the expression of genes in DNA synthesis and cell cycle pathways (Figure 67), directly 
related to cell proliferation and growth. The key genes in this process including CDK2, 
CDK4 and E2F. Several genes in G1 phase such as CDK4/CCND complexes were also 
significantly inhibited. While, G1/S transition phase was the most down–regulated of 
CDK2 and Cyclin Es complex. The process was also disphosphorylated by the expression 
of CDKN1A and GADD45A resulting in blocking the DNA polymerase and DNA 
replication. While, the gene in G2 phase–M phase such as CDK1 was not significantly 
affected by the OXY–treatment. The expression signals of key genes in MCF7 cells 
treated with 0 µM, 50 µM and 100 µM for 24 h were elucidated in Figure 68; CDK2, 
CDK4, E2F1, FoxM1, TP53 and TGFB1 were significantly down–regulated, while 
CDKN1A and GADD45A were significantly up–regulated. 
The relative quantity of mRNA expression of the relevant genes to cell proliferation and 
growth was validated by qPCR using specific primer sets. The gene expression was 
consistent with the data acquired from microarray shown in Figure 69; CDK4 and E2F1 
were significantly down–regulated, while CDKN1A and GADD45A were significantly 







Figure 66 Gene expression in TFG–beta receptor pathway altered by 100 µM–OXY 
treatment in MCF7 breast cancer cells and then the genes were imported to the database 













Figure 67 Gene expression in G1 to S phase of cell cycle control pathway altered by 100 
µM–OXY treatment in MCF7 breast cancer cells and then the genes were imported to the 















Figure 68 The expression signals of key genes in cell cycle control pathway of MCF7 
treated with two different doses of OXY( 50 µM and 100 µM) for 24 h. Data are the mean 
± SEM (n=3). Statistical analysis was carried out using One-way ANOVA analysis of 
variance followed by Dunnett's test. The significant difference was compared relatively 









Figure 69 Relative quantity of mRNA expression acquired from qPCR of MCF7 cells 
treated with different two doses of OXY. Data are the mean ± SD (n=3). Statistical 
analysis was carried out using unpaired t-test. The statistical difference between the two 








































































8.3.1.2 Cell cycle analysis 
To investigate the effect of OXY on cell growth and division, the cell cycle analysis was 
implemented using flow cytometry technique. Generally, after receiving signals for 
proliferation, diploid cells exit the resting state Gap 0 (G0) phase and enter the Gap 1 
(G1) phase. At this stage, the diploid cells maintain their ploidy by retaining two complete 
sets of chromosomes (2N). As the cells enter the synthesis (S) phase, DNA replication 
starts, and in this phase, cells contain varying amounts of DNA. The DNA replication 
continues until the DNA content reaches a tetraploid state (4N) with twice the DNA 
content of the diploid state. Tetraploid cells in the G2 phase start preparing for division 
and enter the mitosis (M) phase when the cells divide into two identical diploids (2N) 
daughter cells. Therefore, when based on DNA content, cell cycle is commonly described 
by the G0/G1, S, and G2/M phases.  
The results show (Table 23–26) that although OXY did not affect DNA content in MCF7  
and HepG2 cells following three hours of exposure. the compound decreased DNA 
content dose-dependently in G0/G1 phase of the cell cycle at 24 h. Compared with the 
untreated control (0 µM), 25, 50 and 100 µM OXY decreased the percentage of the cell 
population from 85.43±0.34 to 75.39±0.75, 72.34±0.82 and 62.27±0.68%, respectively. 
S phase also significantly decreased from 19.37±0.09 to 19.35±0.48, 16.47±0.63 and 
14.66±0.57%, respectively. Whereas G2/M phase was likely to be induced from 
3.52±0.11 to 4.50±0.46, 3.68±0.17 and 7.40±0.38%, respectively during the time 
incubated.  
Likewise, there were no changes in the DNA content of HepG2 cells within 6 h exposure. 
However, the cell population in G0/G1 and S phases was decreased dose–dependently. 





Table 22 Effect of OXY on cell cycle distribution in MCF7 cells determined using flow 
cytometry. The histograms showing the numbers of cells in different phases after MCF7 
cells were treated with OXY 25–100 μM for 3–24 h and then subject to flow cytometric 
analysis. 
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Table 23 Effect of OXY on cell cycle distribution in MCF7 cells determined using flow 
cytometry. Bar graphs showing the percentages of MCF7 cells in G0/G1, S phases and 
G2/M when treated with OXY 25–100 μM for 3–24 h and then subjected to flow 
cytometric analysis. Data are the mean ± SD (n=3). 
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Table 24 Effect of OXY on cell cycle distribution in HepG2 cells determined using flow 
cytometry. The histograms showing the numbers of cells in different phases after HepG2 
cells were treated with OXY 50–200 μM for 3–24 h and then subjected to flow cytometric 
analysis. 
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Table 25 Effect of OXY on cell cycle distribution in HepG2 cells determined using flow 
cytometry. Bar graphs showing the percentages of HepG2 cells in G0/G1, S phases and 
G2/M when treated with OXY 50–200 μM for 3–24 h and then subject to flow cytometric 
analysis. Data are the mean ± SD (n=3). 
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8.3.2 Effect of OXY on cell migration, invasion and metastasis 
8.3.2.1 Gene expression results 
OXY was found to down–regulate genes involved in chemotaxis and metastasis (Figure 70) 
including chemokine (C–X–C motif) receptor 4 (CXCR4), chemokine (C–C motif) receptor 7 
(CCR7) and chemokine (C–X–C motif) ligand 12 (CXCL12). Moreover, the compound also 
down–regulated the important genes in the  PI3K/Akt signal transduction pathway (Figure 70) 
including phosphoinositide–3–kinase, PI3KR1, phosphoinositide–3–kinase, regulatory subunit 2 
(beta); interferon, gamma–inducible protein 30 (PI3KR2), phosphoinositide–3–kinase, regulatory 
subunit 3 (gamma) (PI3KR3), AKT1, AKT2 and other down–stream genes, which inhibited cell 
growth, migration and survival. The average signal (log2) of the key genes in cell migration, 
invasion and metastasis pathways of MCF7 treated with 0 µM, 50 µM and 100 µM for 24 h 
retrieved from microarray shown in Figure 71. Gene CXCR4, CCR, XCL12, PI3KR2, PI3KR3, 
AKT1 and AKT2 were down–regulated significantly compared to the controls.  
The relative quantity of mRNA expression of the several genes in cell migration, invasion and 
metastasis pathways was also validated by qPCR using specific primer sets. The gene expression 
was consistent with the data acquired from microarray shown in Figure 72; all gene selected 
including CXCR4, CXCL12 and PIK3R were significantly down–regulated dose–dependently, 



















Figure 70 Chemotaxis, metastasis and PI3K/AKT signal transduction pathways 
integrating expression data of MCF7 cells treated with 100 µM OXY for 24 h. Genes 
labelled in green were up regulated and in red were down regulated. 
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Figure 71 The expression signals of key genes in cell migration, invasion and metastasis 
pathways of MCF7 treated with two different doses of OXY( 50 µM and 100 µM) for 24 
h. Data are the mean ± SEM (n=3). Statistical analysis was carried out using One-way 
ANOVA analysis of variance followed by Dunnett's test. The significant difference was 














Figure 72 Real–time qPCR from MCF7 cells treated with OXY. Validation of selected 
genes differentially expressed from MCF7 cells treated for 24 h with 50 µM or 100 µM 
of OXY versus the control data set. Data are the mean ± SD (n=3). Statistical difference 














































8.3.2.2 Wound–healing assay 
The wound–healing assay was developed and implemented to study directional cell 
migration in vitro. This method mimics cell migration during wound healing in vivo 
(Rodriguez et al., 2005). OXY inhibited the cell migration dose–dependently.  Figure 73 
elucidated the gaps and wound–closure folds of MCF7 cells treated with different three 
doses of OXY; 25 µM, 50 µM and 100 µM compared to untreated control (0 µM). The 
untreated cells migrated to each other and nearly closed the gap at 48 h. The cell treated 
with 25 µM–OXY the gap also closed time–dependently in 24 h. However, the gaps 
remained the same at the doses of 50–µM and 100–µM treatments. The wound–closure 
folds compared to the gaps at the beginning of each treatment.  The untreated cells did 
not close the gaps completely moving around half of the wounds. The 25–µM OXY made 
the fold a bit closer than the control at 24–h and 48–h treatments. While 50–µM and 100–
µM OXY inhibited the wound closure to around 0.1 and 0.2 fold at 24–h and 48–h 
treatments, respectively. 
Likewise, wound–healing results in HepG2 were also dose–dependently effect shown in 
Figure 74. The monolayer cells closed the gap time–dependently in 48 h and some cells 
closed the gaps completely at 48–h treatment of untreated control and 50–OXY. Whereas, 
the gaps tended to be constant at 24–h and 48–h of 100 µM–OXY and 200 µM–OXY 
treatment. Figure 74 shows line graphs of the wound–closure fold of HepG2 treated with 
different three doses of OXY(50 µM, 100 µM and 200 µM) compared to the untreated 
control. The untreated control cells closed the gaps linearly given around 0.4 fold and 0.7 
fold at 24 h and 48 h treatment. Similarly, the closing fold of 50–µM treatment was in 
linear given the values around 0.25 fold and 0.5 fold at 24 h and 48 h treatment, 
respectively. Whereas 100 µM OXY made the gaps close at around 0.1 fold and 0.2 fold 
at 24 h and 48 h treatment, respectively. Moreover, the wound–closure tend to be 







Figure 73 OXY inhibits MCF7 cell migration; average number of cells migrating to the 
scratch lines and treated with 50 µM 100 µM and 200 µM OXY compared to the untreated 
group. The gaps were measured at 0, 24 and 48 h after exposed to the compound. Data 










































Figure 74 OXY inhibited HepG2 cell migration; average number of cells migrating to the 
scratch lines and treated with 50 µM 100 µM and 200 µM OXY the gaps were measured 








































8.3.2.3 Invasion assay  
Transwell invasion assay was conducted in HCC1937 (invasive breast cancer cells) and 
HepG2 cells. Cells were plated into the matrigel–coated upper chamber of a 24–well 
format transwell plate and then challenged with OXY. Total 5µg/mL fibronectin was used 
as a chemoattractant. After 24 h of incubation, cells that invaded through the membrane 
were stained with crystal violet. The representative fields of three independent 
experiments are shown in Table 26. The relative invasion was evaluated by counting the 
number of stained cells shown in Figure 75. HCC1937 and HepG2 cells invaded through 
matrigel at some certain numbers. The two kinds of the cell were inhibited the invasion 
dose–dependently. The relative invasion of HCC1937 cells was reduced to roughly 25% 
and 10% in 50–µM and 100–µM OXY treatments, respectively. Likewise, OXY also 


















Table 26 OXY inhibits HCC1937 and HepG2 cell invasion; cells migrating through 
matrigel in the medium treated with 50 µM 100 µM µM OXY compared to the untreated 
group for 24 h. Each of the figures is representative of three separate experiments. 
Magnification = ×20; scale bars = 200 µm. 
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Figure 75 Relative invasion through Transwell of HCC1937 breast cancer and HepG2 
cells treated with 50 µM and 100 µM OXY. The data were expressed as the mean ± SEM 
(n=3). Statistical analysis was carried out using One-way ANOVA analysis of variance 
followed by Dunnett's test. The significant difference was compared relatively to the 























































































8.3.3 Effect of OXY on DNA repair pathway 
8.3.3.1 Gene expression 
OXY–mediated DNA repair gene expression in MCF7 cells dose–dependently, especially 
genes associated with homologous recombination (Figure 76) including RAD51 
recombinase (RAD51), MRE11 homolog A, double–strand break repair nuclease 
(MRE11A), Nibrin (NBN), breast cancer 1, early onset (BRCA1), breast cancer 2, early 
onset (BRCA2),  RAD54 homolog B (S. cerevisiae); fibrinogen silencer binding protein 
(RAD54B), RAD50 homolog, double strand break repair protein (RAD50), RAD52 
homolog, DNA repair protein (RAD52) and poly(ADP–ribose) polymerase 1(PARP1). 
RAD51, MRE11A, NBN, BRCA1, BRCA2, RAD54B and PARP1 found to be down–
regulated, while RAD50 and RAD52  were not affected by the compound (Figure 77).  
The qPCR was implemented to confirm that expression of the selected genes using 
validated specific primer sets to the genes. Most of the relative quantity mRNA were 
consistent with the results of the microarray. OXY decreased the expression of RAD51, 
NBN, BRCA1, BRCA2 and PARP1 dose–dependently. Interestingly, RAD51 was the 
most significantly down–regulated (p < 0.0001). Whereas, MRE11A and RAD50 gene 
were not significantly different (Figure 78).  
Total cell lysates were blotted and identified as described in the materials and methods 
section with RAD51, PARP1 and BRCA1–specific antibodies and the appropriate 
secondary antibody with anti–β–actin as a loading control. The western blot analysis 
demonstrated that OXY also inhibited the enzymatic expression of RAD51 and PARP1 








Figure 76 Homologous recombination pathways integrating expression data of MCF7 
cells treated with 100 µM OXY for 24 h. Genes labelled in green were up regulated and 








Figure 77  The expression signals of key genes in DNA repair pathway of MCF7 treated 
with two different doses of OXY( 50 µM and 100 µM) for 24 h. Data are the mean ± 
SEM (n=3). Statistical analysis was carried out using One–way ANOVA and Dunnett’s 











Figure 78 Real–time qPCR from MCF7 cells treated with OXY. Validation of selected 
genes differentially expressed from MCF7 cells treated for 24 h with 50 µM or 100 µM 
of OXY versus the control data set. Data are the mean ± SD (n=3). Statistical difference 
between the two treatments was carried out using unpaired t-test (*P < 0.5, **P < 0.05 

























































































Figure 79 Western blot analysis of DNA repair proteins in the MCF7 breast cancer cells 
treated for 24 h with 50 and 100 uM of OXY compared with the untreated control. Data 
are the mean ± SD (n=3). Statistical analysis was carried out using One-Way analysis of 






8.3.3.2 OXY enhanced the sensitivity of breast cancer cell lines to cisplatin 
Cisplatin and OXY caused cytotoxicity to MCF7 cells (IC50 of 18.32 µM and 385.1 µM 
following 24–h exposure)(Figure 80). Cisplatin was prepared and diluted with the 
medium at the concentration between 5–200 µM and then exposed to the cells for 24 h. 
While OXY was diluted with the medium between 5–500 µM for eight concentrations. 
The MTT assay and the calculation of the IC50 values were indicated in Chapter 2.  
OXY enhanced the sensitivity of MCF7 to cisplatin. The anti–proliferative effect of 
cisplatin combined with 50–µM and 100–µM OXY was also investigated using MTT 
assay.  The IC50 of cisplatin decreased significantly (P < 0.05) given 18.32 µM, 15.78 µM 
and 5.22 µM in 0–µM, 50–µM and 100–µM OXY, respectively (Figure 81). OXY 













Figure 80 OXY and cisplatin toxicity to MCF7 cells treated for 24 h with different 
concentrations of OXY and cisplatin. The results are mean ± SD (n=3). The IC50 values 






OXY      IC50 = 385.1 µM 
Cis         IC50 = 18.32 µM 
 







Figure 81 OXY enhanced the toxicity of cisplatin in MCF7 cells treated for 24 h with 
different cisplatin concentrations alone or together with 50 or 100 µM OXY. The results 











Cis      IC50 = 18.32 µM 
Cis + 50 µM OXY  IC50 = 15.78 µM 
Cis + 100 µM OXY IC50 = 5.22 µM  
 





The TGFβ signalling pathway regulates not only cancer progression, but also cell growth, 
differentiation, apoptosis, motility and invasion, extracellular matrix production, 
angiogenesis and immune response (Smith et al., 2012). However, the TGFβ signalling 
deregulation is in all steps of carcinogenesis. OXY down–regulated the expression of 
genes in TGFβ signalling pathways including TGFβ1, TGFRB2 and LTBP1 including 
mild inhibition of SMADs expression. The key genes in this pathway included TGFβ1, 
TGFβ2, TGFβR1 and TGFβR2, which are targets of anti-cancer drugs in development 
(Smith et al., 2012; Katz et al., 2013). However, OXY showed inhibition of TGFβ1 and 
TGFβR2, not TGFβ2 and TGFβR1 in canonical (SMAD–dependent) pathway. Therefore, 
the genes in the non–canonical pathway (SMAD–independent) such as PI3K/AKT, NF–
κB, TNF–α were also taken in consideration as the results shown in Figure 70.  
The inhibition of gene expression in the PI3K/AKT may be the key pathway through G1 
to S phase of cell cycle control pathway and affected the downstream process of cell 
growth, proliferation, cell cycle, migration, metastasis and survival.  
OXY significantly inhibited CDK2/CCNE1 (cyclin E1) complex. The overexpression of 
CDKN1A (a potent cyclin–dependent kinase inhibitor) and GADD45A, suppressed the 
phosphorylation of several proteins including E2F1 decreasing the synthesis of histone 
proteins and DNA replication involved in this phase (Jin et al., 2002; Caruso et al., 2018; 
Wood et al., 2019).  
Chemokines and their respective receptors that regulate chemotaxis were recently 
observed to play an important role in the metastasis of various cancers. Specifically, 
breast cancer cells express high levels of the CXCR4 and CCR7 receptors (Youngs et al., 
1997). CXCR4 and its ligand CXCL12 have also been shown to be involved in metastasis 




be the potent inhibitor of leukocyte migration through the inactivation of MEK/ERK 
signalling cascade (Chen et al., 2013).  
Rad51 and its paralogues (RAD51B, RAD51C, RAD51D, XRCC2 and XRCC3) 
including genes in homologous recombination pathway (Figure 76), are central players 
in the regulation of DNA repair and centrosome number, involved in the maintenance of 
genome stability and double–strand DNA repair (Helleday et al., 2007). It has been 
reported that the up-regulation of DNA repair mechanism, especially RAD51 and 
homologous recombination, is also associated with the resistance of chemotherapeutics 
and radiation. Protein expression of RAD51 in 17 cancer cells increased 2–7-fold 
compared to the control primary cells. Treatment of some chemotherapeutics decreased 
the expression of the protein (Chaney and Sancar, 1996; Raderschall et al., 2002; Yang 
et al., 2012; Leon-Galicia et al., 2018). The significantly down–regulated expression of 
RAD51 by OXY may have a key role to play in cancer inhibition. This selective property 












































OXY was the dominant compound in water, ethanol and ethyl acetate extracts of A. 
lakoocha heartwood. Extracting with ethanol gave a higher yield than what was achieved 
using either water or ethyl acetate presenting 3.60 %, 2.44 % and 2.15 %, respectively. 
Whereas using ethyl acetate as the extracting solvent gave higher purity (64.23%±0.03%) 
than others (37.81%±0.90% using ethanol and 33.55%±0.08% using water). The 
chemical profile of the extracts showed the main peak to be OXY and other peaks 
including resveratrol, which was lower than 1% detected.  Authentication of the 
predominant peak was carried out using NMR with the 13C–NMR and 1H–NMR; the 
chemical shifts and structure elucidated were in good agreement with the standard. Mass 
spectra of the main peak detected at RT 14.0 supposed to be OXY showed the spectra 
patterns were the same as the standard. Its molecular formula C14H12O4 was deduced from 
the ESI-MS spectrum in positive ion mode by the hydriated molecular ion peak at m/z 
245 [M + H]+. OXY was stable in different solutions including aqueous and DMSO–d6, 
CD3OD and Acetone–d6 in the normal lab environment up to 48 h. These provided the 
phytochemical information of OXY for studying its chemical and biological activities. 
In cell–free model, OXY exhibited the pro–oxidant activity generating ROS in the 
specific presence of copper (II) ions, not Fe(II) or Zn(II). This could cause damage to 
double–stranded DNA into the open chain or linear forms. OXY was able to show higher 
capability than resveratrol at the same doses, while trans–stilbene did not show the 
activity. The three A. lakoocha extracts also showed the ability to damage DNA consistent 
with the amount of OXY presented. OXY generated ROS in dose–dependent manner, 
reduced copper (II) to copper (I) and depleted GSH. In consideration of these findings, 
OXY has the potential to be developed as a promising anticancer drug candidate and to 




OXY caused toxicity in cancer cells including MCF7, HepG2, PC–3, RAW 264.7 and 
A549 with the EC50 of 30.64±4.79, 104.47±0.82, 106.90±8.63, 115.95±11.28 and 
148.63±4.48µM, respectively without causing toxicity to the normal cells (MCF10A and 
MRC–5 cells). Copper made OXY less toxic. Moreover, OXY and OXY–copper (II) did 
not increase intracellular ROS in MCF7 and HepG2 cells. OXY also did not cause damage 
to cellular DNA as investigated using the comet assay. 
The gene expression profiling and biological pathways involved in the OXY–mediated 
cytotoxicity in human breast cancer cells (MCF7) were elucidated. The Clariom 
Affymetrix microarray was implemented to investigate the expression of more than 
20,000 human well-annotated genes in the cells treated with two different OXY doses (50 
μM and 100 μM) for 24 h. Total of 686 genes was found to have altered mRNA expression 
levels of two–fold or more in the 50 μM OXY–treated group (262 upregulated and 424 
downregulated genes). While the total of 2,338 genes was found to be differentially 
expressed in the 100 µM–treated group (907 upregulated and 1,431 downregulated 
genes).  Interestingly, OXY was found to moderate  genes mainly involved in apoptosis 
by activating key genes involved in both extrinsic and intrinsic apoptotic pathways  (FAS, 
TNFR1 and APOL2/TRAIL) and mitochondrial apoptotic genes (BAX, BAK, DIABLO 
and APAF1), respectively through the caspase cascade. Cyclin–dependent kinases 
(CDKs) are the main enzymes that play a crucial role in cell proliferation including 
CDK2, CDK4 and cyclin proteins, which were also suppressed by OXY resulting in 
blocking DNA synthesis in G1 and S phase and the cell cycle was subsequently arrested. 
OXY also inhibited the expression of CXCR4 and its ligand (CXCL12) causing anti–cell 
spreading or metastasis. Most importantly, OXY inhibited the genes in cancer DNA repair 
pathway; the most affected were RAD51 and genes in homologous recombination, which 
can break the mechanism of self–repair resulting in enhancing cisplatin sensitivity or 






Figure 82 OXY moderated gene expression of apoptosis, cell cycle control, metastasis 
and DNA repair. 
 
This study showed that OXY posed cytotoxicity to several kinds of cancerous cells with 
some molecular pathways illustrated. These support the use of OXY as an alternative and 
complementary medicine for the treatment and prevention of cancer.  
Future studies may involve modification of the chemical structure of OXY and 
corresponding investigations into cytotoxicity in various cancerous cells to investigate if 
the efficacy of OXY in inducing cancer cell death can be improved.  Concurrent with that 
would be continued investigations into the mechanism of action. The ability of OXY to 
induce similar effects to those observed in this thesis, in vivo, in both animals and then 
ultimately in human would be the ultimate goal of the research that was initiated in this 
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Figure  Standard curve of 0.00 – 250 µM OXY measured using a Phenomenex liquid 
chromatography system, separation was achieved on a Luna@ C18 column (4.6 mm × 15 
cm, 5 μm), mobile phase were water (0.5% acetic acid) and acetonitrile, absorbance 




Figure  Standard curve of 0.00 – 25.00 µM resveratrol measured using a Phenomenex 
liquid chromatography system, separation was achieved on a Luna@ C18 column (4.6 
mm × 15 cm, 5 μm), mobile phase were water (0.5% acetic acid) and acetonitrile, 

















































Figure  HPLC chromatogram of the standards and the extracts; OXY and Resveratrol at 
the concentration of 10.00 µg/mL analysed using a Phenomenex liquid chromatography 
system, separation was achieved on a Luna@ C18 column (150 × 4.6 mm, 5 μm), mobile 
phase were water (0.5% acetic acid) and acetonitrile, absorbance measured at 320 nm  
 




In the presence of Cu(II) In the absence of Cu(II) 
Average SD Average SD 
1.56 824.67 54.24 177.67 44.43 
3.13 1071.67 116.38 195.67 30.01 
6.25 1322.67 77.22 160.33 10.26 
12.50 1642.33 90.16 139.00 25.51 
25.00 1990.33 160.22 161.67 36.12 
50.00 2412.00 72.69 114.00 26.00 
100.00 2692.00 190.25 145.00 31.95 








OXY Resveratrol Trans–stilbene 
Average SD Average SD Average SD 
1.56 650.00 32.19 579.67 44.99 422.67 33.84 
3.13 674.00 57.66 611.00 41.04 435.33 69.87 
6.25 831.00 46.03 645.67 7.23 418.33 38.42 
12.50 1135.67 60.93 845.00 87.07 430.00 81.96 
25.00 1562.00 65.39 1028.00 56.56 355.67 38.00 
50.00 2085.33 103.59 1410.00 43.55 413.33 90.00 
100.00 2835.33 216.32 1996.33 85.00 472.33 40.20 
200.00 3411.67 229.40 2632.00 226.93 446.33 17.93 
Table  ROS formation generated by A. lakoocha heartwood extracts; ethyl acetate, ethanol 









Average SD Average SD Average SD 
1.56 877.00 8.72 939.33 71.50 1205.67 88.04 
3.13 955.67 76.17 1066.00 62.36 1477.00 34.66 
6.25 1120.33 52.56 1187.00 71.27 1765.33 27.50 
12.50 1313.33 42.44 1436.00 67.56 2362.33 86.43 
25.00 1722.67 42.39 1846.67 30.07 3078.00 95.36 
50.00 2167.00 64.55 2251.67 71.00 4027.33 191.91 
100.00 2691.00 65.96 2755.67 26.27 5185.67 118.95 





Table The concentration of OXY and the absorbance of the Cu(I)– 




The absorbance of the Cu(I)– 
Bathocuproinedisulfonate complex at 484 
nm 
Average SD 
Replicate 1 Replicate 2 Replicate 3 
1.56 0.0402 0.0432 0.0442 0.0425 0.0021 
3.13 0.0822 0.0872 0.0842 0.0845 0.0025 
6.25 0.1602 0.1622 0.1642 0.1622 0.0020 
12.50 0.2882 0.2902 0.2922 0.2902 0.0020 
25.00 0.5012 0.5132 0.5032 0.5058 0.0064 
50.00 0.6492 0.6492 0.6432 0.6472 0.0035 
100.00 0.6482 0.6492 0.6532 0.6502 0.0026 
 
Table The concentration of OXY, Resveratrol or Trans–stilbene and the absorbance of 




OXY Resveratrol Trans–stilbene 
Average SD Average SD Average SD 
1.56 0.043 0.002 0.019 0.001 0.004 0.007 
3.13 0.085 0.003 0.040 0.001 0.001 0.001 
6.25 0.162 0.002 0.079 0.001 0.000 0.001 
12.50 0.290 0.002 0.155 0.002 0.001 0.001 
25.00 0.506 0.006 0.295 0.004 0.005 0.002 
50.00 0.647 0.003 0.504 0.002 0.013 0.004 












Absorbance at 412 nm Average SD 
7.51 0.061 0.064 0.062 0.062 0.002 
10.01 0.082 0.084 0.083 0.083 0.001 
13.35 0.109 0.110 0.109 0.109 0.001 
17.80 0.142 0.141 0.141 0.141 0.001 
23.73 0.188 0.193 0.190 0.190 0.003 
31.64 0.257 0.254 0.255 0.255 0.002 
42.19 0.338 0.345 0.341 0.341 0.004 
56.25 0.449 0.456 0.452 0.452 0.004 
75.00 0.602 0.593 0.597 0.597 0.005 




Figure The relationship between the standard GSH concentration (nmoles/mL) and the 
absorbance at 412 nm 
 







Standard curve of glutathione




















Table The average and standard deviation of % glutathione incubated with OXY in the 





In the presence of Cu(II) In the absence of Cu(II) 
Average SD Average SD 
6.25 100.29 0.53 99 0.43 
12.5 100.38 0.36 100 1.24 
25 99.45 0.29 100 0.14 
50 98.86 0.67 100 0.38 
100 96.33 0.00 99 0.17 
200 95.32 0.25 100 0.17 
400 91.61 0.53 100 0.14 
 
Table Cell number of A549 cells, which were different initial cells; 5x103, 1x104 and 




5x103 1x104 2x104 
Average SD Average SD Average SD 
Day 1 4218.75 309.36 9406.25 309.36 16500.50 795.50 
Day 2 12687.50 265.17 24750.00 1767.77 46625.00 4419.42 
Day 3 30166.67 5892.56 63000.00 707.11 98625.00 1590.99 







Table Pictures of A549 cell confluence, which were different initial cells; 5x103, 1x104 
and 2x104 cells/ well during 4 days cultured in 96–well plate. 
Initial ells (cells/well) 5x103 1x104 2x104 
Day 1 
   
Day 2 
   
Day 3 
   
Day 4 
   
 
 
Table  Cell numbers of CACO–2 cells, which were different initial cells; 5x103, 7.5 x103, 




5x103 7.5x103 1x104 2x104 
 Average SD Average SD Average SD Average SD 
Day 1 5250.0 353.6 7625.0 176.8 9875.0 530.3 20625.0 1591.0 
Day 2 7187.5 88.4 12312.5 972.3 18812.5 265.2 27812.5 2740.0 
Day 3 19125.0 1060.7 30875.0 530.3 51000.0 3182.0 74000.0 1414.2 









Table Pictures of CACO–2 cell confluence, which were different initial cells; 5x103, 
7.5x103, 1x104 and 2x104 cells/ well during 4 days cultured in 96–well plate 
Initial Cells 
(cells/well) 
5x103 7.5x103 1x104 2x104 
Day 1 
    
Day 2 
    
Day 3 
    
Day 4 
    
 
 
Table Cell number of HepG2 cells, which were different initial cells; 5x103, 1x104 and 




5x103 1x104 2x104 
 Average SD Average SD Average SD 
Day 1 8250.0 1237.4 15333.3 1178.5 25187.5 1149.0 
Day 2 22875.0 530.3 31750.0 2474.9 42250.0 353.6 
Day 3 36625.0 530.3 44250.0 4596.2 48500.0 1414.2 









Table Pictures of HepG2 cells, which were different initial cells; 5x103, 1x104 and 




5x103 1x104 2x104 
Day 1 
   
Day 2 
   
Day 3 
   
Day 4 
   
 
 
Table Cell number of MCF10A cells, which were different initial cells; 5x103, 1x104 and 




5x103 1x104 2x104 
 Average SD Average SD Average SD 
Day 1 1500.0 88.4 5750.0 1060.7 15875.0 1767.8 
Day 2 5031.3 221.0 10562.5 265.2 32687.5 1502.6 
Day 3 14531.3 221.0 34750.0 707.1 54750.0 353.6 








Table Pictures of MCF10A cell confluence, which were different initial cells; 5x103, 
1x104 and 2x104 cells/ well during 4 days cultured in 96–well plate 
 
Initial Cells (cells/well) 5x103 1x104 2x104 
Day 1 
   
Day 2 
   
Day 3 
   
Day 4 
   
 
 
Table Cell number of MCF7 cells, which were different initial cells; 5x103, 7.5 x103, 




5x103 7.5x103 1x104 2x104 
 Average SD Average SD Average SD Average SD 
Day 1 5000.0 353.6 7500.0 353.6 10000.0 707.1 17500.0 353.6 
Day 2 8312.5 441.9 9750.0 353.6 15125.0 1591.0 34750.0 3182.0 
Day 3 12125.0 176.8 19875.0 883.9 28750.0 2474.9 49500.0 4242.6 









Table Pictures of MCF7 cell confluence, which were different initial cells; 5x103, 7.5x103, 




5x103 7.5x103 1x104 2x104 
Day 1 
    
Day 2 
    
Day 3 
    
Day 4 
    
 
 
Table Cell number of MRC–5 cells, which were different initial cells; 7.5x103, 1x104 and 




7.5x103 1x104 2x104 
 Average SD Average SD Average SD 
Day 1 2937.50 265.17 5562.50 265.17 10187.50 2032.93 
Day 2 9937.50 795.50 15875.00 1237.44 21125.00 707.11 
Day 3 19687.50 441.94 27125.00 707.11 29625.00 1590.99 
Day 4 29375.00 883.88 34750.00 3181.98 35500.00 707.11 
 
95-100% confluency 




Table Pictures of MRC–5 cell confluence, which were different initial cells; 7.5x103, 




7.5x103 1x104 2x104 
Day 1 
   
Day 2 
   
Day 3 
   
Day 4 
   
 
 
Table Cell number of PC–3 cells, which were different initial cells; 5x103, 1x104 and 




5x103 1x104 2x104 
 Average SD Average SD Average SD 
Day 1 3656.25 928.08 9000.00 618.72 22062.50 176.78 
Day 2 9812.50 265.17 18937.50 2032.93 45500.00 1060.66 
Day 3 19812.50 618.72 42375.00 3712.31 65625.00 1237.44 







Table Pictures of PC–3 cell confluence, which were different initial cells; 5x103, 1x104 
and 2x104 cells/ well during 4 days cultured in 96–well plate 
 
Initial Cells (cells/well) 5x103 1x104 2x104 
Day 1 
   
Day 2 
   
Day 3 
   
Day 4 
   
 
 
Table Cell number of RAW264.7 cells, which were different initial cells; 5x103, 1x104 




5x103 1x104 2x104 
 Average SD Average SD Average SD 
Day 1 3562.50 265.17 4312.50 265.17 10562.50 1502.60 
Day 2 18437.50 1149.05 37125.00 2298.10 63750.00 1767.77 
Day 3 35500.00 2474.87 77500.00 4242.64 99750.00 1060.66 












Table Pictures of RAW264.7 cell confluence, which were different initial cells; 5x103, 
1x104 and 2x104 cells/ well during 4 days cultured in 96–well plate 
Initial Cells (cells/well) 7.5x103 1x104 2x104 
Day 1 
   
Day 2 
   
Day 3 
   
Day 4 
   
 
Table Cell viability of A–459 cells in different concentrations of Cu(OAc)2. 
Concentration 
(µm) 
Cell viability (% of control) Mean  SD 
0.13 105.58 101.11 98.33 101.67 3.66 
1.25 92.78 92.47 94.78 93.34 1.26 
12.50 93.08 87.84 88.46 89.79 2.87 
25.00 88.61 82.90 86.60 86.04 2.90 
50.00 84.75 84.91 91.39 87.02 3.79 
100.00 70.25 72.72 76.27 73.08 3.02 
200.00 63.47 64.55 71.80 66.60 4.53 












Cell viability (% of control) Mean  SD 
0.13 106.85 101.28 100.90 103.01 3.33 
1.25 93.79 99.74 98.78 97.44 3.20 
12.50 92.83 99.74 94.18 95.58 3.66 
25.00 90.72 93.41 91.68 91.94 1.36 
50.00 76.13 84.96 87.26 82.78 5.88 
100.00 67.68 64.99 65.95 66.21 1.36 
200.00 45.60 38.50 44.06 42.72 3.74 
400.00 7.78 9.31 9.70 8.93 1.02 
 




Cell viability (% of control) mean  SD 
0.13 103.59 95.34 115.83 104.92 10.31 
1.25 83.11 95.88 106.25 95.08 11.59 
12.50 100.50 89.76 105.45 98.57 8.02 
25.00 111.57 109.71 110.64 110.64 0.93 
50.00 93.75 103.86 111.84 103.15 9.07 
100.00 83.91 87.90 108.91 93.57 13.43 
200.00 57.57 67.15 91.62 72.11 17.56 









Cell viability (% of control) Mean  SD 
0.13 110.71 95.14 107.81 104.56 8.28 
1.25 77.04 78.85 78.31 78.07 0.93 
12.50 72.70 69.44 83.92 75.35 7.60 
25.00 64.92 58.76 61.30 61.66 3.09 
50.00 71.61 68.90 66.73 69.08 2.45 
100.00 48.08 51.16 43.74 47.66 3.73 
200.00 23.47 22.20 25.46 23.71 1.64 
400.00 7.00 8.63 4.65 6.76 2.00 
 




Cell viability (% of control) Mean  SD 
0.13 95.14 106.15 97.52 99.60 5.80 
1.25 109.18 110.47 92.98 104.21 9.75 
12.50 104.86 106.15 93.63 101.55 6.89 
25.00 95.36 101.62 97.52 98.16 3.18 
50.00 90.39 97.73 88.23 92.12 4.98 
100.00 89.96 93.20 89.96 91.04 1.87 
200.00 80.00 82.18 80.89 81.02 1.10 









Cell viability (% of control) Mean  SD 
12.50 127.06 86.30 99.21 104.19 20.83 
25.00 100.57 73.40 102.38 92.11 16.23 
50.00 92.87 96.72 99.89 96.49 3.51 
100.00 56.87 95.58 100.11 84.19 23.77 
200.00 84.72 102.60 113.25 100.19 14.42 
400.00 48.94 50.08 36.72 45.25 7.41 
 
 




Cell viability (% of control) Mean  SD 
0.13 103.64 97.90 99.43 100.32 2.97 
1.25 96.36 97.90 98.28 97.51 1.01 
25.00 96.36 87.95 91.39 91.90 4.23 
50.00 94.83 89.86 97.90 94.20 4.06 
100.00 98.66 80.68 86.80 88.71 9.14 
200.00 92.16 90.00 74.55 85.57 9.60 










Cell viability (% of control) Mean  SD 
0.13 104.32 105.78 93.89 101.33 6.48 
1.25 91.56 93.41 95.84 93.60 2.15 
25.00 104.81 95.65 92.63 97.69 6.34 
50.00 94.77 91.94 86.20 90.97 4.37 
100.00 88.63 95.16 96.43 93.41 4.18 
200.00 81.23 90.78 89.22 87.07 5.12 
400.00 74.60 101.98 88.05 88.21 13.69 
 
 
Table Viability of A549 cells treated with different concentrations of Doxorubicin. 
Values express mean ± SD (n=3). 
Concentration 
(µM) 
Cell viability (% of control) 
Rep 1 Rep 2 Rep 3 Average SD 
0.08 100.11 100.25 100.12 100.16 0.08 
0.16 100.00 100.36 123.98 108.11 0.16 
0.31 66.24 64.26 58.19 62.89 0.31 
0.63 38.99 38.28 34.47 37.25 0.63 
1.25 19.65 14.85 16.82 17.11 1.25 
2.50 12.02 10.47 13.01 11.84 2.50 
5.00 33.20 27.98 37.86 33.01 5.00 




Table Viability of A549 cells treated with different concentrations of OXY;  cells pre–
treated with 50µM Cu(OAc)2 for 24 h (OXY–Pre–Cu), OXY in medium supplemented 





Cell viability (% of control) 
OXY–Pre–Cu OXY +Cu OXY 
Average SD Average SD Average SD 
1.56 84.03 2.82 132.87 31.99 96.76 3.38 
3.13 80.00 1.73 86.79 9.01 85.55 1.44 
6.25 82.04 4.53 90.53 7.94 83.10 3.11 
12.50 78.65 1.44 94.05 3.87 88.41 0.11 
25.00 104.86 25.09 107.98 10.26 91.58 1.90 
50.00 87.55 0.51 104.46 11.06 88.74 3.82 
100.00 80.77 2.37 95.05 0.07 69.30 3.61 













Table Viability of CACO–2 cells treated with different concentrations of Doxorubicin. 




Cell viability (% of control) 
Rep 1 Rep 2 Rep 3 Average SD 
0.08 96.49 114.00 117.07 109.19 11.10 
0.16 93.42 106.32 103.86 101.20 6.85 
0.31 96.19 103.56 105.09 101.61 4.76 
0.63 96.80 100.79 90.35 95.98 5.27 
1.25 67.01 84.51 82.36 77.96 9.55 
2.50 34.45 51.96 66.70 51.04 16.14 
5.00 30.15 42.13 35.68 35.99 6.00 
















Table Viability of CACO–2 cells treated with different concentrations of OXY in the 
medium; cells pre–treated with 50µM Cu(OAc)2 for 24 h (OXY–Pre–Cu), OXY in 
medium supplemented with 50µM Cu(OAc)2 (OXY+Cu)  and no Cu(OAc)2 (OXY). 




Cell viability (% of control) 
OXY–Pre–Cu OXY+Cu OXY 
Average SD Average SD Average SD 
1.56 97.85 7.08 97.91 3.68 95.82 7.50 
3.13 92.64 3.75 87.90 7.12 91.15 9.40 
6.25 97.09 2.67 100.11 5.01 91.86 9.24 
12.50 93.20 3.56 98.24 4.66 108.10 5.82 
25.00 90.58 3.28 101.87 3.25 84.50 2.54 
50.00 89.26 4.71 100.88 3.72 70.40 6.94 
100.00 75.67 5.32 91.97 1.51 57.65 19.63 













Table Viability of HepG2 cells treated with different concentrations of Doxorubicin. 




Cell viability (% of control) 
Rep 1 Rep 2 Rep 3 Average SD 
0.08 92.89 75.55 84.58 84.34 8.67 
0.16 81.01 74.84 77.21 77.69 3.12 
0.31 90.75 77.93 91.47 86.72 7.62 
0.63 80.30 71.99 79.35 77.21 4.55 
1.25 10.93 12.12 12.35 11.80 0.76 
2.50 23.04 20.91 24.00 22.65 1.58 
5.00 28.98 24.71 34.92 29.54 5.13 
















Table Viability of HepG2 cells treated with different concentrations of OXY; cells pre–
treated with 50µM Cu(OAc)2 for 24 h (OXY–Pre–Cu), OXY in medium supplemented 





Cell viability (% of control) 
OXY–Pre–Cu OXY +Cu OXY 
Average SD Average SD Average SD 
1.56 101.23 3.12 77.17 1.77 95.82 7.50 
3.13 100.10 11.11 89.05 5.11 91.15 9.40 
6.25 126.87 0.46 111.88 18.17 91.86 9.24 
12.50 107.99 4.80 104.40 10.14 108.10 5.82 
25.00 96.01 7.90 97.95 6.68 84.50 2.54 
50.00 78.40 1.52 94.16 9.37 70.40 6.94 
100.00 65.29 2.51 93.14 6.76 57.65 19.63 













Table Viability of MCF10A cells treated with different concentrations of OXY; cells pre–
treated with 50µM Cu(OAc)2 for 24 h (OXY–Pre–Cu), OXY in medium supplemented 





Cell viability (% of control) 
OXY–Pre–Cu OXY+Cu OXY 
Average SD Average SD Average SD 
1.56 92.69 15.62 87.43 21.19 102.76 1.25 
3.13 99.60 13.46 100.20 16.78 92.55 5.61 
6.25 85.26 0.21 138.93 13.55 96.20 4.34 
12.50 84.72 9.53 155.70 8.63 90.45 9.34 
25.00 106.29 12.82 214.85 8.31 92.46 5.04 
50.00 85.19 12.68 151.22 4.30 88.54 7.25 
100.00 56.78 6.38 153.50 14.93 87.72 3.43 













Table Viability of MCF7 cells treated with different concentrations of OXY; cells pre–
treated with 50µM Cu(OAc)2 for 24 h (OXY–Pre–Cu), OXY in medium supplemented 





Cell viability (% of control) 
OXY–Pre–Cu OXY+Cu OXY 
Average SD Average SD Average SD 
1.56 92.41 35.33 119.45 28.06 83.79 24.14 
3.13 139.80 32.56 127.79 5.34 93.70 7.15 
6.25 107.94 46.54 127.08 2.79 85.95 27.86 
12.50 77.49 7.45 79.65 14.66 73.88 14.19 
25.00 61.52 27.52 75.60 2.50 53.42 6.99 
50.00 43.26 7.64 67.74 7.14 37.48 5.02 
100.00 18.69 5.02 49.51 12.29 28.86 3.60 













Table Viability of MRC–5 cells treated with different concentrations of OXY; cells pre–
treated with 50µM Cu(OAc)2 for 24 h (OXY–Pre–Cu), OXY in medium supplemented 





Cell viability (% of control) 
OXY–Pre–Cu OXY+Cu OXY 
Average SD Average SD Average SD 
1.56 81.71 2.56 83.41 11.06 90.09 23.88 
3.13 82.43 6.45 90.03 9.30 89.91 14.81 
6.25 78.85 2.35 91.33 15.38 111.52 9.70 
12.50 78.03 5.48 95.29 8.34 115.26 9.14 
25.00 72.47 3.03 97.68 6.39 102.14 7.63 
50.00 91.28 7.01 103.14 2.59 91.52 6.07 
100.00 72.08 4.81 69.12 6.39 94.11 3.01 













Table Viability of PC–3 cells treated with different concentrations of OXY; cells pre–
treated with 50µM Cu(OAc)2 for 24 h (OXY–Pre–Cu), OXY in medium supplemented 





Cell viability (% of control) 
OXY–Pre–Cu OXY+Cu OXY 
Average SD Average SD Average SD 
1.56 86.94 3.90 96.49 2.97 80.88 4.39 
3.13 102.01 29.10 100.17 7.90 79.60 9.81 
6.25 99.80 23.54 94.90 2.57 96.99 11.78 
12.50 93.67 12.57 93.31 18.14 87.30 11.13 
25.00 109.60 8.35 100.60 7.90 117.12 2.28 
50.00 81.79 4.73 115.48 24.55 81.47 20.15 
100.00 56.43 3.32 92.33 11.46 52.87 8.75 













Table Viability of RAW264.7 cells treated with different concentrations of OXY; cells 
pre–treated with 50µM Cu(OAc)2 for 24 h (OXY–Pre–Cu), OXY in medium 
supplemented with 50µM Cu(OAc)2 (OXY+Cu)  and no Cu(OAc)2 (OXY). Values 




Cell viability (% of control) 
OXY–Pre–Cu OXY +Cu OXY 
Average SD Average SD Average SD 
1.56 138.31 21.95 89.66 7.52 156.32 7.36 
3.13 118.23 18.76 96.01 12.09 136.14 24.61 
6.25 127.49 6.20 94.09 5.78 141.07 32.20 
12.50 161.71 36.42 98.88 5.25 154.99 38.86 
25.00 136.50 8.80 96.30 3.02 132.32 18.05 
50.00 131.09 16.57 100.99 3.61 134.87 51.76 
100.00 65.57 7.43 53.01 46.20 48.49 6.15 






























18159_1 MCFCon_1 2.1 2.15 162.7 30 4.88 
18159_2 MCFCon_2 2.13 2.03 332 30 9.96 
18159_3 MCFCon_3 2.1 2.08 388.7 30 11.66 
18159_4 MCFOxy50_1 2.15 2.21 187.4 30 5.62 
18159_5 MCFOxy50_2 2.13 2.2 761.1 30 22.83 
18159_6 MCFOxy50_3 2.13 1.24 730.9 30 21.93 
18159_7 MCFOxy100_1 2.14 2.09 585.3 30 17.56 
18159_8 MCFOxy100_2 2.15 2.19 632.4 30 18.97 













Figure An Agilent Bioanalyzer 2100 gel showing a separation of extracted total RNA 
obtained from MCF7 cells treated with OXY 50–100 µM. L = ladder (nucleotide length); 
lanes 1 – 3 = MCF7 cells control; lanes 4 – 6 = MCF7 cells treated with 50 µM OXY; 











Figure Microfluidic electrophoretic separation and RNA integrity numbers 
(RIN) analysis using Agilent Bioanalyzer 2100. (A) electrograms of total RNA samples 








Table Amount of cRNA analysed by Nanodrop 2000 
Sample ID Concentration 
(ng/µL) 
Amount for 15 
µg  
Vol. of water 
to 24 µL 
Vol. of 2nd 
cycle primer 
18159_1 2640.9 5.68 18.32 4 
18159_2 2527.1 5.94 18.06 4 
18159_3 2301.4 6.52 17.48 4 
18159_4 2454.8 6.11 17.89 4 
18159_5 2744 5.47 18.53 4 
18159_6 2175.9 6.89 17.11 4 
18159_7 2655.8 5.65 18.35 4 
18159_8 2937.7 5.11 18.89 4 
18159_9 2839.3 5.28 18.72 4 









Figure An Agilent Bioanalyzer 2100 gel electrophoresis showing a separation of  
cRNA synthesized by in vitro transcription. L = ladder (nucleotide length); lanes 1 – 3 = 
cRNA synthesized from MCF7 cells controls; lanes 4 – 6 = cRNA synthesized from 
MCF7 cells treated with 50 µM OXY; lanes 7 – 9 = cRNA synthesized from MCF7 cells 










Table Amount of ss–cDNA analysed by Nanodrop 2000 
Sample ID ss–cDNA conc.n 
(ng/µL) 
Amount for 5.5 µg             Vol. of water to 
31.2 µL 
18159_1 668.5 8.23 22.97 
18159_2 665 8.27 22.93 
18159_3 643.2 8.55 22.65 
18159_4 654.7 8.40 22.80 
18159_5 639.4 8.60 22.60 
18159_6 636.8 8.64 22.56 
18159_7 644.1 8.54 22.66 
18159_8 681.3 8.07 23.13 
18159_9 650.1 8.46 22.74 










Figure  Agilent Bioanalyzer 2100 gel electrophoresis showing a separation of  
ss–cDNA synthesized by the reverse transcription of cRNA using 2nd– Cycle Primers. L 
= ladder (nucleotide length); lanes 1 – 3 = ss–cDNA synthesized from cRNA of MCF7 
cells controls; lanes 4 – 6 = ss–cDNA synthesized from cRNA of MCF7 cells treated with 
50 µM OXY; lanes 7 – 9 = ss–cDNA synthesized from cRNA of MCF7 cells treated with 









Table Amount of template RNA for RT PCR analysed by Nanodrop 2000 
 
Sample ID Concentration 
(ng/µL) 
Amount for 2 µg  Vol. of water to 28 
µL 
MCFCon_1 176.10 11.4 16.6 
MCFCon_2 344.40 5.8 22.2 
MCFCon_3 412.70 4.8 23.2 
MCFOxy50_1 201.27 9.9 18.1 
MCFOxy50_2 800.07 2.5 25.5 
MCFOxy50_3 753.50 2.7 25.3 
MCFOxy100_1 566.83 3.5 24.5 
MCFOxy100_2 619.20 3.2 24.8 

















Table Amount of cDNA for qPCR analysed by Nanodrop 2000 
 
Sample ID Concentration 
(ng/µL) 




Vol. of water 
to 20µL 
MCFCon_1 1269.35 0.7878 8 12 
MCFCon_2 1147.9 0.8712 9 11 
MCFCon_3 1288.45 0.7761 8 12 
MCFOxy50_1 1204.3 0.8304 8 12 
MCFOxy50_2 1061.8 0.9418 9 11 
MCFOxy50_3 1115 0.8969 9 11 
MCFOxy100_1 1106.3 0.9039 9 11 
MCFOxy100_2 1252.2 0.7986 8 12 



















Picture Four exogenous, premixed control spikes including Lys:AFFX-r2-Bs-lys 
(1:100,000), Phe: AFFX-r2-Bs-phe (1:50,000), Thr: AFFX-r2-Bs-thr(1:25,000) and Dap: 













Picture Four hybridisation controls including AFFX-r2-Ec-BioB, AFFX-r2-Ec-BioC, 
AFFX-r2-Ec-BioD and AFFX-r2-P1-Cre were added in the hybridisation buffer have 










Picture The area under the curve (AUC) was generated by evaluating how well 
the probe set summary separates the positive controls from the negative controls; 
An AUC of 1 reflects perfect separation whereas as an AUC value under 0.5 








Table QC summary of all samples generated by Transcriptome Analysis Console (TAC) 
Software; all samples passed the criteria of labelling, hybridising and the positive vs 




































Picture Amplification curves of Bax, CDKN1A and GADD45A genes using quantitative 





Picture Amplification curves of CASP8, DIABLO, FAS, MAPK8 and TNFSF10 genes 










Picture Amplification curves of AKT, ESR1, GABARAPL2, MAP1LC3B and SQSTM1 



























Picture Melting curves of Bax, CDKN1A and GADD45A genes using quantitative 




Picture Melting curves of CASP8, DIABLP, FAS, MAPK8 and TNFSF10 genes using 


















Picture Melting curves of AKT1, ESR1, GABARAPL2, MAP1LC3B and SQSTM1 














Table concentrations and the absorbance values at 595 nm of bovine serum albumin 
(BSA) used for western blot analysis 
Conc. 
(µg/mL) 
Absorbance at 595 nm Average SD 
Replicate 1 Replicate 2 Replicate 3 
25.00 0.444 0.517 0.434 0.465 0.045 
12.50 0.278 0.289 0.267 0.278 0.011 
6.25 0.206 0.210 0.152 0.190 0.032 
3.13 0.113 0.112 0.110 0.112 0.002 
1.56 0.046 0.047 0.054 0.049 0.004 
0.78 0.006 0.017 0.022 0.015 0.008 




Picture Standard curve of bovine serum albumin (BSA) used for western blot analysis 
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